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Abstract
More than | in 4 deaths reported in 2006 resulted directly from cancer. Radiotherapy
remains the most efficacious non-surgical medium for the treatment and cure of
malignancies and overcoming radioresistance is a major obstacle in the positive
outcome for the majority of cancer therapies. Though radiation has been employed in
a curative capacity for over 100 years, there are still no predictive markers as to
indicate whether a tumourwill be radioresponsive.
Radiation has been shown to be capable of inducing a variety of reversible delays
throughout the mitotic cell cycle. Thus it is likely that proteins involved in the
regulation of cell cycle progression may play a role in influencing radiosensitivity.
Progress continues to be made in elucidating the molecular mechanisms, the clock
and dominoes, which regulate the cell cycle. Identified as central in regulation of the
cell cycle was the tumour suppressor gene p53. The protein of this gene, p53, has
been ascribed to have many functions and activities, and along with the positive
signal transduction factors such as RAS, RAF-1 and MYC maynotonly play an
importantrole in cell cycle progression but might also be predictive of malignancy
and radiotherapeutic outcome. I therefore elected to undertake a study into the
possible relationship between the level of proteins involved in cell cycle regulation
andtheir relationship to radiosensitivity following the clinically relevant dose of 2Gy
perfraction.
I have demonstrated here that the intrinsic level of the proto-oncogene RAF-1 is
predictive of radiosensitivity in a variety of human cancercell lines. Thesecell lines,
which reflect the range of common human cancers, demonstrated a post-radiation
induced accumulation in the G)+M cell cycle phase This Gp+ M accumulation was
found to be reversible. Indeed, the rate at which the cells exited G2+M accumulation,
xiii
deemed Tso, following exposure to ionising radiation correlated with the level of
RAF-1 and also radiosensitivity as measured by clonogenic survival (surviving
fraction) following 2Gy (SF2), but only in cells possessing wild-type p53. This
relationship between the intrinsic level of RAF-1, Tso, and survival fraction was not
present at higher doses of radiation of 4 and 8Gy.
Disruption of p53 function with the small molecule inhibitor Pifithrin-a negated the
relationship between RAF-1 protein level and Tso, and SF2 and Tso in p53-wild-type
cells. These data support the observation that RAF-1 and wild-type p53 co-operate in
modulating G.+M transit and radiosensitivity at clinically relevant doses of y-
radiation.
Xiv
Chapter 1
Introduction
1.1 Overview
Although disruptions to somatic cell division following exposure ofcells to ionising
radiation were first described over 50 years ago by Howard andPele [1],it is still not
fully understood howthearrest ofcells at discrete cell cycle checkpoints is related to
radiation-inducedcell death. Whilst early work concentrated on DNA damage andits
repair, it has become apparent since the early 1980’s that cellular radiosensitivity
may also be related to proteins that promote or suppress cell cycle progress.
Discoveries of cyclins and their kinase partners, the cyclin dependent kinases (CDK),
along with the kinase antagonists, the cyclin dependent kinase inhibitors (CDKI) and
tumour suppressors such as p53 and the Retinoblastomaprotein (Rb), have provided
molecular mechanismsto explain the original observations of Howard andPelc [1].
Described in this thesis is an exploration of the relationship(s) between ionising
radiation dose, clonogenic human cancercell post-irradiation survival and post-
irradiation cell cycle delay, in the context of our increased understanding of the
molecular control of the cell cycle and protein expression of the tumour suppressor
protein p53 and the mitotically significant RAF-1 protein. This introduction thus
reviews;
1- A description of the cell cycle.
2- The molecular control of cell cycle progression and the cell cycle
checkpoints.
3- Theeffect of radiation on cancercell survival.
4- A review ofrelevant aspects of p53 and RAF-1 with relation to the
above points.
1.2 Somatic cell proliferation
1.2.1 Introduction
Thediscovery that cells reproduce by dividing into two identical daughter cells gave
an insight into the very origin, and nature of cells and became a cornerstone of cell
theory. Walther Flemmingfirst used the term ‘Mitosis’, in 1882 to describe the
process by which cells proliferate following the observation of the formation of
thread-like structures, the mitotic chromosomes [7].
1.2.2 Arrest at discrete points in the progressionofcell division
Mitotic cell devision wasinitially described asa series of visually accessible physical
events and divided into two stages, the intermitotic and mitotic stages. The four-
phase convention that is now routinely used to describe the asexual proliferative
process in somatic cells was first described over five decades ago and is depicted in
Figure 1 below [1]. This four-phased cell cycle followed observations by Howard
and Pelc on post-irradiation DNA synthesis and chromosome breakage in the root
meristem of the bean species Vicia faba, where the terms G,, S, Gp and D werefirst
used to describe the key stages of molecular as well as structural activity in dividing
cells.
Using radio-labelled 2pdetermination of the duration of DNA synthesis (S-phase)
was achieved andtissue section staining was undertaken to determine the mitotic
index. From these parameters the length of division (D - time taken for mitosis) was
ascertained. Two periods of apparent inactivity were also noted (G; and G). D is
now widely termed M-phase, for mitosis, where chromosome separation and
cytokinesis results in the production of two identical daughter cells. These
experiments, carried out prior to the discovery ofthe structure ofDNA, werethe first
to show that the inhibitory effect of ionising on cell division wasrestricted to clearly
definable checkpoints in what became knownasthecell cycle.
The two apparent gap phases, G; and G», have now been established as periods of
intense metabolic activity. Further to the conventional four-stage cell cycle is the less
well understood quiescent state. This resting state, often refered to as Go [11], lies
between cycles of somatic/mitotic cellular proliferation is being seen as an
increasingly important cell cycle component that may well contribute to
differentiation fate [12, 13]. An overview of the mitotic cell cycle compartments of
Go, Gi, S, G2 and M is given below;
Quiescence  
 
  
    
Cell Cycle
Progression
 
Somatic
Cell
 
Figure 1. The mitotic cell cycle
The four stages of the mitotic cell cycle and the visible characteristics of this cycle
are depicted in the above pictogram. Adapted from Mitchison and Salmon [7].
1.2.3 Quiescence (Go)
Yeasts, bacteria and other unicellular organismswill proliferate continuously, taking
advantage of the availability of nutrients in their immediate environment as
circumstances dictate. In a multicellular organism however, cells must maintain a
balance of proliferation and differentiation and cell death via senescence and
programmedcell death, apoptosis [16], in accordance with the growth criteria of the
organism as a whole, rather than merely that of the individual cell. Following
observations of non-dividing cells in many tissues, Lajtha proposed, in 1968, the
existence of anothercell cycle phase, that of Go [18].
Quiescence, a pseudo-G,state, so determined becauseit precedes DNAsynthesis, is
that of a cell that, although not presently undertakingcell division, has the ability to
do so, given an appropriate stimulus. In contrast to certain cells which have lost the
ability to divide, such as neuronsthat are described as terminally differentiated, these
diploid quiescent cells, though not actively reproducing, are still very much
metabolically active. For example, liver cells that are continually metabolically
active, may be quiescent for long periods oftime before entering into division [20],
whereas some gut epithelia can have a far shorter Go, typically dividing daily [21]. In
damaged liver, hepatocytes in the uninjured portion of the liver will undergo
successive roundsofproliferation until the liver is restored to near normal mass [22].
Cells undergoing somatic cell proliferation, be it from continual division, or
induction into division from quiescence, proceed via a series of regulated sequential
temporally and biochemically separated stages, termed thecell cycle. Individualcells
of the same type that do enter mitotic cell division have been shown to quickly
become asynchronous with respect to their entry into the cell cycle following exit
from a quiescent state [23]. The stochastic nature of Go confers an advantage on the
organism, since simultaneous mitoses of large numbers of cells and the associated
structural and functional changes therein, could well be harmful to the integrity of
individualtissues.
1.2.4 Thefirst growth/gap phase (G;)
G; and Go, occupy theperiod traditionally described as interphase.Initially perceived
as a state ofproliferative inactivity, G; is the stage in the cell cycle in which the cell
preparesitself for the coming S-phase. During G; phase the cell commits to a round
of mitotic cell division when it elects to pass the ‘Restriction Point’ (R). Prior to the
R point, cells must continually receive external mitotic signals to ensure entry into
mitosis, whilst once passed, the cell becomes independent of these signals [24].
During G, rRNA and tRNAsynthesisis initiated and protein synthesis occurs [25-
27].
1.2.5 S-phase
S-phase is also a feature of interphase. S-phase is typified by the induction of
genomic DNAreplication. This is probably the mostcritical stage of the cell cycle,
as it is here that the faithful and complete duplication of the cellular genomeis
undertaken. Errors during this stage couldresult in the loss, incomplete, or erroneous
replication of important genetic elements, resulting in the loss of long term cellular
viability. Indeed, cells that have been prevented from completing S-phase by
pharmacological agents, such as hydroxyurea, often develop gross chromosomal
abnormalities or die [28, 29]. It is now that centriole replication (budding) occurs [30]
and the chromosomescan be observed to separate [31] and mRNAsynthesis occurs
[32].
1.2.6 The second growth/gap phase (G2) and mitosis
Following the completion of genomic replication the cells undergo a second phase of
growth, during which the cell must undergo cellular organelle synthesis as the cell
grows dramatically in density along with the synthesis of mitochondrial DNA [33]
and mRNA [34]. It is during this phase of the cell cycle that the cell undergoes the
‘visibly accessible’ stages of the cell proliferative process; prophase, metaphase,
anaphase and telophase normally result in the production of two ‘identical’ daughter
cells.
The purpose of M-phase of the cell cycle is to achieve equal segregation of
chromosomesto the daughter cells. This physical process is readily observed under
the microscope as in prophase; the duplicated centrosomes condense into two
chromatids and migrate around the nucleus. This is then followed by the breakdown
of the nuclear envelope and golgi apparatus [35] during prometaphase along with
equatorial alignment of the chromatids. Then during metaphase, the sister chromatids
align, followed by the migration of the two chromatids to ‘opposite’ poles of the cell
in anaphase.Finally, the cells enter Telophase, where they undergocell-cell scission,
nuclear envelope reassembly and abscission, resulting in the completion of mitosis
with the production oftwo separated daughtercells.
1.3 Molecular events controlling the cell cycle
1.3.1 Introduction
A proliferating cell must coordinate DNA-replication and chromosomalseparation to
ensure that the genome is passed faithfully through successive generations. The
molecular events that control the somatic, mitotic cell cycle have evolved to
guaranteethat this principal goal is achieved and the step-wise progression of these
events has been known for almost two decades, with Murray and Kirchner [36, 37]
describing the cell cycle as ‘being akin to dominoes and clocks’. Work with yeasts
suggested a direct triggering of responses as in a biochemical pathway and Murray
and Kirschner used the analogy of a chain of tumbling dominoes to describe the
committal to each successive phase of the cell cycle being dependent upon the
completion ofan earlier stage. Secondly, oscillations of proteins at different stages of
the cell cycle in Xenopusextracts presents a picture ofstrict time-dependent controls
in a clockwork-like mechanism[38].
Co-ordination of the temporal and sequential events ofthe cell cycle are governed by
 a family of conserved and constitutively
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 family [40]. In addition to molecular
. Figure 2. Cyclin/CDK regulation. Depictioneventsthat drive the cell cycle onward, a ofthe basic molecular controlof the dimericcyclin/CDK complex in eukaryotes. Arrows
ends indicate inhibition.     
negatively regulate cell cycle progression. A diverse family of proteins that are the
CDKI undertakes this negative control of the cell cycle [41].
1.3.2 Cyclin dependent kinases
Thetransfer of a y-phosphate from ATP to the hydroxyl group of a Serine/Threonine
residue ofa regulatory protein is the primary controlling mechanism that underpins
the entire complex progression of the eukaryotic cell cycle. The proteins central to
this process, dictate when cell cycle progression can begin and proceed, belong to a
family of kinases, the CDK [42]. Central to cell proliferation, the CDK’s are highly
regulated, both in responseto intra- and extra-cellular signals [41, 43-45].
CDK nomenclature is chronological with respect to their discovery; CDC2 (cell
division cycle protein 2) [46], first discovered in yeasts is now designated CDK1.
Meyersonet al. [47] cloned a series of CDK’s identified through shared sequence
motifs. This led to the realisation of the possibilities of combinatorial regulation of
the CDK’s through discrete interactions with the cyclins.
The physical association with a cyclin positively regulates CDK activity. This
association results in a conformational change in the CDK [48]. Further activation of
the CDKis achieved through phosphorylation of the T-loop threonine by the CDK-
activating Kinase (CAK), a serine/threonine kinase that is also involved in
transcription and DNArepair [49].
Though the CDK’s activity is dependent upon binding to their cyclin partner, this
‘marriage’ of molecules is far from monogamous, for either the cyclin or the CDK.
In addition to the association of cyclin B1 with CDK1, cyclin A can also binds
CDK1although the function of cyclin A in the regulation of DNA synthesis depends
upon binding to CDK2 [50, 51]. The cyclin A/CDK2 complex can then bind to and
phosphorylate the Rb protein and has a role in maintaining the integrity of DNA
synthesis [52].
1.3.3 The cyclins and cell cycle progression
1.3.3.1 Introduction
The catalytic subunits of the
CDK’s are only active when the
CDK molecule is complexed with
unstablethe transient and
regulatory subunits whose
fluctuations in abundance during
the cell cycle led to their being
termed ‘cyclin’, derived from
observations of proliferating cell
nuclear antigen (PCNA) at the
induction of the cell cycle [53].
Cyclin degradation occurs via
phosphorylation dependent [54]
and independent ubiquitination
[55].
 
 
 
  
Cyclin Function
S Phasetransit and G,/M entry and
A transition. Anchorage-dependent
growth
BI, B2 G exit, and mitosis
Cc Transcriptional regulation,
Gp to S-phasetransition
D1, D2, D3 Go to G; progression and G;,to S-
phasetransition
E G, and G;,to S-phasetransition
F G, to Mitosis progression
G1, G2 DNA damageresponse
H CDKactivation, transcriptional
regulation, DNA repair
I Anti-apoptotic
J Nuclear Division
K Transcriptional regulation, CDK
activation
L1, L2 mRNAsplicing
O Apoptosis in Lymphocytes
Ss Memory
T1, T2 Transcriptional regulation
Xx Transcriptional activation of c-MYC Tablel. The eukaryotic cyclins Summaryof the cyclinseukaryotic cells. Adapted from a review byJohnson and Walker [2] Cyclins and cellcycle checkpoints. and their function in     
A summary of the mammalian cyclins and their function throughoutthe cell cycle is
given in the adjacent Table 1, with a fuller description of their activity and
interactions with other proteins that facilitate their activity below.
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1.3.3.2 G; cyclins
Thefirst cyclins to be induced during the mammalian mitotic cell cycle, the D-type
cyclins facilitate progress of cells as they traverse from Go to Gj, stimulating entry
into the cell cycle [56] and then progression through G;. Three D-type cyclin
homologous isoforms are differentially and combinatorially expressed in various in
vitro cell types andin vivo in an organ andtissue specific manner [57, 58]. Mostcells
express D3 and D1 or D2. Thelevels of cyclin D protein levels do not spontaneously
oscillate during the cell cycle; their presence depends on persistent growth factor
stimulation [59], suggesting that the D-type cyclins provide a link between mitogen
signalling and the cell cycle machinery.
D-type cyclins are found in the nucleus [60] and cyclin D1 has been implicated in
control of cell cycle progression at the late G; restriction point, which determines
whetherthe cell will proceed into DNA synthesis [61]. Microinjection of antibodies
or antisense molecules to cyclin D1 into normal fibroblastsis effective in halting cell
cycle progression up to the G;/S boundary [60, 62].
Depending on cell type, D-type cyclins associate with CDK4, CDK2, CDK5 or
CDK6 [63, 64]. On binding to cyclin D, CDK4 becomesactivated as a kinase by
phosphorylation on Thr172 [65], an event mediated,as in p34, by CAK [66-68].
Cyclin D/CDK holoenzyme complexes can fully phosphorylate their substrates in
vitro, but the formation of quaternary complexes maybecritical to their cellular
function, as when isolated from proliferating mammalian cells they have also found
to be associated with the CDKI p21”“F!“"! and PCNA[69].
Cyclin D exerts its influence on the regulation of G;/S by its association with the
protein product of the Rb tumour suppressor gene, which is phophorylated from the
G;restriction point through to mitosis [70, 71]. Since cyclin D can bindto Rb protein
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[72, 73] and its CDK-bound holo-enzyme kinase activity has been demonstrated to
phosphorylate Rb protein in vitro [63, 64, 74] it is assumed that Rb protein is a cyclin
D/CDKé4substrate in vivo. Hypophosphorylated retinoblastoma protein functions as
a “pocket protein” binding and thus sequestering the E2F transcription factors. In this
way hypophosphorylated Rb protein negatively regulates G,/S transit induction [75].
Upon further phosphorylation by cyclin D/CDK4,Rb protein can no longer bind E2F
and the transition from G; to S-phaseis initiated. E2F-binding by cyclin A/CDK2 has
been suggested as an inactivation step for DNA synthesis [76, 77].
In Rb-negative tumourcells, whether Rb loss results from genetic silencing [78] or
where DNA tumour virus oncoproteins - including SV40 T-antigen [79] and
adenovirus protein, E1A [80], inactivate the growth-suppressive function of Rb,
cyclin D levels are reduced and CDK4 and CDK6 bind to form inactive complexes
with p16 [81].
Through the activation of E2F, cyclin E appears next in the cell cycle progression
through G, [82, 83]. Exhibiting periodical expression, peaking at the G,/S boundary
[84, 85], cyclin E associates with CDK2 [85]with consequent kinase activity peaking
in late G;. Microinjection of antibodies to either cyclin E or CDK2 proteinsresults in
cell cycle arrest in G,, implicating both components of the cyclin E-CDK2
holoenzyme complexas being required for the initiation ofDNA synthesis [86, 87].
Cyclin E transcription is activated when the retinoblastoma protein is hyper-
phosphorylated and it then participates in maintaining retinoblastomaprotein in the
hyper-phosphorylated state [71, 88]. Cyclin E is thus involved in a positive feedback
loop resulting in the accumulation of active E2F. The subsequent accumulation of
cyclin E may also depend uponthe activity of cytosolic chaperones, which mediate
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the ATP-dependent folding of newly translated cyclin E into a mature form that can
associate with CDK2 [89].
1.3.3.3 S-phase cyclins
Cyclin A, whichis also regulated in part by E2F [90], accumulatesat the G)/S-phase
transition boundary andpersists throughout S-phase, being required for S-phaseentry,
transition and entry into mitosis [91-93]. Following cyclin E degradation, cyclin A is
found to associate initially with CDK2. Cyclin A/CDK2 complex then participate in
DNAsynthesis via bindingto a transcription factor [94].
1.3.3.4 G,+M cyclins
Thefirst cell cycle regulatory proteins to be assigned a role were those governing the
pre-mitotic checkpoint. The cdc2 gene product, CDK1, was isolated from a
temperature sensitive mutant of S. pombe and demonstrated to be homologous to
cdc28 in S. cerevisiae [95], a gene first identified by Hartwell in 1974 [96]. The
product of cde2 gene, CDK1, initially referred to as p34“, was shown to be a
protein kinase [97] and its human homologue was subsequently identified due to its
ability to complement a mutant of cdc2 gene in S. pombe[98].
Gautier [99] revealed that purified maturaton promoting factor (MPF) contained a
component that was the Xenopus homologue of CDK1 and Draetta [100]
subsequently identified cyclins as the essential binding partners for active MPF. The
resulting holoenzymeis regulated by CDK1andentry into mitosis has been shownto
be blocked by the abrogation of CDK1activity upon microinjection ofrat fibroblasts
with antibodies directed against it [101]. Activation of CDK1 requires binding to a
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cyclin of which there are many types. First described in sea urchins [102], they have
since been identified on the basis of sequence homology in fission yeast, as the
product of the cdc]3 gene [36, 103-105] and Xenopus [106]. Two types of mitotic
cyclin have been described, A and B, both of which have been shownto bind to
CDK1but which form distinct complexes [100, 107].
B-type cyclins follow the typical cyclical pattern of accumulation and several types
have been identified. Two classes, B1 and B2, were isolated in Xenopus [106] and a
human cyclin [108], which has homology with Xenopus B1. A third B-type cyclin,
B3, initially described in chickens [109] and C. elegans [110] and more recently in
humansand mouse [111].
There are several B-type cyclins in yeasts. These B-type cyclins fulfil a varity of
functions. In S. cerevisiae cyclins B1 and B2 function in mitosis whereas cyclin B3-6
undertake roles prior to mitosis; cyclin B3 and cyclin B4arestill active in M-phase,
including involvement in spindle assembly [112-114]. In S. pombe, in addition to
CDC13, two other B-type cyclin proteins function in the cell cycle; cig] is a G;
cyclin [115] whereas CIG2 has a role in both G1 andat mitosis [116, 117].
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genomicintegrity. Thus, it is critically important that the activity of the CDK family
can be negatively regulated. This process is undertaken by the CDKI, the induction
of which can be multifaceted [118, 119] and providescritical links to other signal
transduction pathways duringproliferation, differentiation and senescence[41].
In mammalian cells there are at least two classes of CDKI’s, the INK4 proteins [81,
120, 121], which, containing four members, bind competitively to the monomeric
forms of CDK4 and CDK6,the partners ofthe D-type cyclins and as such can inhibit
G; progression [122, 123]. The second class of inhibitors, the CIP/KIP family
demonstrate significant conserved homology and are permissive in cyclin/CDK
binding. The three members of this CIP/KIP family form heterotrimeric complexes
with the G,/S cyclin/CDK complexes. This second group of CKDI’s only bind after
the cyclin/CDK complex has formed and the binding of two CDKI’sis required for
the inhibition of the cyclin‘;CcDK complex. It should be noted that the CIP/KIP
CDKI’s also function as adaptors to promote cyclin/CDK complex assembly [124].
p21 (alternatively known as WAF1, CIP1, OR SDI1) is a universal CDK inhibitor
[125] that is directly regulated by p53 [126]. The induction of p21 by p53 causes
both cell cycle arrest in G; and G2+M phasesand inhibition of DNA synthesis in
response to genotoxic assault and the subsequent inhibition of transition from the S
to M phasesofthe cell cycle. In the absence of p21, cells with damaged DNAarrest
in G» and then undertake repeated cycles of DNA replication without undergoing
mitosis. The loss of p21, or ofits regulator p53, resulting in the uncoupling of the S
to M phase transition control may contribute to the acquisition of chromosomal
abnormalities manifested in many tumourcells when apoptosis pathways have been
circumvented.
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The CDKI, p21 has several distinctive features. The carboxyl terminus of p21
contains a PCNA binding sequence and inhibits PCNA-dependent DNAreplication
[127]. This carboxyl sequence is overlapped by a cyclin-binding motif and has been
shownto inhibit CDK activity both in vitro and in vivo [128]. This would indicate
that p21 modulation of the cell cycle is complex and multifaceted. The carboxyl
nuclear localization signal in p21 can facilitate the sequestration of cyclin/CDK
complexesto the nucleus [124].
In the structural context, p21 forms a quaternary complex with a cyclin/CDK and
PCNA, which functions in DNA replication and repair as a subunit of DNA
polymerase 6 [125]. p27 (Kip1) is a p21-related CDKI [129] that mayact to regulate
both cyclin E/CDK2 and cyclin D/CDK4activity by virtue of its stoichiometic
binding with the cyclin D/CDK complex. p27 has also been shownto bind CDK6,
which again affects the activity of the D-type cyclins. Cyclins A and B can also be
inhibited by this p27 [130]. p27 is negatively regulated by mitogens, suchasplatelet
derived growth factor (PDGF), facilitating the progression of cells from quiescence,
to mitotic division [131]; blocking p27 function with anti-sense cDNA results in
unrestrained cell proliferation [132].
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1.4 Cellular effect of ionising radiation and radiosensitivity
1.4.1 Introduction
On 8" November 1895 Wilhelm Conrad Roentgen discovered the existence of
ionising radiation (X-rays) byits ability to blacken unexposed photographic film and
used this phenomenonto producethe first X-ray of the hand of his colleague Herr
KOlliger [133]. Antoine Henri Becquerel then discovered spontaneous radioactivity
the following year (1896), for which he shared the 1903 Nobel Prize in Physics with
Pierre and Marie Curie [133] and in 1897 Professor Leopold Freund demonstrated,
before the Vienna Medical School, that X-rays were capable of destroying a hairy
mole [134]. Since these early observations ionising radiation has become
increasingly utilised as an effective physical agent at the centre of cancer therapy.
Cellular susceptibility to ionising radiation is varied. As a result of aberrant cell
division and loss of genomic surveillance, one of the key alterations in cancercells is
that chromosomal and genetic organisation may be de-stabilised such that variant
cells arise with higher frequencies [135, 136]. These events may influence both the
growth and malignant characteristics of the tumour and the tumours responsiveness
to radiotherapy.
The radiotherapeutic responsive and particularly the intrinsic radiosensitivity of
tumours, both across tumour types [137] and within a tumour [138], differs largely,
reflecting the varying radio-sensitivities of individual cancercells [139, 140]. This
spectrum of therapeutic responsiveness can be seen in vivo, in patients following
radiotherapy andis reflected by the in vitro radiosensitivity of cancer cell lines at the
clinically relevant radiation dose of 2Gy [4, 141-146].
17
1.4.2 Cell cycle delays and cellular radiosensitivity
One of the most obvious and profound responses of cells to ionising radiation is a
delay in progress through the mitotic cell cycle. Such observations have prompted
manystudies seeking a putative relationship between the degree of post-irradiation
cell cycle delay andthe intrinsic radiosensitivity of that particular cell line.
The identification of a relationship to post-irradiation cell cycle delay could
potentially lead to a more detailed understanding of the mechanisms of post-
irradiation cell survival. A longer G; delay (see section 1, The mitotic cell cycle)
might allow damaged DNAto be assessed and possibly repaired prior to replication.
A pause in G2 may be necessary to repair damage following DNA synthesis and
increase the chancesof a viable mitosis. The loss of G; or G2 checkpoint could relate
to increased radiosensitivity. The studies prompted by such a hypothesis have
elicited someinteresting but often conflicting information.
1.4.3 Does loss of G; delay relate to radiosensitivity?
G; delay is not a ubiquitous response ofall cells to ionising radiation and there is
scant compelling evidence for a link between the degree of G; delay andthe intrinsic
radiosensitivity of the cell. Some studies have shown both positive and negative
relationships.
A positive relationship came from a study in 1983 by NagasawaandLittle [147].
They investigated a mechanism for a link between chromosomalaberrations and cell
killing in fibroblasts after X-irradiation. The above study compares Retinoblastoma
cells of differing sensitivity with Ataxia Telangiectasia (AT) derived cells, a human
autosomal recessive disorder conferring hypersensitivity to ionising radiation. The
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AT cells had a much higher incidence of chromosomal aberrations than the
Retinoblastoma cells. Investigation of cell cycle kinetics using [°H] thymidine
labelling revealed G, delay at 2Gy and 4Gy in Retinoblastomacell but no G; delay in
AT cells at either dose. Interpretation of these data howeveris not straightforward.
The different shapes of the Retinoblastoma and AT survival curves, however, made
it impossible to provide a meaningful interpretation of this data in terms of any clear
relationship between loss of the G; checkpoint delay and radiosensitivity. Thus these
experiments did not necessarily support the concept of inherent radiosensitivity being
attributed to G; delay.
Painter and Younghadearlier proposed that a lack of G; arrest in AT cells increased
their radiosensitivity [148]. Subsequent work sought to demonstrate that the loss of
the p53 mediated G,arrest increased the radiosensitivity of the humancancercells
[149]. A mutant-p53 gene wastransfected into a wild type p53 (wt-p53) cellline.
Though decreasing the G; delay, there was howeverno effect on radiosensitivity.
Other studies have indicated increased radioresistance did accompanya lack of G,
arrest. p53 mutations in murine bone marrow cells were shownto related to
increasedresistance to ionising radiation [150]. Moreover, a significant correlation at
2Gy between Gy,arrest and increasing radiosensitivity was observed.In a study in
thirteen human tumourlines with SF, (surviving fraction of cells at 2Gy) with values
ranging from 0.11 to 0.8; that is 11-80% of cells survive after 2Gy, the radiosensitive
cells, i.e those with a low SF, value undergoing a G; delay. Radioresistant cells with
a high SFhaving hadlittle or no G; delay. Wt-p53 was shownto be necessary to
mediate this responseandlossofthis function could lead to induced radioresistance
[151]. No correlation between G; arrest and p53 mutational status was described.
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However, in this study samples were taken at 6, 12, 24 and 48 hours (H) and a
relatively short G2 delay may not have been noticed.
1.4.4 Studies supporting the concept that Gdelay is related to radiosensitivity
In 1975, Tobey had postulated that a surveillance mechanism might operate in G» to
repair or remove the cells not deemed capable of completing mitosis [152]. A wide
range of studies have linked a prolonged G2 delay with increased radio-resistance.
Rat embryo fibroblasts transfected with the oncogenes H-ras and v-myc.
demonstrated a more radio-resistant phenotype, which correlated with an increase in
G» delay, not attributable to differences in induction or repair of DNA double
stranded breaks (DSB) [153]. The effects of H-ras and v-myc have been shownto
confer the greatest resistance is S and G2 phases [154]. A similar relationship was
reported for activated ras and/or SV40 T-antigen transfected human diploid cells
irradiated at 2 to 8 Gy [155] and humantesticular cancer cells rendered resistant by
transfection with SV40 virus sequences [156]. Conversely, the radio-sensitising drug
caffeine both reduces radiation-induced G2 delay and concomitantly increases cell
killing [157].
AT cells demonstrate a less pronounced post-irradiation decrease in mitotic index
that was associated with a radiosensitive phenotype. Additionally, cells irradiated
whilst in G2 were significantly more radiosensitive than cells in other cell cycle
phases [158, 159]. In AT lymphoblastoid lines exposed to BrdU labelling and 3 Gy
y-rays, AT cells irradiated in S phase had an increase in G)/M arrest whilst those
irradiated in G2 showed a reduction [160-162]. Overall however, they described a
decrease in arrest for the first 2h post-irradiation, but a greatly increased delay
thereafter.
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Manyofthe control mechanisms underlying the cell cycle have been elucidated from
work in yeast. In Saccharomycescerevisiae wild-type haploid cells demonstrate a G2
delay induced followingirradiation. Cells irradiated in G2 left this arrest at a time
proportional to the dose given and continued to divide successful. Cells with mutant
Rad9 however, failed to arrest and died within a few generations. They highlighted
the importance of the delay by blocking the mutantcells post-irradiation using the
protein synthesis inhibitor cycloheximide. 4h was sufficient to produce a dramatic
increase in survival rate [163].
In the fission yeast Schizosaccharomyces pombe further evidence for a correlation
between radiosensitivity and lack of Gp arrest exists. Rad/ cells, having a mutated
version of the rad] gene were moreradiosensitive than the wild type rad/ cells and
did not arrest in response to y-rays. After 6h of density inhibition of division they
showeda greatly inceasedresistance, thus rad/ werestill repair proficient and had a
radiosensitive phenotype directly as a result of failure to arrest [164]. Mutations of
rad1, 3 and 17, result in reduced Gp arrest after UV irradiation [165]. Later, again in
response to UV radiation, a gene termed chk1 (for checkpoint kinase) was shown to
be responsible for a lack of arrest when in a disrupted form. When over-expressed in
chk1 wild-type cells, a delay in mitosis was observed. Overexpression of chk1 in
rad] mutant cells resulted in mitotic arrest. Another group of genes, hus/-hus5,
originally noted as hydroxyurea sensitive, were demonstrated to possess a UVsensitive
checkpointrole [166].
A greater G, delay along with an increasing radiosensitivity was shown by van Oostrum
et al. In five human tumour xenografts in nude mice which where exposure to ionising
radiation no effect on the timing of maximal accumulation in G2 was observed, however
the duration of this G2 delays appeared to relate to cell cycle time [167]. In three
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radiosensitive mutants of V79 cells (irs1-3), a range of Gp delays after 4 and 6 Gy were
observed. The relationship with sensitivity was not explainable by DNA damage as
measuredby differences in the induction ofDSB [168].
One of the earliest studies by Terasima and Tolmach implicated G2 as the major
componentofcell cycle delay followingirradiation with relatively low doses ofradiation
(2-6 Gy). A G» arrest of 10-20h wasseen before cells moved semi-synchronously into
mitosis [169]. Cells irradiated in M-phase did not arrest immediately, but did so in G2
after another round of division. The robust nature of this G, block was observed
following high doses (20-50 Gy) in mousecells [170]. Whilst the sensitivity of the G2
perturbance was observed to contribute to overall depression of division in HeLacells,
murine lymphoma and CHO (Chinese Hamster Ovary) cells [171]. An observation
repeated in CHOcells by Leeper and co-workers[172].
These observations are controversal. Smeets et al. irradiated two human squamous
carcinomalines, SCC61 (sensitive) and SQ20B(resistant) and found the same degree of
G» delay and induction and repair of DSB at 5 or 10 Gy [173] A larger study of six
sensitive and seven resistant human tumourlines at 2 Gy also revealed nolink between
radiosensitivity and survival [151].
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1.5 The tumour suppressor gene p53
1.5.1 Introduction
The p53 protein was originally thought to be a tumour antigen because it co-
precipitated with SV40 T-antigen; subsequently, following a convoluted process,it
wasidentified as a tumour suppressor, the function of which is central to the control
of checkpoint pathways, coordination of DNA repair with cell cycle progression,
survival or apoptosis. This vast array of functions has lead to p53 being declared the
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[178], breast [179] and brain [180]. The loss of wt-p53 protein in tumour cells
appears to provide the cell with a selective growth advantage, both in vitro and in
vivo.
p53 is clearly influential in tumourogenesis. In p53 null-mice models, a very marked
increase in the incidence of malignancies is indicative of a role of p53 in tumour
suppression. However the mere existence of mice that are p53 null indicates that p53
expressionis notin itself essential for survival [181].
Two models have been proposed to explain the role of p53 as a tumour suppressor;
briefly these could be described as cell survival, or cell death. In the cell survival
model, p53 participates in the cellular response to DNA damage by delaying cell
cycle progression. Cells have evolved elaborate mechanisms (checkpoints), the
nature of which are conserved throughout evolution to ensure genomic integrity
through faithful and accurate transmission of genetic information from generation to
generation ofthe cell and eliminating lesions and mutations that might otherwise be
perpetuated in progenycells.
In support of the cell death model, p53 protein has been shownto initiate apoptosis
in response to agents that cause DNAstrand breakage. Failure to eliminate cells that
have undergone genetic alterations following DNA damage could lead to the
appearance of transformed clones with increased growth capacity. Genetic and
biochemical studies indicate that the two properties of p53 protein, namely site-
specific binding to double stranded DNA andtranscriptional activation of genes
bearing p53-responsive elements, are closely associated with its ability to act as a
tumoursuppressor. p53 protein exhibits double stranded DNA binding activity that is
both sequence-specific and sequence-independent [182-184].
A key function of the wt-p53 protein is that it is a transcription factor; wt-p53
transactivates genes containing p53 response elements and represses a number of
genes independently of these elements [185, 186]. These p53 induced elementsactas
significant effector proteins of p53 function [187].
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With such diverse and critical activities, p53 can be thought of as a critical node in
the cellular circuitry [188]. A more detailed review of the p53 gene, the structure of
the protein and covalent modifications of the protein and how this profoundly
influences the function of p53 andits interactions with other proteins is given below.
1.5.2 Location and structure of the p53 gene
First identified as a co-immunoprecipited protein of 53 KDa with large T antigen
from monkey virus SV40 [189], it was concluded that p53 was a cellular-encoded
protein present in relatively abundant levels in transformed tumourigenic cells.
Thoughinitially thought of as a tumour antigen [190] and then later an oncogene
[191-193], it was subsequently concluded that p53 was a tumour suppressor gene
following demonstration that wt-p53 was unable to transform cells [194, 195] and
that, the wt-p53 gene or cDNA could inhibit or block the transformation of cells by
other oncogenes [196] and that wt-p53 alleles suppressed the tumourigenic potential
of p53 null cells [197].
The whole human p53 gene (introns and exons) encompasses 20kb of DNA andis
located in the short arm of chromosome 17 at position 17p13.1 [198]. A p53
homologue has been found to be present in a variety of vertebrates and is
evolutionary conserved, a further indication of its central importance to a variety of
cellular processes. The p53 mRNAis a 2.8-3.0 kb molecule that is ubiquitously
expressed.
1.5.3 Structure of the p53 protein
Analysis of the amino acid sequence of p53 protein from human, monkey, mouse,rat,
chicken, frog and rainbow trout, reveals five clusters of highly conserved amino
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acids (domains I to V) [199-204]. A contiguous stretch of 18 amino acids within
domain IV and a 12 amino acid stretch in domain V are conservedin all of the above
species (representing amino acids 237-254 and 270-282 respectively in human p53).
p53 self-associates to form homo-oligomers; the predominant form in vivo and in
solution has been found to be the tetramer [205, 206]. The oligomerisation of p53
was further supported by the observation that p53 containing mutations within its
DNA binding domain interfere with the ability of wt-p53 protein to bind DNA
following hetero-oligomerisation [194]. The mediation of this oligomerisation is
thought to be a function of the carboxyl terminus [207, 208] and occur independently
of DNA interactions [209]. Proteolysis experiments have subsequently identified
amino acids 326-355 as being responsible for the tetramerisation domain and amino
acids 363 to 393 comprising a regulatory region [210]. The tetramerisation domainis
also present in the other membersofthe p53 family, p63 and p73 [211], although the
sequenceofthis domainis less well preserved when comparedto other regions ofthe
protein [212]. This tetrameric protein structure is highly symmetrical and comprises
a dimer of dimers. Each monomeric unit contains a turn, a B strand (amino acids 326
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Figure 3. The linearised structure of p53
The above diagram depicts the lineararised p53 protein. Indicated are the
five conserved domainsalong with the regions which have been ascribed
specific and importantsites of interaction.     
to 333), a second turn and relatively stable a helix (amino acids 335 to 355). Each
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unit interacts with another unit such that the helices and B strand are anti-parallel.
Two such dimers interact, forming a four-helix bundle [213-215]. The mainly
hydrophobic interactions between the helices are stabilised by several salt bridges,
possibly between Arg337 from one monomer and Asp352 from the other monomer
[213, 216].
This carboxyl terminus does not appearto be required for interactions with DNA,nor
does the tetrameric association of p53 appearto be required. The nuclear localisation
sequence overlaps with the tetramer-structural association sequence, amino acids
316-325 suggesting that a partial DNA binding sequenceis sufficient for p53 to bind
DNA[217]. Truncated p53 protein fragment corresponding to amino acids 94-312,
which exists as a monomerin solution is capable of binding DNA in a sequence
specific manner [218] indicating that the amino acids 316-325 are not required for
DNA binding. However, etramisation of p53 increases binding as the monomers
exhibit a 10 to 100 times loweraffinity for DNA than the tetromeric form [219].
The core domainstructure consists of two anti-parallel B sheets that act as a scaffold
for three distinct structures. These structural elements include a loop-sheet-helix
motif that binds the chromatin major groove making contact with the DNA bases and
two large loops arround a core of a zinc atom. One of these loops binds the
chromatin minor groove. These three structural elements form the DNA binding
surface of p53 and contain the majority of the p53 mutations occurring in tumours.
The location of the majority of mutations within the p53 DNA binding regions
support the importance ofDNA binding and sequence-specific transactivation for the
biologicalactivity of p53 [220].
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1.5.4 Control of p53 activity
The p53 tumour suppressor protein is involved in many cellular processes. These
include cell cycle regulation, senescence, apoptosis, differentiation, angiogenesis and
DNArepair (by DNA annealing and a 3’->5’ exonuclease activity). Regulation of
p53 appears to be complex and manifested at many levels. These regulations and
activities of p53 are mediated by localisation, transcriptional activation,
transrepression, stabilisation, translation, conformational changes and various
covalent and non-covalent modifications [221, 222].
The diverse actions of p53 functions involve many target genes and interactions a
variety of proteins [175, 223-228]. The anti-proliferative function of p53 is one such
process involving protein-protein interactions and covalent modifications. This is
seen throughtheactivity of the cyclin A/CDK2 complex.Thisproliferative complex
potentiates the phosphorylation of murine double minute 2 (MDM2), reducing the
phosphorylation of p53 by MDM2 andhencepartially inhibiting MDM2-mediated
degradation of p53 by ubiquitination and providing a feed-back mechanism to
proliferation [229], a process that could be especially essential during normal growth
and development. A more complete over-view of the multitude of the events that
regulate the function of p53 is given below.
1.5.4.1 p53-protein interactions
Several proteins can interact with p53 and regulate its stability with in the cell.
Calpain 1 is capable of undertaking proteolytic cleavage of p53 [230]. Conversely,
high levels of B-catenin promotes the accumulation of transcriptionally active p53
[231], whilst Sin3a binds to the proline-rich domain of p53 and prevents the
ubiquitination dependentproteolysis of p53 in response to DNA damage [232].
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1.5.4.2 Phosphorylation of p53
Covalent modifications such as phosphorylation can regulate conformational and/or
promote specificity to p53 for protein binding and promotion of transcription.
Phosphorylation of the p53 protein in vivo has been shown to occur at multiple serine
and threonine residues. The phosphorylation sites have been identified by several
approaches including phosphopeptide mapping, direct sequencing of
phosphopeptides andsite-directed mutagenesis. These sites of phosphorylation are
 
 
Proteins interacting Aminoacidwith p53 chosphordaed Effect on the p53 protein
ATM Ser 15 Stabilization, transcriptional activation, growtharrest.
DNA-PK Ser 15, 37 Stabilization, transcriptional activation.
ATR Ser 15 Stabilization, transcriptional activation.
JNK Thr 81 Stabilisation (in UV stressed cells).
CDK7/CycH/p36 Ser 33 Transcriptional activation.
Homeodomain-. . Transcriptional activation of p53A1P1 and apoptosis
interacting protein Ser 46 . .inducing genes.
 
 
Kinase-2
p53DINPI Ser 46 Promotion ofApoptosis
Wipl Ser 46 Dephosphorylatory inhibition of apoptosis
CHK1 Ser 20 Stabilisation
CHK2 Ser 20 Stabilisation
CDK4
CDK’s Ser 315 Transcriptional activation.
COP9 Thr 155 Proteolysis
p38 Ser 392 Transcriptional activation.
CK2/hSpt16/SSRP1 Ser392 Transcriptional activation
Casein Kinase I
Casein KinaseII Ser 392 Transcriptional activation.
Polo-like kinase-3 Ser 20 Stabilisation
Phosphorylation led ubiquitination/proteolysis.
Protein Kinase C Ser 371, 376, 378 , . ,Dephosphorylation induced transcriptional activation.
RAF-1 Serine Unknown     
Table 4. Theprotein interactions with p53, and the phosphorylation events
associated with these protein-protein interactions.    
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summarised in Table 4 above. Phosphorylation of p53 on Serine 46, for example, is
required for the induction of the apoptotic gene p53A1P1 [233] and inhibition of the
kinase responsible for Serine 46 phosphorylation by the phosphatase WIP1, whichis
also p53-inducable, inhibiting the ability of p53 to activate apoptosis [234]. The
induction of tetramerisation of p53 could be stimulated by the phosphorylation of
p53 at serine-392 [235]. A number of kinases have been implicated in the
phosphorylation of p53. Double-stranded DNAactivated protein kinase (DNA-PK)
[236], Casein Kinase I [237] and Casein Kinase II [238] have been shownto affect
the DNA binding potential ofp53 [239]. The cell cycle kinase CDK4, whoseablation
results in the non-phosphorylation of p53 [240] and of significance to this study the
MAP Kinase pathway has been shownto phosphorylate p53 [241, 242].
1.5.4.3 Ubiquitination
Ubiquitination of p53 represents an essential activity of MDM2in the regulation of
the level of cellular p53 protein. The half-life of p53 protein is relatively short [243].
However, following DNA damage, such as that caused by ionising radiation, there is
a rapid accumulation of the p53 protein [225]. A key componentin this regulation of
p53 protein level is MDM2. This MDM2 regulation of p53 is multifaceted. MDM2
acts specifically as an E3 ligase for p53 by linking E2-conjugated ubiquitin
molecules to p53 via an isopeptide bond [244] and has been shownboth in vitro and
in vivo to cause p53 degradation [245]. Additionally, MDM2 binds p53
transactivation domain, inhibiting p53 promoted transcription and promotes p53
nuclear export to the cytosol whereit is degraded by the 26S proteosome [246, 247].
The human papillomarvirus HVP E6also utilises the same process to promote p53
degradation by the ubiquitin-proteasome [248]. Limiting p53 protein life-span may
seem beneficial in promoting tumourogenesis, as elevation of MDM2 has been
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observed in tumours retaining wt-p53 [249]. However, MDM2 mediated
ubiquitination and destruction of p53 is essential for embryonic development and
survival [250], in the adult MDM2over-expression can subvert cellular mechanisms
to give rise to cancer [251].
1.5.4.4 Acetylation of p53
Acetylation has been shown to be an important modification of histone proteins and
correlates with transcriptional activity [252, 253], although the precise role played in
transcriptional regulationisstill unclear. Recent studies revealed several proteins that
can stabilise the p53 protein. The transcriptional co-activator CBP/p300, which can
mediate p53 transcription and activation is a histone acetyl transferase (HAT), has
been shown to be active both in vitro and in vivo [254-257]. Acetylation directly
influences DNA binding, protein-protein interactions and protein stability. p53 is
acetylated at multiple lysine sites at the carboxyl terminus [258], with the level of
acetylation being enhanced in vivo and has been shownto be essential for radiation
induced accumulation of c-JUN protein through activation of wt-p53 [259]. The
acetylation of p53 by p300is inhibited by MDM2 [260]. These acetylation sites of
p53 are essential for ubiquitination and the subsequent degradation of p53 by MDM2
as described above [261, 262].
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1.5.4.5 Sub-cellular localisation of p53
p53 transcriptional activity requires nuclear localisation of p53 protein [263].
Nuclear localisation of cytosolic p53 has been observed as a cellular response to
various cellular assaults [264]. The active transport of p53 by dynein and the
microtubule network is fundamentally important [265, 266], as are the C-terminal
nuclear localisation motifs on p53 itself [267]. Following nuclear localisation
relocation to the cytosol is an actively process. p53 possesses several nuclear export
sequences, one in the oligomerisation domain [268] and a second in the N-terminal
MDM2 binding region [244, 269]. The activity of the N-terminal nuclear export
sequenceis regulated by phosphorylation and is down-regulated in response to DNA
damage[69].
1.5.5 Determination of cellular fate and p53 function
p53 may promote growth arrest and potentially survival, or conversely cell death via
apoptosis. How the cell decides between these twocellular responsesis unclear [270,
271]. The determinants of these alternatives appear to be diverse and include the
origin of the cell, the oncogenic genotype, external cellular stimuli and the intensity
and duration of the genotoxic stress incurred, as well as the level of p53 expression
within the cell. These processors are not activated in a simple linear fashion because
the damage recognition elicits multiple signal transduction cascadesthat can trigger
both repair and apoptosis. Individually, and in concert, these factors may all
influence the response ofthe cells decision-making process.
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1.5.6 The natureof the cellular assault and p53 response
The different nature and the severity of cellular damage may contribute to the level
of, and be surveyed by p53 within the cell. Exposure offibroblasts to different doses
and different forms of UV-irradiation induced different expression responcses. Low
doses of UV-B (50 J/m’) caused a p53 dependent induction of p21 gene expression,
whilst at higher doses (>200 J/m?), the pro-apoptotic protein, bax was induced [272].
Similar trends were observed following exposure to UV-C [273]. However, in
contrast to UV-irradiation, high doses of y-radiation act to further potentiate p21
gene transcription [274], whilst Matrix metalloproteinase-1 is elevated by UV
radiation and may promote long term cell damage and cancer by suppressing p53
expression by recruiting p300 and c-Jun [275].
1.5.7 Anti-proliferative nature of p53
As previously descussed, p53 is capable of mediating powerful inhibition of cell
proliferation. It is not unreasonable to surmise that the tumour suppressor function of
p53 dependsprincipally on its ability to prevent cellular proliferation in response to
stress stimuli that are encountered during tumour genesis. In this context, activated
p53 has been shownto lead to cell cycle delays and apoptosis. Activated p53 can
also play a role in the induction of differentiation and the cellular response to
ionising radiation [276-278].
The role of wild type p53 as a negative growth regulator was indicated following
studies of p53 complexingto viral oncogene protein products when it was found that
wt-p53, but not mutant-p53, binds to SV40 large T antigen, thereby indicating that
p53 interaction with the cellular homologue of T antigen could becritical for cell
cycle control [279]. This has been further demonstrated in gene transfer experiments
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in which a functional wt-p53 gene wasre-introduced into transformed cells that had
lost endogenous p53 gene expression through a recessive mutation. The most
common outcome of these studies was growth arrest of the recipient cells in a
quiescent manner [280, 281]. In other studies, wt-p53 protein expression resulted in
apoptosis [282, 283]. A third outcome of wt-p53 expression in p53-null tumourcells
was the induction of differentiation [284]. Moreover, in many cell types terminal
differentiation resulted in apoptosis. Hence, three different outcomesfrom restitution
of wt-p53 protein reconstitution may be dependent on the lineage and maturation
potential of the recipient cells.
1.5.8 p53 mediated responseto ionising radiation
The ability of ionising radiation to induce cell cycle perturbation was demonstrated
in human andrat fibroblasts, where it induced a transient and prolonged G, delay
[285]. Ionising radiation induces a large variety of DNAlesions, including single-
strand breaks and DSB, as well as base and sugar damage [286-288]. Though cells
can adaptto low levels of irreparable DNA damage [289, 290]; one DNA DSB ina
multicellular organism can be sufficient to kill a cell if it is located in an essential
gene. In response to DNA damage, checkpoints induce the signal transduction
cascades, whichconsist of sensors, transducers and effectors [291-293]. The ionising
radiation induced effectors respond to DNA damagebya) perturbation ofcell cycle
progression, b) DNA damagerepair or c) apoptosis [294].
One of the key components of cell response to ionising radiation is p53, “the
guardian of the genome’ [174]. Whether a cell undergoes cell cycle arrest or
apoptosis in response to p53 depends on complex array of mechanisms [295].
Several factors comeinto play, such asthe presence ofextra cellular survival factors,
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the presence of other oncogenic alterations, the level of p53 and the availability of
additionaltranscription factors or cofactors [296].
1.5.9 Ionising radiation mediated p53 expression level and activity
The type and magnitude of cellular stress may modulate p53 function by affecting
the level or activity of the p53 protein that is induced. Modulating p53 expression
level may protect cells or promote apoptosis. Interestingly, relatively low levels of
p53 have been observed to possess anti-apoptotic functions [297], whilst activation
of apoptosis is associated with higher levels of p53 than those required forcell cycle
arrest [298]. These independent observations are further supported by the response of
bone marrowcells to ionising radiation. The presence of one p53allele is associated
with induction of an intermediary response between that induced by homozygous,
two allele, wt-p53 and p53-null cells which lack both p53 alleles [299]. How the
level of p53 orchestrates the cellular response to ionising radiation isstill unclear.
However, promoters regulating expression of apoptotic genes could bind p53 with a
loweraffinity than those involved in cell cycle arrest, as would appear to be the case
for p21 and Baxtranscription. This would inducecells to undergo cell cycle arrest in
preference to apoptosis. Several mutants of p53 show selective loss of the ability to
activate apoptosis target genes and to induce apoptosis. Such cells potentiate cell
cycle arrest [300-303]. Alternatively, the affinity of p53 to target promoters may be
regulated by conformational change [304].
Beside the intrinsic level of p53 at the time of the induction of DNA damage, the
level of p53 following genotoxic assault is observed to rise. In fibroblasts this
elevation was associated with alterations in mediation of cell cycle distribution [305],
which further increased the potential cellular response of p53 to DNA damage. This
ES)
increase of p53 level could tilt the cell balance away from cell cycle delay and
survival, towardscell death and apoptosis [306].
1.5.10 Cell cycle delay mediated by p53
Cell exposure to genotoxic assault frequently results in abolition of cell cycle
progress [307]. As previously suggested, it is assumed that the transient delays
observed in G;, S and G2+M provide time for repair of damaged DNA prior the
initiation or continuation of replicative DNA synthesis or the onset of mitotic
reproduction. Such damaged DNAifnot repaired could facilitate the propagation of
potentially deleterious mutagenic lesions, contributing to the progressive
accumulation of genetic changes that typify neoplastic transformation.
The cell cycle arrest function of p53 correlates strongly with its ability to function as
a transcription factor [308, 309]. Its pivotal roles in checkpoint control result from its
unique biochemical features. As stated earlier in the ‘Structure of the p53 protein’
(section 1.5.3) there are five conserved domains. It is within these five regions that
the majority of mis-sense mutations are found in human tumours as reviewedby EI-
Deiry [310]. wt-p53 can both activate and repress gene transcription resulting in the
mediation of the cellular response to ionising radiation and genotoxic assault. The
role of p53 as a tumour suppressor protein is significantly influenced through its
‘effector’ proteins that are producedas a result of p53 transcriptionalactivities.
Of the myriad of p53 target genes identified, p21”! “?' appearscritical in the
processess influencing cell cycle delay [126, 311]. p21 acts as a CDKI that can
activate both G; and G>+Marrest in a similar manner to those seen in response to
p53 induction itself [312, 313]. Besides the potential modulation ofcell cycle delay,
it has been demonstrated that p53 can play a direct role in the repair ofDNA damage,
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both through nucleotide excision repair and base excision repair [314-317]. This
complex and diverse nature of p53 in cell response to genotoxic events further
underlines p53’s importance to the cell, as of North and Hainaut put it ‘Having a
finger in every pie’ [188].
1.5.10.1 p53 in G, cell cycle checkpoint control
Checkpoints are control mechanisms that ensure the proper timing of cell cycle
events by requiring the completion of earlier processes before the initiation of later
cell cycle events [318]. The p53-mediated G, checkpoint can be disrupted in a
numberofdifferent ways including mutation of the p53 gene [319], by expression of
certain cellular or viral proteins that interact with p53 protein and interfere with its
transactivation function, as well as by other mechanisms that affect upstream or
downstream components of the p53 growth-control pathway. For example, over-
expression of MDM2 protein results in p53-MDM2interactions and loss of p53-
mediated transactivation and G; checkpoint function in response to irradiation [320].
Cells from individuals with AT show an abnormalresponseto irradiation;relatively
higher dosesofirradiation are required for p53 induction [321]. It has been suggested
that the ATM geneproductis required for the induction of p53 protein. Expression of
the human papilloma virus HPV-E6 and E7 sequences abrogate the p53-dependent
G, checkpoint in a number of humancells treated with PALA, y-irradiation and
actinomycin D [322, 323]. In these models it has been suggested that E6 promotes
the degradation of p53 while E7 protein binds and inactivates Rb protein.
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1.5.10.2 Role of p53 in the S-phase completion checkpoint
Inhibition of DNA synthesis triggers the S-phase completion checkpoint, which
blocks entry into mitosis. The signal that activates this checkpoint is generated when
cells are blocked in S-phase. Signals that activate the S-phase completion checkpoint
mayincludestalled replication machinery and DNA damagethat results in prolonged
inability to undertake DNA synthesis. Ionising radiation is capable of inducing
progression delaysin the cell cycle [324].
Treatment of cells with caffeine, okadaic acid or staurosporine can override the S-
phase completion checkpoint, causing apoptotic like phenotype of premature
chromatin condensation, DNA fragmentation and cell death [325-328]. In fibroblasts
derived from Li-Fraumeni cells (MDAH041), treatment with hydroxyurea induces
the above phenotype. But following transfected with wt-p53, prevention of cell entry
into mitosis by hydroxyurea treatment is reinstated, implicating wt-p53 in S-phase
checkpoint control [329]. Similarly, HPV-E6 transformation of the in vitro normal
lung fibroblasts IMR-90, cells are more prone to caffeine-induced premature
chromatin condensation than the parentalcell line with functional wt-p53 [330]. The
lack of functional ATM negates the S-phase checkpoint, whichis also influenced by
NBS1, CHK2, CDC25A, BRCA1, SMC1 and MRELI in response to ionising
radiation [331-335].
1.5.10.3 Regulation of the G,+M transition and checkpoint control by p53
The deregulation of the G2+M transition is a commonfeature of cell immortalisation
and malignant transformations [336-339]. The G2 checkpointis triggered in cells that
have completed DNA synthesis but contain damaged DNA.Intuitively, this would be
essential in preventing the proliferation of genetic defects to progeny cells and both
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the S-phase and G2 checkpoint block entry into mitosis and could hence ensure
genetic integrity. However, the G2 checkpoint causescells to arrest; determination of
the significance of the role of p53 in Gp arrest is problematic due to the existence of
p53-independent mitotic bocks. p53-null cells still demonstrate a G2 response to
genotoxic events [305]. However, the nature of the response, such as the duration of
cell cycle delay, may besignificant in cell fate and dependent upon the function of
p53, rather than solely its p53 mutational status. The role of p53 as a secondary
regulator in Gp delay appears convincing [338, 340].
Studies employing viral oncogenes have implicated wt-p53 in the operation and
maintenance of the Gy checkpoint. In IMR-E6 cell, HVP-E6 infected and
transformed cells undertake an increased entry into mitosis in response to ionising
radiation [341]. Thus suggesting that wt-p53 is involved in progression through the
mitotic checkpoint. Alternatively, E6 could encourage genetic and epigenetic events
that negate the G) checkpoint [342]. Studies utilising large T antigen of SV40 in
IMR-90 cells demonstrated that thoughcells still delay in Gp, the duration ofthis
reversible delay was reduced [330]. Although both these viral oncogenes implicate
p53 in G> checkpoint progression, they both may act in a p53-independent manner.
However, further studies using homologous recombination in the human colorectal
carcinoma cell line HCT116 [343] reinforced the importance of wt-p53 in G)
progression, by demonstrating that the duration of G2 delay was shortened by the
absence of functional wt-p53.
1.5.10.4 Mechanisms of G, arrest
Progression of G)+M is dependent upon CDK1 which is encoded by the cdc2 gene
[344]. Several of the transcriptional targets of p53 can inhibit CDK1. Briefly, p21
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can inhibit CDK1 directly, via inhibition of nuclear localisation [345], as does weel
by phosphorylating threonine14 and tyrosine15 and preventing the cdc25c mediated
dephosphorylation and activation [346], 14-3-3 blocks nuclear localisation of CDK1
gain through the inhibition of cde25c [347] and GADD45, which causes CDK1 to
dissociate from cyclin B1. Repression of both the genes for cyclin B1 and CDK1 by
p53 can further inhibit G2+M progression. A further potential mediator of the G7+M
arrest is Reprimo [348]. Reprimo is a glycosylated cytoplasmic protein; its
expression is induced following cellular exposure to ionising irradiation. Reprimo
causes cells to arrest in Gy and over-expression of this protein results in hypo-
phosphorylation of CDK1, although the mechanism involvedis uncertain.
Another way that p53 may regulate CDK1is by inhibiting cyclin B1 transcription.
Following over-expression of wt-p53, p53 has been shownto bind to a region of the
upstream promoter of the cyclin Bl gene, inhibiting cyclin Bl expression and
resulting in a reduction in cyclin B1 protein level, hence inhibiting CDK1activity
which is dependent on forming a holoenzyme complex with cyclin B1 [349, 350].
Though CDK1 maybe central to wt-P53 induction of G2+M cell cycle delays, it is
not the only mechanism by which such delays may occur. Two such CDK1 —
independent mediators of G2+Mtransit may be B99 and MCG10 [351, 352].
1.5.11 Conclusion
Therole of p53 in mediating progress through the mitotic cell cycle has been studied
in great detail. Despite this extensive interest, the involvement of the tumour
suppressor gene p53 in the transition of G2+M isstill unclear. A growing body of
evidence is beginning to suggest that a link betweenthe anti-proliferative effects of
p53 and the mitogenic role of the MAP Kinases is significant in cell cycle
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progression, not only in Gj, but also in G)+M phasesofthe cell cycle [353, 354]. It
may well be that p53 is involved in the checkpoint control mechanismsthat ensure
the proper timing of cell cycle events through enforcing the dependency oflate
events on the completion of earlier events [318].
Indeed there is muchliterature supporting p53-mediation of the G; checkpoint which
can be disrupted in a numberofdifferent ways including mutation of the p53 gene
[319], by expression of certain cellular or viral proteins that interact with p53 protein
that interfere with p53 trans-activation, as well as by other mechanismsthat affect
upstream or downstream components of the p53 growth control pathway. For
example, over-expression of MDM2protein results in p53-MDM2interactions and
loss of p53-mediated transactivation and G, checkpoint function in response to
irradiation [320]. Cells from individuals with AT show an abnormal response to
irradiation; relatively higher dosesofirradiation are required for p53 induction [321].
It has been suggested that the ATM gene productis required for the induction of p53
protein. Expression of the human papilloma virus HPV-E6 negates the p53-
dependent G; checkpoint in a number of human cells treated with PALA, y-
irradiation and actinomycin D [322]. In these models it has been suggested that E6
promotes the degradation of p53. Further studies utilising viruses, in this case the
large T antigen of SV40 in IMR-90 demonstrated that thoughcells still delay in Gp,
the duration of this reversible delay is reduced [330]. These data highlight a role for
p53 in determining cellular response to DNA damageprior to the completion of
mitosis.
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1.6 The proto-oncogene RAF-1
1.6.1 Introduction
The importance of the signal transduction pathway incorporating MAP Kinases in
the progression and induction of human cancers was suggested when RASprotein
wasidentified as the first human oncoprotein with its gene being a mutated version
of a normal H-RASallele [355]. Effectors of the RAS protein were then sought in an
attempt to understand the molecular function and role of this oncogene. The
elucidation of RASastheinitiator of a MAP Kinase pathway subsequently followed
[356]. Upon stimulation ofcell surface receptors by mitogenic stimuli, RAS acts as
an effector molecule, conveying the signal at the plasma membrane to the nucleus
via a series of complexsignal transduction cascades containing many members [357].
One such cascade is the RAF-1/MEK/ERK signaltransduction cascade [358].
1.6.2 The Raf family
The RAF family of serine/threonine-specific kinases consists, in mammals, of three
members, A-RAF, B-RAF and c-RAF or RAF-1. RAF-1 has been shown to be
highly conserved [359] and ubiquitously expressed in normal and tumour tissues
[360, 361]. Whereas RAF-1 is ubiquitously expressed, the tissue distribution of A-
RAF and B-RAF is morerestricted. A-RAF is predominately expressed in urogenital
tissues [362] and B-RAF in neuronal tissues [363]. In addition, the B-RAF gene
encodesseveral isoforms ofB-RAF whose expression is regulated in a tissue-specific
mannerbyalternative splicing [364].
B-RAF hasgained prominencein the literature recently because of the relevance in
carcinogenesis. Moreover B-RAF has become an important target of anti-cancer
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therapy. B-RAF mutations have been reported to be extensive in human astrocyte,
melanomas, colon, lung and thyroid cancers [365-372]. With miss-match mutants
being identified that dissociates B-RAF from the MEK/ERK signal transduction
pathway [373]. Similarly, A-RAF and RAF-1 are implicated in rat cell proliferation
[374]. Somewhat contradictory though, not only can over-expression of B-RAF
mutants result in an increase in proliferation, but cell cycle arrest has also been
observedin several cell types [375], and activated RAF-1 causes cell cycle arrest in
small cell lung cancers [376]. Thus the type ofRAF expressed, the isoforms, and the
tissue that it is expressed in, are instrumental in determining the outcome of RAF
involvementin cell cycle regulation.
The ubiquitous distribution of RAF-1 is indicative of a significant role in cellular
regulation. The preservation of normal RAF-1 expression in tumours, although
sometimes abrogated, suggests a significant role in cell survival as well as in tumour
development.
1.6.3 MAP kinases and the RAF-1 signal transduction pathway
The mediation ofa variety of cellular events is undertaken by protein members ofthe
Mitogen-Activated Protein Kinase (MAP Kinase) cascade. These events are manifest
in diverse actions including the induction of cell division [377, 378], differentiation
[379], transcription of proto-oncogenes [380] and promotion of tumourogenesis in
both in vitro and in vivo systems [381, 382], as well as, somewhat paradoxically the
induction and prevention [383] of programmed cell death and the induction of
senescence [384].
The MAP Kinase cascade consists of three enzymes, which undergoserial activation;
an example ofthis is depicted in Figure 4. RAF-1, which acts as a cytosolic signal
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transduction factor [385], is a MEK Kinase,
MEKK
a member of a diverse multi-gene family (MEK Kinase, RAF-1)
[386]. RAF-1 is the primary memberofthis
MAP kinase cascade. RAF-1 binds to 14-3- MEK
(MAP/ERK Kinase)
3, a specific phosphoserine-binding protein
[387], via the amino-terminal region of MAP Kinase or ERK1/2
RAF-1 to former a dimeric complex [388]. (Mitogen Activated ProteinKinase)
This RAF-1-14-3-3 dimer then undergoes
oligomerisation to a second RAF-1-14-3-3 Figure 4. Depiction ofthe MAP
Kinase protein kinase cascade
dimer produce a quaternary dimeric (dimer     
of dimers) complex [389, 390]. RAF-1 is then sequestrated from the cytosol to the
plasma membrane [391].
RAF-1 is activated following binding to and phosphorylation by the active tyrosine
kinase Gs (GTP-binding, stimulator of adenylate cyclase) [392]. GTP
phosphorylation of RAF-1 is carried out by the GTPase, G,; protein, a membrane
bound GTPase membrane bound GTPase[393-396].
The RASbinding domain in RAF-1 is located towards the amino terminal, within
amino acid residues 51-131 [397], with a secondary site of interaction at residues
139-184 [398], within the conserved cysteine finger motif within the cysteine-rich
domain (Figure 6, RAF-1 structure). This secondary RAS interaction site may be
responsible for RAS-mediated 14-3-3-RAF-1 complexdissociation [399]. Additional,
and as yet uncharacterised phosphorylation-dependent and _phosphorylation-
independent modifications of RAF-1 activity result in complete activity of RAF-1
kinase function [400]. Activation and indeed inactivation of RAF-1 appears to be
regulated by at least seventeen sites as summarised in the Table 5 [400-412].
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Activated RAF-1 species then “Amino Acid Site ofphosphorylation
. Serine 29, 43, 58, 218, 222, 228,phophorylate and activate the 733. 259. 289. 296. 301
: : : . 338, 339, 494, 497, 499,intermediary serine/threonine 619. 621. 624. 642
Threoni 268, 2kinase MEK. This is achieved Tyrosin == ZI  
through the phosphorylation of Table 5. Summary of phosphorylation sites of
RAF-1  two serine residues (Ser), Ser-    218 and Ser-222 [402].
RAF-1 is expressed at a relatively low abundance within cells when comparedto its
target kinase MEK [413]. This feature allows for rapid signal amplification from
RAF-1 to MEK1/2, which can in turn be conferred to the subsequent and final
memberof this cascade, ERK1/2 an effector molecule with many cellular targets.
Following phosphorylation of MEK, RAF-1 activity is down-regulated to pre-
stimulated levels, levels that are associated with phosphorylation of RAF-1 at Ser-
259 [406]and Ser-621/624 [411], re-binding of 14-3-3 to the amino terminus ofRAF-
1, and recycling of RAF-1 to the cytoplasm [400].
MEK demonstrates a dual specificity with regards to its ERK kinase role, as it
phophorylates ERK on both a tyrosine anda threonineresidue [414], thus promoting
activity [415]. Tyrosine phosphorylation precedes threonine phosphorylation in vitro
[416], and the phosphorylation of both aminoacids is required for full and significant
activation of RAF-1 [417].
The activated ERK1/2 are pleiotropic modulators of cell function. The activated
MAPkinases exert an influence on gene expression patterns by phosphorylating
cytosolic proteins, which trigger target gene transcription. ERK1/2 is also
translocated to the nucleus, where ERK1/2 can then affect gene expression both
directly and indirectly by phosphorylating several transcription factors [418, 419].
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 OMitogen
Plasma .InactiveMembrane
 
Activation
  Figure 5. Summary of the MAP kinase pathway.Depiction ofthe signal transduction pathway from a mitogen activatedtyrosine kinase receptor to nuclear transcription through the RAF-1, MEK,and ERK pathwayas described in the abovetext.   
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The sequential phosphorylation cascade from RAF-1 to ERK is thought to be
coordinated by the Kinase Suppressor of RAS (KSR) scaffolding protein. This KSR
scaffolding protein holds the three kinases of the MAP kinase pathway in close
special proximity, thus facilitating the phosphate relay [420]. This mammalian
homologue of the Drosophila and C.Elegans protein, associates with RAF-1 at the
membrane in a RAS-dependent manner. Both RAS and RAF-1 are proto-oncogenes,
so it is not surprising to find that this MAP Kinase pathwayis principally involved
with growth regulation, be it apoptosis, or differentiation, with the biological
outcomebeing determined by the strength and duration of the MAP Kinase pathway
activation [421]. Though considerable investigation has been undertaken into the
activities of the ERK members of the MAP Kinase cascade [422], it is the primary
memberofthis cascade, the MEK kinase RAF-1 that may prove the mostsignificant
determinantfor cellular response in radio-sensitivity.
The controls that regulate the MAP kinase pathway activity appear to operate at the
level of RAF-1 [423, 424]. The MAP kinase cascade that is comprised of RAF-
MEK/ERK MAP kinase is described as a “singularly linear signalling pathway”
[425]. RAF-1 demonstrates stronge substrate specificity for MEK both in vivo and in
vitro. Additionally, ERK1/2 is the only identified substrate for MEK [426]. However,
several lines of investigation have indicated that RAF-1 may have other effectors in
addition to those of MEK/ERK MAP Kinase pathway (See Table 6) [427]. Similarly,
several groups have indicated that MEK Kinaseactivity is not required for RAF-1
activity [428-443], be it in differentiation in neuronalcells [444], or adipocytes [445],
or even the induction of apoptosis in cells transformed by viral oncogenes [446].
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Though the exact mechanisms by which RAF-1 exerts its influence are complex and
still imperfectly understand, it is obvious that RAF-1 is instrumental in determining
cellular fate.
 
Substrate Cellular responce
P70 S6 Kinase Cell proliferation
 
 
 
 
pRb Cell Cycle regulation
p53 Unknown
Tvl-1 Transcription
CK2 Cell Survival
BAD Cell Survival
ASK-1 Cell survival
Cdc25A Cell Cycle
MEK Proliferation
RIP2 Stress Signalling
Bcl-2 Apoptosis
Grb10 Growth
MEKK-1 Cell proliferation  Table 6. The abovetable contains a summary ofRAF-1 substrates and the effect upon the cell bythe RAF-1-substrate interaction.    
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1.6.4 The RAF-1 protein
The RAF-1 gene codes for a 74 kDa cytosolic protein, which is positively regulated
by serine/tyrosine phosphorylation [447]. The cytosolic localisation of RAF-1 may
be a function of the protein complex formed between RAF-1 and the Heat Shock
Protein HSP90. The interaction with the HSP90 chaperone appears essential for
RAF-1 stability and function [448]. The structure of RAF-1 is depicted in Figure 6
below. RAF-1 comprises of three conserved regions [449]: CRI is a regulatory
domain containing a zinc finger-like motif homologousto that found in PKC,andis
located towards the N-terminal; CR2 is a serine/threonine rich region prompting
speculation that this region contains sites of regulator phosphorylation; CR3 is
located in the C-terminal region and contains the protein kinase domain [450] which
is negatively regulated by the CR2 domain [398, 451].
 
CRI CR2 CR3
1 62 195 255 268° 330 608 648
N’ Cc
51 131
RBD
Zinc finger-like motif
Regulatory Komain Catalytic Domain  
Figure 6. RAF-1 protein structure.
Thefull, linearised, length of the RAF-1 serine/threonine protein kinase is shown
above. The three conserved functional regions of the protein (CR1, 2 and 3), and
areas of other significant protein-protein interactions and amino-acid numbersare
also indicated.    
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RAF-1 becomes oncogenic asa result of automatous up-regulation of the C-terminal
kinase region. A common wayin which this can happen is by partial expression,
whichresults in a truncated 48 KD protein [94]. The binding site of RAS to RAF-1
(RAS binding site-RBD) overlaps the N’-terminal region of CR1: amino acids 51-
131 appear to comprise a minimalbinding region for activated RAS [452, 453]. The
association of the RBD with the RAS effector domain is a high-affinity interaction
(Kp=20nM) [454], which is mediated primarily by residues Glutamine-66, Lysine 84
and Arginine 89 of RAF-1, with Lysine 84 appearing central to RAF-1 effector
discrimination [455]. The secondary RASbinding site within the CRD may mediate
RAF-1 interactions with 14-3-3 [399], and a putative lipid ligand [358].
1.6.5 Cell cycle regulation by RAF-1
Several mitogenic growth factors stimulate the entry of somatic cells into the cell
cycle and subsequentcell division. Exogenoussignals, which stimulate cell division
via the MAP Kinase pathway, include Epidermal growth factor [456], and PDGF
[457].
1.6.5.1 Relationship ofRAF-1 regulation in G;
Over-expression of A-RAF, B-RAF, and RAF-1, results in opposing outcomes of
cell cycle proliferative response, and appears mediated through the MAP kinase
cascade. The RAF-1 MAP kinase signal transduction cascade plays
a
critical role in
the regulation of growth factor-induced cellular proliferation. Cell proliferation has
been observed in several model systems, both human and murine, following the
over-expression of activated RAF proteins [458, 459]. RAF-1 protein, transcribed
underthe inducible oestrogen receptor (ARAF:ER), have been used to determinethe
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role of RAF kinases in the cell cycle control of fibroblasts through the regulation of
cyclins, CDK’s and CDK inhibitors including p21 and p27 [460]. When over-
expressed p21 and p27 been shownto inhibit cell proliferation in human fibroblasts
[125]. Prolonged strong RAF-1 signalling through the MEK/ERK proteinsresulted in
significant induction of p21 and cell cycle arrest [460].
1.6.5.2 The role of RAF-1 in mitosis
RAF-1 is hyper-phosphorylated on serine residues resulting in RAF-1 activation in a
wide variety of cells reguardless of tissue origin [461-463], although ERK is a likely
candidate as it demonstrates multiple potential phosphorylation sites [412]. The
hyper-phosphorylation retards RAF-1 electrophoretic mobility, although the number
of sites, or effect on activity, is uncertain. In Jurkat cells, Lck, a member of the Src
kinase family, binds and activates RAF-1 during mitosis. This activation is absent in
Lck-negative Jurkat cells [464].
Localisation to the plasma membraneorinteractions with 14-3-3 does not appear to
be required for RAF-1 involvement in mitosis. However the zinc-finger like motive
does appear instrumental for RAF-1 mitotic activations and hyper-phosphorylation,
with phosphorylation at either Ser-338 and Ser-339, or Tyrosin (Tyr)-340 and Tyr-
341 facilitating activation of RAF-1 in mitosis [465].
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1.6.6 RAF-1 and cancer
RAF-1 wasoriginally identified as the normal cellular counterpart of v-RAF [466],
the oncogene of murine transforming sarcoma retrovirus 3611, which encodes a
fusion protein comprising the kinase domain of RAF joined to a myristylalated viral
gag sequence [467]. Oncogenic RAF-1 has been reported in a variety of cancers, and
RAF-1 has been shownto transform erythroid, fibroblasts and epithelial cells [468].
RAF hasalso been shown to promote transformation when co-expressed with the
oncogenes Myc and Hras [469, 470], whilst a number of oncogenes activate the
MAPKinase pathway, which is thought to aid oncogenic transformation [471].
Besides RAS activation, RAF-1 may be activated in a RAS independent manner
[399], and though the MAP kinase signal transduction pathway is often considered a
singularly linear process, RAF-1 has also been reported to interact with the
eukaryotic cyclin dependent kinase cdc25, in particular with cde25B [436], directly
affecting cell cycle progress. RAF-1 may also directly influence cell cycle events
through the key proto-oncogene Retinoblastomaprotein, and has also been shown to
phosphorylate p53 in vitro [427].
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1.6.7 The response of RAF-1 to ionising radiation
RAF-1 localisation and activation has been demonstrated following ionising
radiation, to result in sequestration to the plasma membrane. RAF-1 subsequently
undergoes tyrosine phosphorylation [472]. RAF-1 has been associated with cellular
radio-resistance in several studies. Activation of the ERK pathway following
radiation is influenced by both the RAS and p53 status (mutant or wild type) of a
given tumour type [473]. RAF-1 has been linked with resistance to radiation in
fibroblasts from patients with the Li-Fraumeni syndrome [474] and subsequent
transfection of DNA from those cells into NIH3T3 mouse fibroblasts resulted in a
RAF-1 linked increase in radio-resistance [475]. Similar transfections were achieved
with DNA from a range of radio-resistant squamouscell carcinomas of head and
neck origin with the same resultant increase in resistance of the recipient fibroblasts
[476]. RAF-1 was further implicated by the use of anti-sense RAF-1 cDNAin the
human laryngeal carcinoma cell line SQ20B, increasing radio-sensitivity whilst
reducing tumourigenic potential [477]. Furthermore, humanbronchialepithelialcells,
immortalised with RAF-1 displayed an increased resistance to ionising radiation
[478], and antisense oligonucleotides to RAF-1 have been shown in vitro and in vivo
to enhance the radiosensitivity of tumour cells [479]. By contrast, in an extensive
panel of 19 Humancancercell lines representing a variety of malignancies, high
levels of RAF-1 protein correlated with radio-sensitivity [480]. Activation of the
RAF-1 Map Kinase pathway following irradiation has been found to promote
radiosensitivity in somecell types by abrograting the G2+M checkpoint[481, 482].
In addition to playing a role in the activity of the ERK pathway, it is important to
note that radiation-stimulated RAF-1 may act upon substrates other than MEK1/2,
such as the myosin-phosphatase-binding protein [483]. RAF-1 has also been
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proposedto act as an inhibitor of apoptosis signalling kinase 1 (ASK1) by bindingto
ASK1: the inhibitory action of RAF-1 was reported to be independent of RAF-1
protein kinase activity [435].
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Chapter 2
Materials and methods
55
2 Materials and methods
2.1 Routine culture of the human cancercell lines
2.1.1 Introduction
Six Human cancercell lines were chosen to reflect a variety of histological types of
malignancy and also represent a range of intrinsic cellular radiosensitivities and
RAF-1 protein levels as previously determined [480], and it was found that the rate
of Go+M exit following radiation induced G)+M delay correlated with RAF-1
protein level and radiosensitivity [481]. It was subsequently established by DNA
sequencing that the six cell lines initially chosen to study G2+M delay transition
expressed wt-p53, and an additional 13 human cancercell lines, those used in the
1994 studies, were then screened to select a further 6 cell lines that expressed a
mutant-p53 [484]. The cell lines and their histological phenotype are given in Table
7 (page 59). The intrinsic SF, and a values of their radiation-survival response to
ionising radiation as determined by clonogenic assay are shownin Table 8 (page 63),
whilst the mutational status of p53 is given in Table 9 (page 64). The culture media
required for each of the twelve cell lines used here are given below, and summarised
in Table 7.
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2.1.2 Culture media of the 12 human cancercelllines
A2780, Colo 320, NCI-H417 (H417) and RT112, were grown in RPMI 1640
(Sigma). NCI-H322 (H322), HEp2, HRT18, HT29.5, 1407, MGH-U1, OAW 42 and
RPMI 7951 were grown in Dulbecco’s Modified Eagles Medium (DMEM) (Sigma).
Medium was routinely supplemented with 10% v/v Foetal Calf Serum (FCS)
(Serotec), which had been heat-inactivated by incubating at 56°C for 30 minutes
(min) before aliquotting and storage at —20°C), and 2mM Glutamine (Gibco).
OAW42 culture media was also supplemented with 10ug.mIInsulin (Gibco) and
Hydrocortisone (Gibco), whilst RPMI 7951 wasalso additionally supplemented with
Sodium Pyruvate (Gibco) and Non-Essential Amino-Acids (NEAA) (Gibco). Cells
were maintained in antibiotic free media asthe introduction of any xenobiotic to the
cultures might have unforeseen consequences. Thehistological origins, culture media
andoriginal references are summarised in Table 7.
2.1.3 Passaging of cancercelllines
Cells were passaged approximately every 2-3 days to maintain a sub-confluent,
asynchronously growing exponential culture. Adherent monolayers were passaged as
follows:
The Culture media was pipetted from the flask and discarded into bleach (final
concentration greater than 20% v/v) (Domestos). Any residual media was then
washedoff by the addition of 10ml of PBS, which was pipetted onto the cells. The
PBS wasthen decanted into bleach. Trypsin/EDTA (0.25% w/v porcine Trypsin in
PBS supplemented with 0.2 w/v EDTA) waspipetted into each flask. Iml, 2m] and
3ml of Trypsin/EDTA wassufficient to cover the surface of a 25cem?, 75cm” and
162cm”culture flask respectively. The cell monolayer was then coated with a layer
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of Trypsin/EDTA by rocking the flask from side to side and the excess
Trypsin/EDTA wasthen decanted.
The culture flask was then transferred to a 37°C incubator for typically less than 6
min, checking approximately every min until the adherent cells had detached from
the culture flask. This was confirmed by examining the flask under a microscope.
Oncethecells had detached from the culture flask supplemented media was added to
the Trypsin/cell suspension andthis resultant cell suspension was then pipetted into a
25mluniversal tube and centrifuged for 5 min at 200G at room temperature.
The supernatant was then decanted andthecell pellet was resuspended in 10mlofthe
appropriately supplemented media. Iml of this cell suspension was then pipetted
back into the culture flask along with S5ml, 20ml, or 40m1 of supplemented mediaper
25cm’, 75cm? and 162cm? flasks respectively.
For H417, which grows as a cell suspension, the media containing the cells was
pipetted into a 25ml universal tube and centrifuged as above. For Colo 320, which
grows as a semi-suspension cell line, any attached cells were suspended by tapping
the side of the flask until they all detached, as confirmed by examination under a
microscope. As with the H417 cellline, the cell suspension wasthen transferred to a
25ml universal tube and centrifuged as for the monolayercell lines.
Oncepelleted, the supernatant was decantedandthecells were resuspended in 10m]
of supplemented media. A cell count was undertaken, and then 2.5x10° cells were
pipetted back into a 75cm” culture flask, along with 25ml of supplemented media.
The suspension cells were always maintained below 10°cells/mI’ to ensure
exponential growth.
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Cell Line Histology Culture media Reference
A2780 Ovarian Carcinoma RPMI+10%v/v FCS Behrenset al [3];
Colon jColo 320DM . RPMI+10%v/v FCS Quinnet al [5]Adenocarcinoma
NCI-H322. Non Smalleell DMEM + 10%viv FCS Gazdar etal [6]ung carcinoma
nerH4i7 Smallcell Lung) Rpmi+10%v/v FCS} Mariniefal [8]carcinoma
Hep2 Larynx Squamous pyre+ 10%viv FCS Toolan et al [9]carcinoma
HRTI8 Becta) DMEM + 10%viv Ecs Tompkinset afAdenocarcinoma [10]
HT29.5 Colon DMEM+ 10%v/v Fcs Warenlus et afAdenocarcinoma [14]
Embryonic
1-407 Intestinal DMEM+ 10%v/v FCS Henle et a/ [15]
Epithelium
Bladder
MGH-U1 Transitional cell DMEM + 10%v/v FCS Evenset al [17]
carcinoma
DMEM + 10%v/v FCS Marshall et al
OAW 42 Ovarian Carcinoma + Insulin +. [19]Hydrocortisone
DMEM + 10%v/v FCS Deposited in ATCC
RPMI7951 Melanoma + Na Pyruvate + by G Moore,derived
NEAA 1971
BladderRT112 Transitional cell RPMI + 10%v/v FCS ar etal
carcinoma      Table 7. The twelve humancancercell lines utilised in this studyThe culture media, tumouroforigin and the reference for the twelve cell linesused in this study are given above.  
59
 
2.1.4 In situ staining for mycoplasma contaminationofcell lines
Cells were routinely stained to ensure that cultures were kept mycoplasma free. Any
cells found to be infected with mycoplasma were discarded and fresh cells removed
from liquid nitrogen storage. The staining protocol for mycoplasma detection is
given below.
Forceps and lcm? coverslips were first cleaned with 70% v/v Ethanol in reverse
osmosis (RO) water before sterilising in an autoclave for 15 min at pressure of1
atmosphere and a temperature of 125°C.
Cells from asynchronously growing exponential culture were harvested with Trypsin
/EDTAas above. Following centrifugation for 5 min at 200G, 10° cells in 1ml of
supplemented media were pipetted onto sterilised lcm? coverslips that was placed
into a 70mm diameter culture dish (Costar) using the sterile forceps. The seeded
coverslips were then transferred to a humid, 5% v/v CO2 in air incubator and
incubated for approximately 4h at 37°C, with care taken to maintain the meniscus of
the cell suspension on the coverslip. After 4h 3ml of supplemented culture media
was addedto the culture dishes andthe cells were left to grow for 2-4 days, or until
they were at approximately 50% confluence. The media was pipetted from the
culture dish, and the culture plate was then washed twice with 3ml of ice-cold sterile
PBS.Thecells were then fixed by the addition of 2m] of Carnoy’sfixative (75% v/v
Methanol (Sigma); 25% v/v Glacial Acetic Acid (BDH)), for 2 min at room
temperature. The Carnoy’s fixative was then pipetted of the plate, and 2mloffresh
Carnoy’s waspipetted onto the coverslip, and left to fix for a further 10 min. The
Carnoy’s fixative was then pipetted off and the plate was then washed twice with
2ml ofice-cold sterile RO water. The cells were then stained with 100ul of the DNA
intercalating dye Hoechst 33254 (500ng.mIStock, from sigma) for 30 min at room
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temperature in the dark. The stained cells were then washed twice with ice-cold
sterile reverse osmosis water and the coverslip was allowedto air dry for 30 min, in
the dark. The coverslip was then mounted cell side down on a glass slide using
Buffered Glycerol Mountant. This mountant was prepared by dissolving 2.1g of
Citric Acid Monohydrate in 100ml of sterile RO water to make solution A;
Dissolving 2.8g of Disodium phosphate in 100ml of sterile RO water to make
solution B; and then combining 22.2ml1 of Solution A with 27.8ml of Solution B with
50m1 Glycerol. The pH of this mountant solution was then adjusted to 5.5 using
solution A or B as appropriate (A-acidic; B-Alkaline). The cells were then examined
on a microscope under UV light through an x60 objective (Leitz), and a x10 eye
piece (Leitz).
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2.1.5 Establishment of a cryogenic bankofcell lines
Early passage cells were cultured as outlined above. With the number of flasks
expanded until sufficient cells were in culture to allow 20 vials of cells could be
prepared for freezing for each cell line used in the study.
Cells for freezing were harvested as appropriate, as indicated previously and
resuspended in complete media at 2x10° cells per ml. An equal volume of complete
media supplemented with 20% v/v Dimethyl Sulfoxide (DMSO) was added to the
cell suspension and 20 vials of Iml of 1x10° cells was aliquoted into Cryovials
(Nunc). These vials of cells were then transferred immediately to vapour phase of
liquid nitrogen for 1h before transferring and storing by immersion in liquid nitrogen
until required.
2.1.6 Thawing of cryopreserved human cancercelllines
A cyrovial of cells were thawed by removal from liquid nitrogen and standing the
cryovial containing the cells in a type II laminar flow culture hood until the cell
suspension had completely thawed, approximately 10 min, before gently pipetting
the cell suspension into a 25cm’tissue culture flask. The flask containing the cells
was then transferred to a 37°C humid incubator for approximately 4h (or until the
cells had attached to the culture flask for monolayercultures), and the culture media
containing DMSOwasdecanted and replaced with appropriate fresh culture media.
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2.2 Determination of radiosensitivity and clonogenic survival of twelve human
cancercell lines
2.2.1 Introduction
Theradiosensitivity of the 12 human
cancercell lines used in this study
was determined by clonogenic
survival following ionising
radiation. This work was undertaken
priorto the initiation ofmy doctoral
studies, and formedpart ofthe basis
for the rational of the studies I have
undertaken. The survival fractions
for eachofthe cell lines that I have
utilised in my study are given in the
adjacent table (Table 8) and I
confirmedthat these values held for
the celllines I utilised in this thesis
following the establishmentofa cell
line bank by repeating the
clonogenic assay at 2Gy, as outlined
below, andtesting if the resulting
 
 
 
 
  
esi tine Radiosensitivity
Oo SEM SF2
2780/735 0.525 0.05 0.299
Colo320 0.334 0.06 0.34
H322 0.280 0.03 0.529
H417 0.189 0.03 0.48
Hep2 0.113 0.03 0.646
HRT18 0.411 0.04 0.412
H129.5 0.189 0.04 0.589
1407 0.230 0.04 0.539
MGH-U1 0.200 0.06 0.608
OAW 42 0.705 0.07 0.222
RPMI7951 0.111 0.03 0.56
RT112 0.210 |0.10 0.599      Table 8. Clonogenical relevant valuea, the standard error of the mean of a(SEM) and the SF, value for thetwelvecell lines utilised in this studyThe a value of each cell line wasdetermined by clonogenic survivalcalculated following exposure to 0-10Gy of ionising radiation, and theSurvival fraction for each cell line at 2Gy is given above. Adapted fromWareniuset al, 1998 [4].  
survival fraction matchedthe values given in Table 8 (as determinedbyt-test).
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2.2.2 Clonogenic determination of survival fraction for monolayer cultures
Cells were maintained in pre-confluent exponentially growing cultures. For
monolayercultures cells were harvested by trypsinisation as outlined in the section
on Passaging of Culture Cells (see above). This involved pipetting of the culture
media and then washing the flask with 10mlof sterile PBS. This PBS was then
pipetted of, and 2ml of Trypsin in Versene (ImM EDTAin PBS) waspipetted onto
the cell monolayer. The culture flask was then incubated for approximately 5 min,
until the cells were seen to have detached from the culture flask when observed
under a microscope. Once the cells had detached from the flask 10ml of
 supplemented HAMS F12
 
 
    
Cell Number Exposed Dose of
se °(containing 10%v/v FCS, and 10mM Per ml y-lrradiation
L-Glutamine, along with any 10 0 Gy (Control)
additional supplementation 10° 1 Gy
recommended for the culture of that 10° 2 Gy
2
cell line, as summarised in Table oxlt 0 Gy (Control)
5x10° 3 Gy
2.1) was added to the flask. The 55x10 4 Gy
i hresultant cell suspensions were t en 10° 6 Gy
pipetted into a 25ml universal tube 10° 7 Gy
3and centrifuged at 200G for 5 min at 5x10 8 Gy
10* 9 Gyroom temperature. 5x10° 10 Gy
Following centrifugation the Table 9. Cell dilutions and dose of
supernatant was decanted. Gentle radiation received for clonogenic
determination of survival fraction
flicking of the universal was then The above Table contains the typical cell
dilutions utilised for clonogenic assays.used to disrupt the cell pellet. The    
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cells were then resuspended in a known volume of supplemented HAMSF12 media
and a cell count of the number of cells per ml was obtained using a Neubauer
improved haemocytometer. Cell suspensions of 10° to 5x10* cells per ml were then
preparedbyserial dilution, again in supplemented HAMSF12.
The cell suspensions were then exposed to increasing dosesof radiation over a range
of 0-10 Gy from GammaCell 1000 (Atomic Energy of Canada Ltd, Ottawa, Canada)
utilising a '°’Cs source. The GammaCell 1000 utilises a linearised '37Cg source to
irradiate the cells on a revoling platform designed to give a uniform dosetothe cells
within the irradiation chamber. Theirradiated cells were then plated in six well plates
sufficient colonies formed in each well to be able to determine the surviving fraction
at each dose. Iml of the appropriately irradiated cell suspension along with 3ml of
supplemented HAMSF12 wasthenpipetted into each ofthe six well plates, such that
the final volume of media in each well was 4mls. Each cell concentration and
radiation dose wasplated in triplicate with triplicate wells of un-irradiated, control
cells being prepared for the two cell densities of 10° and 5x10’, to allow the
determination of plating efficiency for each assay. This percentage plating efficiency
was then used whencalculating the true surviving fraction of cells at each dose, as
indicated in Figure 7. The seeded six well plates were then incubated at 37°C in
5%v/v CO, in air for 10-14 days to allow the colonies of surviving cells to grow
without merging with neighbouring colonies.
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2.2.3 Clonogenic determination of surviving fraction of semi-adherent and
suspension humancancercell lines
The Small Cell Lung Carcinoma H417 is a suspension culture, whilst the Colon
Adenocarcinoma Colo 320 grows as a semi-adherent culture. Colo 320 can be
suspendedbygentle tapping of the culture flask. At this stage the H417 and Colo 320
could be handled in the same manor. 10ml1of the cell suspension was removed by
pipetting, and transferred to a 25ml universal. The cells were centrifuged, and cell
number was determined as above for the monolayer cultures (2.1.3). As these cells
grow in suspension, there clonogenicity was determined using the Courtenay
technique [485, 486].
2.2.4 Staining and counting of clonogenic assays
Following incubation for 10-14 days at 37°C, the media from six well culture plates
was then decanted and the cells in each well were fixed by the addition of 2ml of
70%v/v Ethanol in RO water overnight at room temperature. The 70%v/v Ethanolin
water was then decanted of and the fixed colonies were stained by the addition of
10%v/v Giemsain Ethanol for 1h at room temperature.
The Giemsa was the pipetted of and retained for subsequent staining, and excess
stain was rinsed of with water and run to waste. The Plates were then allowedtoair-
dry overnight.
Colonies of greater than 50 cells, which represent a single cell undergoing greater
then seven exponential doublings, were then counted and the surviving fraction of
cells at each dose wasthen determined. The choice of 50 cells is such that any colony
formedis as a result of an irradiated cell possessing a long-term proliferative survival
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capability, as demonstrated by Terasima and Tolmach in 1963 [25] with time lapse
photography and reviewed by Okada [487].
Each cell line was assayed in triplicate, with each dose and cell concentration
undertaken in triplicate in each assay. The mean of the triplicate assays was
determined, and the mean of the means for each of the triplicate assays was then
determined.
2.2.5 Calculation of clonogenic survival
Survival fraction for each dose was determined as demonstrated in Figure 7B, with
the plating efficiency being calculated from the control plates as shownin Figure 7A.
Theplating efficiency at 10° and 5x10” wasused to determinethe surviving fraction
for the irradiated cells plated at these two plating efficiencies. The average plating
efficiency for the cells at 10° and 5x10” wasthen used asthe plating efficiency for
cells plated at 10° through 5x10", in determining the survival fraction at doses of5-
10 Gy.
From the determinations of the Surviving Fractions for the doses employed, a curve
of best fit was then generated using the linear quadratic equation given in part C of
Figure 7, by a method of non-linear least-squares regression analysis [488]. The
interpolated value of « representthe initial slope prior to the ‘shoulder’ thatis typical
of a dose response curve, andis indicative of a single hit mode ofcell killing, whilst
B represents cell death as a result of multiple radiation induced cell lesions (See
Figure 8).
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 A) Plating Efficiency
Plating Efficiency (P.E.) = Average No.of Colonies Counted
No.of Cells Plated Per Well
i.e. For an average numberofcolonies from three wells of 81 in the control un-irradiated plated
 
at 100 cells per well;
PE.=+ =081100
B) Surviving Fraction
Average No.of Colonies Counted
No.of Cells Plated x P.E.
i.e. For an average numberofcolonies from three wells of 36 colonies/clonesin the plate
wherethe cells have been exposedto 2 Gyofy-radiation (.. D=2), and with a Plating
Efficiency of 0.81 then;
 Surviving Fraction(SFp) =
36SF2 = ————_ = 0.4100 x 0.81
C) Linear Quadratic Dose Response Curve
SF, = exp(-aD — BD’)
 
  Figure 7 Determination of the surviving fraction The above equations demonstrate thehypothetical surviving fraction of cells exposed to 2 Gy ofy radiation givena plating efficiencyof 81% at a platting density of 100 cells per well in a six well plate. Part A) depicts thedetermination ofPlating Efficiency P.E., whilst part B) depicts the determination of SurvivingFraction at 2 Gy, SF>. Part C demonstratesthe linear-quadratic equation usedto‘fit’ the line ofbestfit to the Surviving Fraction data.  
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Figure 8. Post-irradiative clonogenic survival in the human cancercell lines
HRT18following pre-incubation with the organic solvent DMSO
The depiction of the alpha and beta constants of the non-linear quadratic equation
that is used to fit the logarithmically transformed data obtained from post-
irradiative clonogenic survival curve is shown above.     
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2.3 Determination of G,+M cell cycle delay following 2 Gy of y-radiation
2.3.1 Plating of cells for the determination of G).+M delay
All experiments were carried out on asynchronous, exponentially growing,
mycoplasma-free cultures, which were maintained as outlined in section 2.1. Cells
wereplated out in 25cm”tissue culture flasks (Costar) at a density of 1.5-2.0 x 10°
per flask. The optimum density was determined for each line by culturing the cells
for the period ofthe proposed experiment and ensuring that cells had enough room to
divide unhindered, i.e. were still growing as a pre-confluent culture.
Samples were taken every 2h for a period of 24h. Thus thirteen time points were
undertaken for each experiment of 0, 2, 4, ... and 24h. Each sample was done in
duplicate for both irradiated and control samples, i.e. four flasks per time point, and
52 flasks per experiment. Each time course for each cell line was undertaken in
triplicate.
On the day before the experiment, cells were plated out in 5ml of normal culture
medium.For each time pointa flask for irradiation and a control flask were seeded
and incubated at 37°C in an atmosphere of 5%v/v COQin air. Once the cells had
attached to the culture surface, confirmed by visual inspection using a microscope,
flasks were completely filled with normal medium containing 20mM HEPES and
incubated at 37°C overnightprior to irradiation.
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2.3.2 Irradiation of cells for determination of G).+M delay
Cells were irradiated using a '°’Cs GammaCell-1000 unit (Atomic Energy of Canada
Ltd., Ottawa, Canada) and given a dose of 2 Gy at a dose rate of 3 Gy per min. In
order to ensure an evenradiation dose, flasks were irradiated full of medium, 4 at a
time due to spacelimitation of the source utilised, and the empty space in the canister
wasfilled with bolus (Boots, Nottingham, U.K.). Care was taken to minimise thermal
shock by transporting the flasks to the irradiation source in polystyrene boxes
containing sand, which had been pre-warmed to 37°C. As well as the flasks being
irradiated, the controls were also taken for ‘sham-irradiation’, thus ensuring that the
effects of removingthe culture flasks removal from the incubator were accounted for
when determining cell cycle delay. All flasks were returned to the incubator
immediately and cultured at 37°C followingirradiation.
2.3.3 Harvesting of cells following y-radiation for flow cytometric analysis
For monolayer cultures, the medium was decanted from the culture flask and the
culture flask was then rinsed by the addition of 5ml PBS, which was then decanted.
Cells were then harvesting using I1ml Trypsin/EDTA at 37°C for approximately 5
min. Oncethe cell monolayers had detached, as determined visually by microscope,
Iml of heat inactivated FCS was added to the cell suspension to prevent over-
trypsinisation of the cells. 2m] of PBS was addedto each flask and the resultantcell
suspension waspipetted into a 4ml Falcon tube (Becton Dickinson).
For the suspensioncell line H417, trypsinisation is unnecessary. The post-irradiated
suspension cell culture was transferred directly from the culture flask to the 50ml
Centrifugation tubes. This cell suspension wasthen centrifuged for 6 min at 250G at
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4°C. The supernatant was then decanted andthe cell pellet was resuspended in 4ml
of ice cold sterile PBS. This cell suspension was then pipetted into a 4ml Falcon
tube. Similarly, to harvest the semi-suspension Colo 320 culture, tapping the flask
was sufficient to detach the any adhered cells from the culture flask surface to
generate a cell suspension. This cell suspension was then handled as per the H417
cell lines.
Cell suspensions were then centrifuged at 200G for 5 min at 4°C. The supernatant
was then aspirated and the cell pellet resuspended by gentle agitation, and the
addition of 4ml of PBS. The centrifugation was repeated. The supernatant was then
aspirated to leave approximately 200ul of PBS in each tube, and the cell pellet was
resuspended by initial gentle agitation and then by repeatedly passing the cell
suspension through a p200 Gilsonpipette tip to achieve a single cell suspension. The
cell suspension wasthenfixed by the addition of 4mlof ice cold 70% v/v ethanolin
RO water and stored at 4°C. Samples could be stored for several months without
affecting the quality of the results of the flow cytometric analysis.
2.3.4 Propidium Iodide (PI) staining of ethanol fixed cancer cells for flow
cytometic analysis
Cells that had previously been fixed in 70% v/v ethanol in water at 4°C for a
minimum over night period were pelleted by centrifugation at 250G for 5 min at
room temperature. The supernatant was then aspirated and the pellet resuspendedin
Aml sterile PBS. The samples were then centrifuged as above and the supernatant
was again aspirated to leave the pellet and approximately 2001 of supernatant. The
cells where then resuspendedin the residual PBS initially by agitation, and then by
repeated passing through a p200 pipette tip to give a single cell suspension as
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confirmed by microscopy. 500u1 of PI solution, containing 100ug/ml RNase A
(Sigma) and 20ug/ml PI (Sigma), both in sterile PBS, was then added to each
sample. Samples were incubated at 37°C in the dark for 30 min.
2.3.5 Flow cytometric analysis of PI post-irradiation samples
Following incubation in PI solution, samples were analysised on a FACScan
Fluorescence Activated Cell Analyser (Becton Dickinson). Stained cell suspensions
are passed perpendicularly through the beam of a 488nm Argon air-cooled laser
utilising fluid dynamic focusing. The reflected and refracted light produced as the
cells intersect the laser beam is collected and used to ‘gate’ the cell population from
debris (see Figure 9).
The emitted light from PI fluorochrome used to stain the genomic DNA wasthen
collected via a Photo Multiplier Tube (PMT) on the FL3-channalutilising a 590nm
long-pass filter (Becton Dickinson). This red fluorescent feature was used to
‘threshold’ the flow cytometic data to further eliminate debris. This was achieved by
adjusting the gain-settings and the PMT voltage such that the mean G, peak was
displayed at channel 200 on linear scale. It should be noted that the PMT-voltage
wasalways usedat the linear range of 300-900 volts, with the Gain-settings adjusted
to utilise this range. 1 x 10° events were then captured and recorded in real-time
using List-mode data acquisition of the Consort 32 computer system running LYSIS
II data package.
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Figure 9. The gating protocol for the analysis of PI-labelled ethanol-fixed
human colonic cancercell HT29.5 Initially the threshold value is set at 100 on
the red channel (PMT3),to collect whole cells, and the Region R1 is used to
eliminate any doublet cells by density plot of light scatter (Panel B). The un-
gated PI distribution is shown in the frequency plot ofDNA content, panelC,
with the gated PI population in panel D. The comparative overlaid view of
gated (red), and un-gated(blue) is shown in panel A.    
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  Figure 10. Determinationofcell cycle distribution for flow cytometric data The abovehistogram is the frequencyplotofcell fluorescence following staining of ethanol fixed MGH-U14h control cells with PI. The mathematical modelling program ModFit wasusedto ‘fit’ curves tothe above histogram suchthat the cells distribution throughoutthe cell cycle can be determined.  
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2.3.6 Analysis of flow cytometric data
List-mode data was translated into MS-Dos using HP-Lif to Dos converter,
DataMate2.0 (Dako).Determination ofcell cycle distribution of the analysed samples
was then undertaken using the mathematical modelling program ModFit cell cycle
analysis software (Verity, Topsham, ME, U.S.A.). DNA histograms werefitted with
a model, which calculated the relative distribution of cells in G;, S and G2+M phases
of the cell cycle. The model used was primarily as indicated below in Figure 10.
Both G; (blue) and G2+M (green) peaks were fitted with Gaussian curves. ModFit
automatically locates the G; peak (from a pre-determined estimate value) and then
uses a ‘multiplier’ to determine the location of the Gy+M peak. The S-phase
boundaries are then determined from the location of the G; and G2+M population
peaks, and are fitted with three rectangular curves (yellow curve). The areas of the
curves defining these three populations are then used to calculate the percentage of
cells in each cell cycle population. The red line on the graph depicts the
mathematically modelled distribution of the cell population from the histograms
fitted to the cell data.Only samples that gave a G; and G2+M Coefficient of Variance
(CV)ofless than 9 were analysised. The CV of these Gaussian curvesis calculated
indicated in Figure 11.
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B) Determination ofthe coefficient of variance for a given
distributionis:
_ CurveHeight H
Width W
WhereH is the height ofthe curve, and W is the width of
the curve at 0.6 of the curve height (0.6xH).
CV
   Figure 11. Determination of the CV The CVfor a given curve,asrepresentedin panel A), is determinedascalculated in panel B).   
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2.3.7 Quantification of the duration of Tso following G,+M cell cycle
accumulation
Exit from G2+M accumulation was specified as the time taken from maximal G2+M
phase accumulation (peak value from which the maximum percentage of cells in
G2+M phase begins to decrease) to the point at which the percentage of cells in
G>+M has decreased to 50% ofthis value [479]. This duration is referred to as the
Tso value for each cell line. This method of quantitation is similar to that described by
Cheongetal. [168].
Figure 12 depicts examples of Tso determinations as used in Wareniuset al. [481].
The graphsofthe percentage cells that had accumulated G)+M were produced using
GraphPad Prism version 3.02 (GraphPad Software Incorporated). The percentage of
cells in each part of the cell cycle as determined using ModFit were enteredinto the
Graphpad Prism, and the percentage ofcells present in each phase of the cell cycle
for the controls was subtracted from the matched irradiated samples and plotted as
below along with the calculated + SEM. GraphPad Prism provided coordinate
positions in cm.I utilised this function to measure precisely the exact height of the
G2+M population by ‘drawing’ lines directly onto the graph, and noting the line start
and endposition as given by GraphPad Prism. The length of the x and y-axis was set
to 5cm and 4cm respectively. Thus the mid-point of the G7+M accumulation plot,
and subsequently the duration of the exit time Tso was determined by drawing in a
line from the time of maximum accumulation started to decrease to wherethis line
intercepted the downward slopeofthe graph (as indicated in Figure 12A). The length
of this line could then be determined from the start and end position of the line, as
given by GraphPadPrism, and hencethe Tso time could be calculated (as indicated in
Figure 12B).
76
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Figure 12. Determination of G)+M exit in humancancercell lines The above
figure contains an examplesofthe Tso determinations of G2+M exit for human
embryonic cell line 1407 following exposure to 2Gyofionising radiation. Panel
A showsthepercentage of cells accumulation in G2+M,whilst panel B
demonstrates how the Tso wascalculated. 
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2.4 Determination of protein expression levels by western blotting
2.4.1 Preparation ofcell lysates
Cancer cell lines were grown in asynchronous exponential cultures as described
previously. For monolayer cell cultures, the media was decantedinto bleach and the
culture flask was then washedbypipetting ice cold sterile PBS into the culture flask,
and gently tilting the flask from side-to-side, before the PBS was decanted into
bleach. 2mlof trypsin/EDTA wasthen pipetted onto the cells and the culture flask
was then incubated at 37°C. The flasks were checked microscopically approximately
ever 2 min to determine whether the cells had detached from the culture surface.
Once the cells had detached 8ml of ice cold PBS was pipetted onto the cell/trypsin
suspension andthe resultant cell suspension was then pipetted into a 25mluniversal
tube and centrifuged for 5 min at 200G at 4°C. The supernatant was then decanted
and the universal tube was gentle flicked to disrupt the cell pellet. 10ml of ice cold
PBSwasthen pipetted onto the cells. A 10p1 aliquot was then taken with a Gilson
pipette and the cells loaded onto an improved Neubeuer haemocytometeranda cell
count undertaken. The universal containing the counted cell suspension was then
centrifuged as above. The supernatant was again decanted and the universaltubeleft
inverted for 1 min to drain off any excess PBS. The universal was then righted,
capped, and the tubeflicked to disrupt the cell pellet. One ‘Complete-mini-protease-
inhibitor-cocktail-tablet’ (Roche) wasdissolved in 10mlof lysis buffer (1%w/v SDS,
0.8% v/v glycerol, 50mM Tris pH 6.8 in elga water) and then Imlofthis lysis buffer
with protease inhibitors was addedto the cell slurry per 3x10’ cells. Thecell lysate
wasthen sonicated on ice for 10s. The sonicated lysates werethen left to stand onice
for 5 min. The cell lysate was then transferred to a sterile 1.5ml eppendorf tube and
centrifuged in a chilled rotor at 20,000G for 30 min at 4°C. The centrifuged lysates
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were then aloquated into 1001aliquots in sterile 0.5m1 eppendorftubes andstoredat
~70°C.
2.4.2 Determination of protein concentration of cell lysates
The protein concentration of cell lysates was determined using the ‘MicroBCA-
Protein-Kit’ (Peirce). This method employsbi-chromicacid to stabilise the transition
ae : * . .of Cu’* to Cu’* in the presence of reducing aminoacids.
A standard curve was prepared from the provided lmg.mI' ampoules of bovine
serum albumin (BSA), as indicated in Table 10A. A BSA stock was produced from
an initial dilution of the BSA in lysis
buffer stock (standard diluent, 1 in
125 lysis buffer in sterile RO water)
in 1.5ml eppendorf tubes; each
sample was undertaken in duplicate.
The cell lysates to be assayed was
initial dilution by 1 in 125 in sterile
RO water to produce a sample stock.
This sample stock was then diluted
further in sterile RO water to give
600ul at a final concentration of 1 in
250, 1 in 500, 1 in 750 and 1 in
1000, as indicated in Table 4.
The BCA colourimetric reagents
were then prepared as indicated in
the instructions, with 50 parts of A;
 
A) Preparation of standard curve
 
  
Protein Volume of Volume of Volume of
content BSA standard sterile RO(ug.ml') stock (ul). diluent water(11).
(ul)
0 0 300 300
1.0 12 300 288
2.5 30 300 270
5.0 60 300 240
10.0 120 300 180
15.0 180 300 120
20.0 240 300 60
25.0 300 300 0   
B) Dilution of cell lysate to be assayed
 
Sample |Volumeof Volume of Volume of
dilution sample standard sterileRO
stock (pl). diluent water(ul).
(ul).
1 in 250 300 0 300
1 in 500 150 150 300
1 in 750 100 200 300
1 in 1000 75 225 300      Table 10. Preparation of standardcurve and cell lysate dilutions fordeterminationconcentration To determination theprotein concentration of cancer celllysates, the above standard curve andcell lysate dilutions were undertaken.of protein
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49 parts B; and 1 part C, being combined before 6001 of this mixture being added to
each sample. Enough colourimetric reagents were mixed to do all the samples, the
standard curve,plus five additional tubesfor surplus(i.e. 3ml).
The sample/BSA reagents were then incubated at 70°C for 30 min in a pre-heated
water bath. Following incubation, the samples were then removed and allowed to
cool to room temperature. The sample mixture was then decanted into a Imlplastic
cuvette and the optical density (O.D.) at 560nm was determined using a bench top
spectrometer.
The range of dilutions of BSA used was such that a standard curve of 0-1.0 O.D.
units was produced. This standard curve wasthen analysed by linear regression using
Microsoft Windows Excel by plotting the O.D. on the ordinate, against protein
concentration on the abscissa. Only the sample dilution who’s O.D.fell within this
linear range of the standard curve were usedto calculate the protein concentration of
each cell lysate assayed, by interpolation from the linear regression equation. The
average of the appropriate dilutions was then taken, and the concentration of each
protein determined in mg.mI".
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2.4.3 Polyacylamide Gel Electrophoresisof total cellular protein
Laemmli buffered discontinuous sodium docecyl sulphate- polyacrylamide gel
electrophoresis (SDS-PAGE) was employed to separate proteins by size homogenous
cell lysate solution. The buffersutilised are listed below.
2.4.3.1 Buffers
0.5M Tris; pH 6.7 was prepared byblending the prepared solutions of 0.5M Tris-HCl,
with 0.5M Tris-base to produce the required pH.
1.5M Tris; pH 7.4, was produced by blending the prepared solutions of 1.5M Tris-
HCI with 1.5M Tris-base to produce the required pH.
10% w/v Sodium dodecyl sulphate (SDS); 10g of SDS was dissolved in 90ml of
Sterile RO water. Once dissolved the final volume was madeto 100ml.
Tris buffered saline (TBS) was prepared by dissolving 50mM Tris base and 150mM
sodium chloride in 900ml of RO water. The pH was then adjusted to 7.6 by the
addition of concentrated hydrochloric acid (HCI). The volume was then madeto IL.
Tris buffered saline with Tween-20 (TTBS); Tween-20 was added to TBSto give a
final concentration of 0.1% w/v Tween-20.
Loading buffer; 10% v/v glycerol, 1% w/v SDS, 62.5mM Tris in RO water with the
pH adjusted to 6.8 with HCl
40% w/v Acrylamidesolution ethanol free (BDH)
4% w/v Bis-acrylamide solution ethanol free (BDH)
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2.4.3.2 Sample preparation for polyacrylamide gel electrophoresis
Whole cell lysates prepared as indicated previously werefirst fully thawed at room
temperature before diluting to 1.5mg.ml’ with loading buffer. Sul of a 10% w/v
bromophenol blue and 15yl 2-mercapoethanol were added to each 150ul of diluted
lysate to be loaded. The samples were then denatured by heated to 95°C for 5 min
before being allowed to cool to room temperature. 50ul of this denatured cell lysate
solution was then loaded into each lane of the gel. Empty lanes were loaded with
50ul of loading buffer containing 0.3% w/v bromophenol blue and 10% 2-
mercaptoethanol.
2.4.3.3 SDS-PAGE
Denatured linearised whole cell protein lysates were electrophoretically separated on
vertical discontinuous SDS-PAGEgels. The discontinuous gel consisted of a 4% w/v
polyacrylamide with 2.6% cross-linker at pH 6.8, and the resolving gel utilised was a
10% w/v polyacrylamide gel with 2.6% cross-linker at pH 8.8 were run on a ‘Protein
II’ electrophoresis 16x16cm gel system (Bio-Rad).
2.4.3.4 Blocking of membranes
Following blotting, the nitrocellulose membrane was removed from the blotting
cassette using ethanol cleaned forceps, and transferred to a stainless steel tray
containing 40ml of TBS. The membrane was then washed for 5 min at room
temperature on a rocking platform. The TBS was then decanted and 40ml of TTBS
was pipetted into the tray and the membrane was washed for a further 5 min. The
TTBS wasthen decanted and replaced by 40ml fresh TTBS and the wash repeated.
The second TTBS was then decanted and the nitrocellulose membrane was then
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blocked in decanting 300ml of 5% w/v marvel in TTBSinto the tray for 1h at room
temperature, ensuring that the membrane was coveredat all times.
2.4.3.5 Antibody probing of electrophoretically blotted proteins
The electrophoretically acrylamide-gel separated proteins were measured using a
two-stage ‘sandwich’ antibody staining technique. ‘Blocked’ nitrocellulose
membranes were initially probed with commercially available primary antibody
generatedto the proteinsofinterest.
Following blocking the blocking buffer was decanted and 40ml of TTBS was
pipetted into the tray containing the membrane. The membrane was then washed for
5 min at room temperature on a rocking platform. The TTBS was then decanted and
40ml of fresh TTBS waspipetted into the tray. The wash was then repeated,
followed by a third repeat wash in TTBS.
The third TTBS wash was then decanted and the membrane wastransferred to a
plastic bag using ethanol cleaned forceps, where it was then probed with the
appropriate antibody to either p53 (clone DO-1, Santa Cruz at 1 in 1000), RAF-1
(clone 1H4, Abnovaat 1 in 500), or pan-actin (C-2, Santa Cruz at 1 in 1000)(loading
control) in 10ml of 5% w/v Marvel in TTBSat the appropriate dilution and sealed
using a bag sealer, and incubated under an up-turned tray to protect the membrane
and exclude light. Air-bubbles were squeezed out of the bag immediately prior to
sealing to ensure that all of the membrane could be exposed to the primary antibody
solution.
The bags containing the probed membranes were then carefully cut using a scalpel,
the probing solution was decanted and the membrane was removed from the bag
using ethanol-cleaned forceps, and transferred to a stainless steel tray containing
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40ml of TTBS. The membrane wasthen washed for 5 min at room temperature on a
rocking platform. The TTBS was then decanted and 40ml of fresh TTBS was then
pipetted into the tray and the wash repeated. The second wash was then decanted and
third repeats wash undertaken as above.
The membrane was then transferred to a fresh plastic bag with ethanol-cleaned
forceps, which was then sealed using a bag sealer with air-bubbles excluded after
10ml of a secondary antibody, a Horse radish peroxidase conjugated Goat anti mouse
IgG (Fc) antibody (AbD Serotec) was used at 1 in 1000 dilution in 5% w/v Marvelin
TTBS.
The secondary antibody was then incubated for lh at room temperature on the
rocking with an up-turned tray covering the membrane.
2.4.3.6 Detection of protein following antibody incubation
Amersham ECL™western blotting detection reagent (GE Healthcare) system was
used to visualise the amount of p53, RAF-1 andactin protein present in each sample.
Thenitrocellulose membrane following incubation with the appropriate antibodies as
outlined above was washed three times in PBS prior to incubation with the ECL
reagents as per manufactures instructions. Hyperfilm ECL western (GE Healthcare)
was then exposed to the film in the dark for typically 10 seconds. The film was then
developed and fixed in Tmax 100 professional developer (Kodak) for 1 min and
washed three times in tap water before fixing in Kodak Rapid Fixer (Kodak) for 5
min. The film was then washed in running water for at least 5 min prior to being drip
dried at room temperature.
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2.4.3.7 Re-Probing of nitrocellulose membranes
Nitrocellulose membranes that have been probed for the expression of RAF-1 were
stripped and re-probed for p53. The membrane wasstripped for 30 min in 100ml of
pre-warmed stripping buffer (100mM 2-Mercaptoethanol, 2%w/v SDS, 62.5mM
Tris; pH6.7) at 50°C for 30 min. The stripped membrane wasthen transferred to a
fresh tray containing 40ml TBS for 5 min at room temperature and washed on a
rocking platform. The TBS was then decanted and 40ml of TTBS waspipetted into
the tray. The membrane washedfor a further 5 min at room temperature. This TTBS
was then decanted and 40ml of fresh TTBS wasthen pipetted into the tray, and the
wash repeated. The TTBS was then decanted and the membrane was blocked as
above.
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Chapter 3
p53 mutationalstatus andthelevel of key
cell cycle proteins in relation to radiosensitivity
at 2Gyin twelve humancancercell lines
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3 p53 mutational status and the level of key cell cycle proteins in relation to
radiosensitivity at 2Gy in twelve human cancercell lines
3.1 Introduction
3.1.1 Oncogene expression can berelated to radiosensitivity
Oncogenes may confer both a proliferative and radioresistant phenotype [474].
Transfection of several in vitro cell cultures with a variety of recombinant oncogenes
results in an increase in radioresistance when comparedto that of the parental line
[489]. In the haematopoietic progenitorcell line 32d CL3, transfection with v-abl, c-
jms, and v-myc induced resistance to doses of y-radiation similar to those employed
clinically [476]. Additionally, transfection of cultured cells with oncogenic signal
transduction components such as H-Ras and K-Ras results in both increased
transformation and radioresistance [153, 155]. In the human colon carcinomacell
line HCT 116, H-Ras radioresistance was demonstrated to be heregulin dependent
demonstrating that several disparate cell surface receptors can co-operate to reduce
radiosensitivity as a result of extra-cellular signalling [490].
3.1.2 The relationship of RAF-1 protein expression to cellular radiosensitivity
The mitogen activated signal transduction protein RAF-1 [359] has been observed to
promote transformation, whilst inducing radioresistance in several cultured cell lines
in transfection models [475]. However, in contrast to these observations made
primarily on the oncogenic product of RAF-1, studies in 19 human cancercell lines,
which possessed a full-length 74kDa RAF-1 protein, RAF-1 protein level was found
to be proportional to radiosensitivity, as measured by the clonogenic cell survival
radiosensitivity parameter « [480]. This relationship of RAF-1 level and
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radiosensitivity was not found to be indicative of cell cycle parameters such as
labelling index (Li), or potential doubling time (Tpot). Nagasawa, however had
demonstrated a relationship between radiosensitivity and G2+M delay in the AT
derived fibroblast GM2052 [491], and SCC-61 squamous cell carcinoma derived
head and neck humancell line, as well as an increased delay in radiosensitive rodent
derived cell lines. In addition, asynchronouscells showed that a greater G2 delay was
related to a greater resistance in a comparative study in HeLa cells and the human
melamona line MeWo [492]. Chemical modifications inducing reductions in G7+M
transit following irradiation with caffeine [157], or pentoxifylline has also been
found to increase radiosensitivity [493].
3.1.3 RAF-1 proto-oncogene expression, radiosensitivity and post-irradiation
cell cycle delay
Ofthe 19 cell lines previously reported upon by Wareniusetal. [4], six were initially
selected to further study this potential role of Gz+M delay in radiosensitivity in the
context of RAF-1 protein level. The cell lines chosen reflected the full range ofRAF-
1 protein levels and radiosensitivity as determined by the clonogenic cell survival
value-c. The cell cycle distribution of these six cell lines was then studied following
2 Gyofy-irradiation to determineif Gp arrest correlated with survival.
It was demonstrated that the rapidity of exit from a transient delay in the G7+M
compartmentofthe cell cycle wasreflectedin the intrinsic radiosensitivity ofthe cell
lines, which correlatedpositively to intrinsic RAF-1 protein level [481].
A subsequent study involving an enlarged ‘pool’ of 12 cell lines, however failed to
demonstrate a relationship between post-irradiated G+M exit rates and RAF-1
protein level, but did demonstrate a correlation in post-mitotic accumulation ofcells
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in G;, which wasproportional to RAF-1 protein level and related to radiosensitivity
as determined by clonogenic survival [4]. Though adding to the confusion
surrounding the nature of RAF-1 involvementin cell cycle modulation, this finding
further enforces the role of RAF-1 protein level in cell cycle progression andintrinsic
radiosensitivity of human cancer cell lines, leading to the speculation that this
sensitivity may berelated to insufficient time for cells to repair DNA lesions during
G», or that RAF-1 could somehow negate the G2surveillance checkpoint [494].
3.1.4 p53 and cellular radiosensitivity
The tumour suppressor gene p53 is a central component of the DNAsurveillance
checkpointthat operates in both G; and G2. Mutations to the p53-gene are seen to
promote radiosensitivity in the autosomal disorder of AT. Further, the level of p53
protein within the cell has been seen to become elevated immediately following
irradiation, implying a role in the cell’s response to radiation. Covalent modifications
such as acetylation [495], ubiquitination [496], and phosphorylation [497] have also
been shown to alter p53 activity, function, and level. Indeed, RAF-1 was shown to
phosphorylate p53 in cell free assays [427]. Thus I determined to revisit this Gp+M
cell cycle delay and investigate this putative role of RAF-1 protein level correlation
with the rate of exit from y-radiation induced G2+M delay, and if p53-mutational
status affects the exit of cells from post-irradiation induced G2+M accumulation.
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3.2 Methods
3.2.1 Cell cycle protein levels and their relationship to radiosensitivity
Asthis thesis is concerned withthe intrinsic level of proteins that are pertinent to the
cell cycle, and post-irradiation cell cycle progression and survival, I have
investigated if there was any relationship between the protein-protein levels, and the
post-irradiative survival in the twelve human cancercell lines utilised in this study.
Paul Browning, Matt Jones, Laurence Seabra, and I had worked towards the
accumulation ofthis body ofresults prior to the initiation ofmy thesis.
3.2.2 Intrinsic protein level measurement by western blot analysis
The intrinsic expression ofproteins for the cancercell lines was measured as outlined
in Materials and Methods section 2.4. Antibodies for the detection of CDK1 (clone
C-9, Santa Cruz), CDK4 (clone DCS-35, Santa Cruz), cyclin B (clone D-1, Santa
Cruz), and cyclin D1 (clone DCS-6, Santa Cruz) were usedat a dilition of 1 in 1000.
3.2.3 Determination of p53 mutational status of humancancercell lines
The sequencing of p53 gene was undertaken within the lab by Tracey Gorman. A
brief description of the methods and findings as outlined in Wareniusegal. [14] are
given below.
3.2.3.1 Preparation of RNA and DNAfor p53 mutational determination
Genomic DNA and RNAwereobtained following guanidinium isothiocyanate CsCl
gradient centrifugation [498, 499]. Cells were harvested as outlined in Materials and
Methodssection 2.1.3.
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Following centrifugation, the medium was decanted from thecell pellet and the cells
were then resuspended in ice cold PBS. The PBS cell suspension was then
centrifuged at 200G for 5 min at 4°C. Following the centrifugation the supernatant
was decanted and the cells were resuspended in guanidinium isothiocyanate buffer
(4M Guanidinium isothiocyanate, 50mM Tris pH 7.5, 25mM EDTA pH 8.0,
0.5%w/v sodium lauryl sarcosine and 8%v/v 2-Mercaptoethanol). The cell
homogenate was then cleared by centrifugation at 7,500G for 10 min at 4°C. The
pre-cleared homogenate was then centrifuged through 5.7M CsCl 0.1M EDTAat
100,000G for 20h at 20°C. The RNApellet was then re-dissolved in 0.1%w/v SDS
and precipitated with ethanol overnight at -20°C. The RNA wasthen re-desolved in
molecular grade waterprior to quantification.
3.2.3.2 cDNA synthesis of exons 9-11 of p53 from total RNA
As given in Warenius et al. [14] cDNA synthesis was undertaken from the
incubation of 5ug of total RNA with lug oligo(dT) primer, and 20U of human
placental ribonuclease inhibitor at 70°C for 10 min. Cooling the total RNA mixture
on ice then stopped further primer annealing. 1x first strand buffer (S0mM Tris, pH
8.3, 75mM KCl and 3mM MgCl), 0.01M DTT, dNTPs (0.54M for each
deoxribonucleoside triphosphate), 400U of superscript reverse transcriptase (Gibco)
was then added to the chilled cDNA synthesis reaction mixture, which was then
incubated at 37°C for lh. PCR of exons 9-11 was then undertaken using Syl of this
cDNAtemplate reaction mixture as stated below.
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3.2.3.3 PCR of exons 2-8 and 9-11 for DNA sequencing
PCR Primers were designed to flank each of the exons to be sequenced. The
sequences for each of the primers are given in Table 11 below. Exons 2 and 3 were
co-amplified, as were exons 9 to 11 prior to sequencing. The remaing p53 exons
were amplified separately and sequenced.
Genomic DNA wasdigested with EcoRI, precipitated with ethanol and resuspended
in 50ul of water (Sigma) before undergoing RT-PCR amplification. The DNA (lpg)
was amplified in 20u] PCR reactions containing 20pM of each primer. A ‘hot-start’
PCR protocol was used with the dNTPs and Taq polymerase enzymeinitially
separated from the rest of the reaction components on a wax cushion. The reaction
mixtures were then placed in a pre-heated PCR block at 95°C for 2 min to denature
the template strands before undergoing 30 repeat cycles of RT-PCR and denaturation
at 95°C. For exons 2-3, 4 and 6; RT-PCR was undertaken at 60°C, whilst exons 5,
and 8; were at 65°C, with exon 7 at 68°C, and exons 9-11 underwent RT-PCR at
72°C, with extension being carried out for 1 min. The PCR products were checked
on a 0.8% w/v agarose gel before being purified using a Wizard minicolumn
(Promega), and useddirectly in sequencing reactions.
 
 
Primers
Exons Sense Antisense
2/3 CCC ACT TIT CCT CTT GCA AG AGC CCA ACC CTT GTC CTT AC
4 CTG CTC TTT TCA CCC ATC TA GCA TTG AAG TCT CAT GGA AG
5 TGT TCA CTT GTG CCC TGA CT CAG CCC TGT CGT CTC TCC AG
6 GCC TCT GAT TCC TCA CTG AT TTA ACC CCT CCT CCC AGA GA
7 ACT GGC CTC ATC TTG GGC CT TGT GCA GGG TGG CAA GTG GC
8 T ATC CTG AGT AGT GG T GCT TGC TTA CCT CG
9/10/11 AGA AAG GGG AGC CTC ACC AC CTG ACG CAC ACC TAT TGC AA     Table 11 Primers for PCR of exons 2 through 11 of p53 The above tablecontains the primers used to amplify exons 2 through 11 of p53 genomic DNAand cDNA for DNA sequencing. The primersread 5’ to 3’ as per convention.   
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3.2.3.4 Nucleotide sequencing of amplified p53 exons 2 through 11
Sequencing primers were radioactively labelled with 10pM of y°P-ATP (45 Ci) at
their 5’ end for 30 min at 37°C using T4 polynucleotide kinase (9.7 U, Pharmacia)
and 1xT4 PNK buffer (10M Tris-Acetate, 101M magnesium acetate and 50uM
potassium acetate). The primers are as listed in Table 11 (page 92). The Sanger
method of di-deoxynucleotide enzymatic sequencing was utilised [500], using the
fmol DNA Sequencing System (Promega). Sequencing was repeated and putative
sequencing mutations were confirmed by additional sequencing of the exon in the
antisense direction.
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3.3 Results
3.3.1 Intrinsic protein level in 12 human cancercell lines and radiosensitivity
The relative levels of intrinsic protein expression in the twelve, un-irradiated,
asynchronous, exponentially growing, humancancercell lines used in this study are
shown below in Figure 13. The amount of each protein was measured using western
blotting, with densitometry undertaken to assign valuesto the relative level of that
specific protein. These densitometry values were then collated with all the other cell
lines used in the lab and the mean densitometry level was calculated for each protein.
This mean densitometry value was then equatedto an arbitrary relative mean of 5,
andtheserelative expression patterns were then used to determineif any relationship
existed between any of the protein levels and or the cell lines post-irradiative
survival. The results of protein and radiosensitivity correlations are summarised in
Table 12 below giving the probability of correlation (P) and the correlation
coefficient (r).
As can be seen from thesecorrelations, the only values that showed any degree of
relationship, as determined Least-Squares regression, were the intrinsic level of
CDK1 and CDK4 (which is the subject of a separate thesis in the lab), and the
intrinsic level of the proto-oncogene RAF-1 and radiosensitivity. These findings are
a little surprising because I would have expected the levels ofCDK1 and CDK4to be
related to the levels of their cyclin partners (cyclin B and cyclin D1 respectively),
due to the 1:1 stoichiometric binding that occurs during cell cycle progression.
I thus determined to investigate this negative relationship, i.e. high levels of RAF-1
relating to radiosensitivity (low values of SF2), and compare this observation with
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cell cycle progression and p53 mutational status, as p53 protein level per se did not
appear to influence post-irradiation survival.
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Figure 13. The relative intrinsic protein expression patterns in twelve human cancer
cell lines
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Table 12. The relationship betweencell cycle proteins and radiosensitivity at 2Gy
 
 
 
 
 
 
 
 
   
SF, CDK4 Cyc B Cyc Dl RAF-1 Tp53
CDK1 P=0.866 P=0.712 P=0.655 =0.438 P=0.394
r=0.066 r=0.156 r=0.174 r=0.297 r=0.325
CDK4 P=0.841 P=0.834 P=0.966 P=0.394 P=0.663
r=0.079 r=0.089 r=0.017 r=0.325 r=0.169
Cyclin B P=0.768 P=0.834 P=0.805 P=0.865 P=0.687
r=0.125 1=0.089 r=0.105 ¥21_ 0.072 t=0.170
Cyclin D1 P=0.846 P=0.966 P=0.805 P=0.614 P=0.128
1=0.063 r=0.017 r=0.105 r=0.163 r=0.546
RAF-1 P=0.394 P=0.865 P=0.614 P=0.363
r=0.325 1=0.072 r=0.162 1=0.346
Tps3 P=0.633 P=0.663 P=0.687 P=0.128 P=0.363
r=0.185 r=0.169 r=0.170 1=0.546 1=0.346     
 
Figure 13. Therelative cell cycle protein levels of the key G; and G2+M progression
proteins and those ofthe cell cycle related proteins of p53 and RAF-1 are shown above.
Table 12. Thecorrelation ofthe various protein levels and the relationship of these
intrinsic protein levels to radiosensitivity is shown above. Thered boxesindicate there
the P (probability of correclation) and r (Pearsons product-momentcorrelation
coefficient) values are significant.
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3.3.2 p53 Mutational status of the cancercell lines
Exons 5-8 of p53 messenger RNA were sequenced since these regions have
previously been shownto contain the majority of mutations found to be expressed by
p53 [176]. Screening of these mRNA exonsrevealed that seven of the twelve cancer
cell lines studied utilised in this study carry mutations in their base sequence as
summarised in Table 13 below. The mis-sense mutation observed in the ovarian
carcinomacell line OAW42 wassilent. The CGA to CGGalteration of codon 213
still resulted in a wt- p53 protein as both codons code for Arginine. Thus, six of the
cell lines studied here, 2780, HEp2, HRT18, 1407, MGH-U1, and OAW 42 express
wt-p53 protein.
The melanoma, RPMI 7951, and the small cell lung carcinoma, H417 have truncated
p53, with stop codons at 166 and 298 respectively. The second small cell lung
carcinomaline H322 and the Colonic Adenocarcinoma Colo 320 both posses a mis-
sense mutation of CGG to TGG at codon 245 resulting in a basic Arginine to
hydrophobic Tryptophansubstitution.
 
       
Cell line Location of cDNA Amino-acid p53 protein
alteration sequence change
2780 - Normal None WT
Colo 320 Codon 245 CGG-TGG Arg to Trp Mut
H322 Codon 245 CGG-TGG Arg to Trp Mut
H417 Codon 298 GAG-TAG Glu to Stop Mut/Truncated
HEp2 - Normal None WT
HRT18 - Normal None WT
HT29.5 Codon 273 CGT-CAT Arg to His Mut
1407 - Normal None WT
MGH-U1 - Normal None WT
OAW42 Codon 213 CGA-CGG None WT
RPMI 7951 Codon 166 TCA-TTA Ser to Stop Mut/Truncated
RT112 Codon 248 CCG-CAG Arg to Gly Mut
Table 13 p53 Mutational statuses of the twelve humancancercell lines
The above table contains a summary of the mutationalstatus ofthe cell
lines utilised in this study.    
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The transitional bladder carcinoma cell line, RT112, and the Colonic
Adenocarcinoma derived HT29.5 also had a basic Arginine mutation to an uncharged
Glycine and a basic Histidine. Colo320, H322, and RT112 were homozygousfor p53
gene mutations, whilst HT29.5, RPMI 7951, and H417 were heterozygous, though
only H417 expressedrelatively high levels ofwt-p53 mRNA[484].
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4 Expression of RAF-1 and p53 protein following 2, 4 and 8Gyof y-radiation in
twelve humancancercell lines determined by western blotting
4.1 Introduction
Following exposure ofcells to ionising radiation elevations in the level of p53 have
been observed both in vitro [305] and in vivo [501]. It is thought that these increases
may mediate the response to the damage induced followingirradiation. For instance,
it has been hypothesised that low levels of p53 may actually have an anti-apoptotic
propensity [297], whilst high levels of p53 could have the opposite effect of inducing
apoptosis [298]. The influence oncell fate following exposure to radiation is thought
to be mediated through the down-stream transcriptional targets of p53 [502].
Although no evidence of direct induction of RAF-1 transcription by p53 is known,
RAF-1 level doesdirectly influence post-irradiation survival in the wt-p53 cell lines
and RAF-1 is known to mediate apoptosis through MEK and AKT-dependent
pathways [503, 504]. Further, it has been reported that RAF-1 is subject to
constitutive regulation by manyfactors [505].
Here I investigated by western blot analysis the effects that 2, 4 and 8Gy ofy-
radiation havd on the level of p53 and RAF-1 in twelve asynchronously growing
cultures of human cancercell lines, six cell lines with a wt-p53 protein and six cell
lines with a range of mutations both at the genomic andprotein level [484].
4.2 Methods
Post-irradiated total-cell-lysates were prepared from asynchronously growing pre-
confluent cultures of human cancercell lines. The cells were seeded, irradiated and
harvested as indicated in Materials and Methodssection 2.4.1. The protein content of
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the cell lysates was then determinedasindicated in section 2.4.2 and the level of p53
and RAF-1 determined by SDS-PAGE and western blot analysis as described in
section 2.4.3 using ECL to report the level of protein in each sample.
Therelative level of protein for the control and irradiated cells was then determined
by densitometric analysis. The western blot radiographic image wasfirst digitalised
by scanning with a flat bed scanner and this image was then analysised using
Phoretix 1D software (Phoretix, South Africa). The numerical value assigned to each
sample was then plotted as percentagesofirradiated divided by control for 2, 4 and
8Gy for the paired control at each time. The level of p53 and RAF-1 at any given
time in the controls was assumedto be 100% ofcell normallevel, and fluctuations as
a result of irradiation at 2, 4 and 8Gy would be seen asless than 100% for decrease
in protein level, and increase in protein level of the irradiated samples compared to
the paired control would be observedas a percentage greater than 100%.
4.3 Results
4.3.1 Protein level of p53 and RAF-1in post-irradiated humancancercell lines
Alterations in the level of p53 and RAF-1 protein were determined as indicated
above. Figure 14 (page 101), showsthe protein level of the proto-oncogene RAF-1
and the tumour suppressor gene p53 at control, 2, 4 and 8Gy for the wt-p53
transitional bladder cell carcinoma MGH-U1 and the mutant-p53 small cell lung
carcinoma H322. These results are representative of the twelve cancer cell lines,
2780, Colo320, H322, H417, Hep2, HRT18, HT29.5, 1407, MGH-U1, OAW42,
RPMI7951 and RT112 used in this study and are representative of the triplicate
results obtained for MGH-U1 and H322.
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As can be seen for both H322 and MGH-U1the level of p53 remains constant
throughout the time course. However, fluctuations are seen in the level of RAF-1 for
both H322 and MGH-U1, not only in the irradiated samples but also in the paired
sham-irradiated controls during the duration of the experiment. These changesin the
level ofRAF-1 protein were seenat all doses ofradiation.
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Figure 14. Expression of p53 and RAF-1 in the human cancercell
lines H322 and MGH-U1following 2, 4 and 8Gyofy-radiation over
36h The figure above depicts the protein levels ofRAF-1 and p53 as
determined by SDS-PAGEandwestern blotting. p53 and RAF-1 protein
was then probed for with antibodies and ECL wasusedto visualise the
relative level of protein expressed.    
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4.3.2 Changes in level of p53 and RAF-1 protein in human cancercell lines
following exposureto ionising radiation
Following exposureto ionising radiation the level of p53 and RAF-1 expression was
determined by SDS-PAGEand western blot analysis as outlined above (section 4.2).
Protein level in the control sample was designated as 100%. In post-irradiated cell
lines, levels of p53 and RAF-1 proteins were expressed as relative percentage of
control. The results of the analysis of p53 protein level are given in Figure 15 and 16
(page 103 and 104 respectively) whilst the analysis of RAF-1 level are given in
Figures 17 and 18 (pages 105 and 106 respectively) for the wt-p53 cell lines and the
mutant-p53 cell lines respectively.
In the 12 human cancer cell lines analysised, the mutant-p53 cell line HT29.5
showed the lowest changes in p53 level for the irradiated samples compared to the
controls throughout the duration of the experiment, less than 20% difference to the
control. Conversely, the mutant-p53 small cell lung cancer cell line H417 had the
largest decrease in p53 level following 2, 4 and 8Gy, of up to 25%, whilst several
cell lines had an increase in p53 level of 25%. However, no apparent significant
changes wereobservedin the level of p53 protein from the control samples in any of
the 12 cell lines examined over 36h following exposureto y-radiation at 2, 4 or 8Gy.
The level of RAF-1 protein showed large fluctuations in all the cell lines in the
control, 2, 4 and 8Gy samples throughout the 36h time course (see representative
data in Figure 14). The wt-p53 cell lines 2780/735 and Hep2 had the highest degree
of RAF-1 protein level changes (see Figure 17). For Hep2, increases of 70% and
decreases of 60% were measured for individual time points. In the mutant-p53 cell
lines (see Figure 18) RAF-1 protein levels gave consistent increases, up to 30%
above the control samples throughout the duration of the experiment for all doses
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used. However,changesin the level of RAF-1 protein were notsignificant (as tested
by t-test for individual time points).
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Figure 15. Relative p53 protein level following exposureto 2, 4 and 8Gy
of y-radiation in six wt-p53cell lines The effect of increasing doses of
ionising radiation on p53 protein expression in 6 wt-p53 cell lines is shown
as percentage ofrelative protein level compared to the paired controls.    
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Figure 16. Relative p53 protein level following exposureto 2, 4 and 8Gy
of y-radiation in six mutant-p53 cell lines The effect of increasing doses of
ionising radiation on p53 protein expression in 6 p53-mutantcell lines is
shownaspercentage ofrelative protein level compared to the paired
controls.    
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Figure 17. Relative RAF-1 protein level following exposure to 2,4 and
8Gyofy-radiation in six wt-p53 cell lines The effect of increasing doses of
ionising radiation on RAF-1 protein expression in 6 wt-p53cell lines is
shownas percentageofrelative protein level compared to the paired
controls.    
106
 Colo320 HT29.5
= 200
 
  
 
 
   
= is & irs  26y= = = 4Gy3 180 § 150 + 8 Gy<8 "8 HAGHH
5 @ 00& 75 a 75
& 50 & 30
B as Ba
© 4 roa0 4 € 12 16 20 24 90 36 0 4 8 12 16 20 24 90 96
Time (Hours) Tirme (Hours)
= 200
= is > 2 Oy ~~ 26y3 = 4Cy +4 4Gy
qq “i 8 Gy ~ 8Gy
‘S 1004Bis
2 8RB
& ——_—_—e a0 4 8 12 16 20 24 90 96 0 4 8 12 16 20 24 90 96
Time (Hours) Time (Hours)
= 200= ws > 2 * 26yZ +4 4 Gy + 4Gy
g {80 ~ 8 Gy ~< $Gyc 18
@ 100
E 75
3 40Boa
e 0 a0 4 @ 12 16 20 24 90 96 O 4 8 12 16-20 24 90 36
Time (Hours) Tirne (Hours)
 
Figure 18. Relative RAF-1 protein level following exposureto 2, 4 and
8Gyofy-radiation in six p53-mutantcell lines The effect of increasing
doses ofionising radiation on p53 protein expression in 6 mutant-p53 cell
lines is shown aspercentage ofrelative protein level comparedto the paired
controls.    
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5 The relationship between RAF-1 protein expression, G,+M accumulation and
radiosensitivity in wt-p53 and mutant-p53cell lines following radiationat
increasing dose levels
5.1 Introduction
5.1.1 Radiation studies in cancercell lines
To investigate the putative role played by RAF-1 in determining the cellular response
to ionising radiation, I elected to examinethe relationship of RAF-1 protein level and
clonogenic cell survival following doses of 2, 4 and 8Gyof y-radiation. Such doses
are commonly used in manystudiesof irradiation-inducedalterations in cell cycle
progression. Thus to validate the work already done within the lab at 2Gy and to
potentially give an insight into cell cycle delay and post-irradiation survival in a
clinically relevant context I undertook to measure clonogenic survival and exit from
a GotM accumulation, in the context of p53 mutational status following a single
fraction of y-radiation of 2, 4 and 8Gy.
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5.2 Methods
5.2.1 Rate of G:+M exit (Tso) following 2, 4 and 8Gyofy-radiation
All experiments were undertaken on asynchronous, exponentially growing cell
cultures, and the cells were irradiated at 2, 4 or 8Gy, such that the modulation ofcell
cycle delay andthe rate of exit at these incremental doses of ionising radiation could
be investigated.
Cells were plated in the appropriate culture media, allowed to recover overnight and
irradiated using a '°’Cs source. Samples irradiated with 2Gy where harvested at 2h
intervals until 24h post-irradiation. For cells given 4 and 8Gy, samples were takenat
4h intervals initially for 24h, and then at 30, 36, 48 and finally 60h, a time period
found to be sufficient for over half the cells accumulated in G2+M to exit that
compartmentof the cell cycle. The actual times used vary from cell line to cell line,
and the appropriate times were chosen for each line and dose as needed.
Preparation of cells for irradiation, irradiation of the cells and the subsequent
sampling is given in sections 2.3.1-3. The cells were fixed and stained with the DNA
intercalating dye PI for flow cytometric analysis asindicated in section 2.3.4-5. The
method for determination ofthe percentage ofthe total cell population in each part of
the cell cycle so that the subsequent rate of Go+M exit (Tso) could be calculated is
described in greater detail in the General Methods,section 2.3.6.
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5.3 Results
5.3.1 Survival following higher doses of radiation
Following increasing exposure to ionising radiation, at 2, 4 and 8Gy,radiosensitivity
in twelve humancancercell lines, determined by clonogenic assay and expressed as
SF2, SF, and SF(the survival fraction at 2, 4 and 8Gy ofradiation respectively). The
survival fraction data points for the twelve cancercell lines are shown in Figure 19A.
Asanticipated, the fraction of surviving clonogenic cells diminished as the radiation
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Figure 19. Radiosensitivity as determined by survival fraction in 12 human
cancercell lines at 2, 4 and 8Gyandin the context of p53-mutational status
The progressive decreasein cells surviving in each of the twelve human cancer
sell lines following 2, 4 and 8Gyofionising y-radiation is shownin panel A,
whilst the effect of p53 mutationalstatus is shown in panelB.In panel A, the
single star (*) indicated that the survival fraction at 4Gyis significantly lower
than at 2Gy, whilst the double (**) indicates that at 8Gy the survivalfraction is
significantly lower than both that at 2Gy and that at 4Gy. This was determined
byt-test.     
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dose increased from 2 to 8Gy. These decreases in clonogenic cell survival were
found to be significant at each stepwise increase in the dose ofradiation received.
Theincrease in dose from 2Gy to 4Gyresulted in a decrease in survival fraction from
0.485 (£0.05) to 0.195 (+0.046), respectively. This decrease in survival was very
highly significant as measured by the one-tailed t-test (P<0.0001, r=0.981).
At 8Gy, the survival fraction (SFs) was found to be 0.023 (£0.010). This 2% oftotal
potential of reproductive survival was found to be very highly significant as
compared to both 2Gy (P<0.0001, r=0.967) and also 4Gy (P<0.0001, r=0.890).
5.3.2 p53 mutational status and survival at increasing doses of radiation
A highly significant decrease in clonogenic survival fraction was observed with
stepwise increases in the dose of y-radiation to which the cell lines were exposed.
However, these changesin survival fraction at each single dose did not result in an
alteration in the relative sensitivity of the human cancercell lines in terms of p53
mutational status (Figure 19A, 2, 4 and 8Gy). The degree to which cells were
resistant to 2Gy of ionising radiation, as given by the clonogenic determinant
survival fraction (SF2), and the influence of p53-mutational status on survival is
shownin Figure 19B.
The six wt-p53 cell lines demonstrated a lower mean survival, along with a broader
range of survival (0.455+0.071 (SEM)), as compared to that of the mutant-p53 cell
lines (0.51740.040). The means of the populations, however, demonstrated no
significant difference (twotailed t-test; p=0.4648).
Likewise, at 4Gy, the 6 mutant-p53 cell lines demonstrated an almost identical mean
survival fraction of 0.1993+0.044, as compared to 0.1903+0.048 for the wt-p53 cells.
Thet-test ofthese meansresulted in a very weak value of P=0.8929, r=0.0044.
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At 8Gy, the statistically insignificant relative increase of the mutant-p53 cell lines
was reversed, with the wt-p53 cell lines demonstrating a mean survival fraction of
0.0245+0.0097 as compared to a mean of 0.0220+0.0099 for the mutant-p53 cell
lines. This difference was however found to notbe significant by an unpairedt-test,
P=0.8576, r=0.058.
5.3.3 Accumulation of cells in G:+M cell cycle phase following progressively
highersteps in y-radiation dose
The percentage of cells accumulating in G)+M following 2, 4 and 8Gyofionising
irradiation for the twelve cancercell lines used in this study is shown in Figures 20-
ook
Post-irradiation G7+M accumulation may be expressed as the area under the Go+M
accumulation curve. Where exit is not complete however, this value may be
unreliable, and may not ‘necessarily’ reflect changes in the rate of progress through
the latter phase ofthe cell cycle.
Also indicated on the Figures 20 to 25 are the times taken for the cells to reach 50%
following peak accumulation (Tso) in the pre-division stage, and the method
employed to determine the duration of Tso in G2+M exit, as described in the methods
(section 2.3), is also indicated.
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Figure 20. Percentage of cells in G)+M cell cycle phase following 2, 4 and
8Gyof ionising radiation and determination of Tso.
The amount ofpost-irradiated G2+M accumulation as measured by PI DNA
staining and flow cytometry on 2780/735 and Colo 320 cell lines is shown
above. Enumeration of the percentage oftotal cells in Go+M wasinterpolated
using ModFit (Verity Software), the mathematical modelling package. These
graphs were then used to determine the Tso value, the rate of exit from the
G»ot+M accumulation, for each cell line.   
114
 
 A) HEp?2(wt-p53)
707
60+
50-
404
30+
20+
Pe
rc
en
ta
ge
Cel
l P
op
ul
at
io
n (
%)
70+
60+
504
404
30-
20+
Pe
rc
en
ta
ge
Cel
l P
op
ul
at
io
n (
%)
—-2Gy
Ts9:Exit=4.07Hrs
4.40 ann 40 50
Time (Hrs)
—4Gy
Tso:Exit=9.75Hrs
ne 
704
60-
50+
Pe
rc
en
ta
ge
Cel
l P
op
ul
at
io
n (
%)
¥ + 1 1 110 20 30 40 50
Time (Hrs)
—8Gy
Tso:Exit=32.85Hrs
  40 20 30 40 50Time (Hrs)
B) H322 (mutant-p53)
Pe
rc
en
ta
ge
Cel
l P
op
ul
at
io
n (
%)
Pe
rc
en
ta
ge
Ce
ll
Po
pu
la
ti
on
(%
)
Pe
rc
en
ta
ge
Cel
l P
op
ul
at
io
n (
%)
70:
—-2Gy
Ts: Exit=1.55Hrs
 
60+
50+
404
30+
20+  
70+
60+
504
40-
30+
20+    
Vio 20 30 40 50
Time (Hrs)
—-4Gy
Tso:Exit=12.55Hrs
10 20 30 40 50
Time (Hrs)
—- 8Gy
Tso:Exit=10.6Hrs
10 20 30 40 60
Time (Hrs)
 
Figure 21. Percentage of cells in the G:+M cell cycle phase following 2, 4
and 8Gyofionising radiation and determination of Tso
The amount of post-irradiated G2+M accumulation as measured by PI DNA
staining and flow cytometry on HEp 2 and H322 cell lines is shown above.
Enumeration of the percentage of total cells in G2+M wasinterpolated using
ModFit (Verity Software), the mathematical modelling package. These graphs
were then used to determine the Tso value, the rate of exit from the G2+M
accumulation, for each cellline.   
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Figure 22. Percentage of cells in the G.+M cell cycle phase following 2, 4
and 8Gyofionising radiation and determination of Tso
The amount of post-irradiated G2+M accumulation as measured by PI DNA
staining and flow cytometry on HRT18 and H417 cell lines is shown above.
Enumeration of the percentage of total cells in G2+M wasinterpolated using
ModFit (Verity Software), the mathematical modelling package. These graphs
were then used to determine the Tso value, the rate of exit from the G2+M
accumulation, for each cellline.    
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Figure 23. Percentageof cells in the G2+M cell cycle phase following 2, 4
and 8Gyof ionising radiation and determination of Tso
The amount of post-irradiated G2+M accumulation as measured by PI DNA
staining and flow cytometry on 1407 and HT29.5 cell lines is shown above.
Enumeration of the percentage of total cells in G2+M wasinterpolated using
ModFit (Verity Software), the mathematical modelling package. These graphs
were then used to determine the Tso value, the rate of exit from the Go+M
accumulation, for each cell line.   
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Figure 24. Percentageof cells in the G:+M cell cycle phase following 2, 4
and 8Gyofionising radiation and determination of Tso
The amount of post-irradiated G2+M accumulation as measured by PI DNA
staining and flow cytometry on MGH-U1 and RPMI 7951 cell lines is shown
above. Enumeration of the percentage of total cells in G2+M wasinterpolated
using ModFit (Verity Software), the mathematical modelling package. These
graphs were then used to determine the Tso value, the rate of exit from the
G>tM accumulation, for each cellline.    
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Figure 25. Percentage of cells in the G,+M cell cycle phase following 2, 4
and 8Gyof ionising radiation and determination of Tso
The amount of post-irradiated G2+M accumulation as measured by PI DNA
staining and flow cytometry on OAW42 and RT112 celllines is shown above.
Enumeration of the percentage of total cells in G2+M wasinterpolated using
ModFit (Verity Software), the mathematical modelling package. These graphs
were then used to determine the Tso value, the rate of exit from the G2+M
accumulation, for each cellline.    
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5.3.4 Cells accumulate in G,+M in progressively greater numbers following
increasinglevels of ionising radiation
Asdose increases, the cell lines studied showed a progressively great accumulation
of cell G2+M, as indicated by area under the curve of the percentage of cells in
G»+M over the course of the experiment. I consided the magnitude of the G2+M
accumulation at 2Gy only, as at 4 and 8Gy the majority ofthe irradiated cells used
did not returned to the level of the controls within the duration of the time course
undertaken. At 2Gy, the mean of the two populations (mutant- and wt-p53), was
greater in the wt-p53 cell lines than in the corresponding mutant-p53 cell lines.
However, there was no significantly difference between the set of six wt-p53 and
mutant-p53 cell lines (twotailed t-test; p=0.2483). As can be seen in Figure 26, in
general, the mutant-p53 cell line demonstrated a lower degree of G)+M accumulation
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Figure 26. Effect of p53 mutational status on size G,+M accumulation
following 2Gy of y-radiation in human cancercelllines
The above column scatter plots depict the post-irradiation accumulation of the
six wt-p53 and the six mutant-p53cell lines in G7+M cell cycle phase following
2Gyofy-radiation.     
120
following irradiation. However, in the the mutant-p53 cell line; the colorectal
carcinoma Colo 320, the percentage of cells in G)+M forthe irradiated sample did
not return to the level of the controls by 24h, resulting in the largest G2+M
accumulation of any of the cell lines examined. This single result skewed the
statistical analysis. However, though a formal analysis at 4 and 8Gy for the reason
mentioned above, the mutant-p53 cell lines appeared to demonstrate a progressively
higher accumulation in G2+M following irradiation as compared to wt-p53cell lines.
5.3.5 Higher y-radiation doses result in the later onset of G.+M cell cycle
maximum accumulation
The time at which the maximum accumulation of cells in Gy+M cell cycle phase was
seen to occur in twelve human cancer cell lines increased as doses of ionising
radiation increased (Figure 27A). The average time at which the maximum
percentage of cells accumulated at 2Gy was 11.00h after irradiation. This increased
to 13.33h following irradiation at 4Gy in the twelve cancer cell lines. This increase
of 2.33h, an increase of 21% following 4Gy as compared to 2Gy was, however, not
foundto be significant by t-test (P=0.0839, r=0.408).
As denoted ‘**’ in Figure 27 A, the increase in time taken for the maximum cell
accumulation to occur at 8Gy, 16.33h post-irradiation, was significantly greater than
that at 2Gy (P=0.0042, r=0.695), as was that observed at 8Gy as compared to 4Gy
(P=0.027, r=0.545). Thus, the relatively high dose of 8Gy was shownto significantly
increase the time at which twelve humancancercell lines maximally accumulate in
GotM.
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Figure 27. The time of peak accumulation in G2+M cell cycle phase in 12
humancancercell lines and p53-mutational status at 2, 4 and 8Gy
The influence of increasing doses of radiation and p53-mutational status on the
timing ofmaximum percentage cell accumulation in the G2+M phaseofthe cell
cycle as shown Figures 20-25 (page 113-118), is given above. The timing of
maximalcell accumulation for the twelve human cancersell lines following 2, 4
and 8Gyof ionising y-radiation is shown in panel A, whilst the effect of p53
mutational status at these increasing dosesofradiation is in the 6 wt-p53, and 6
mutant-p53 cell lines is shown in panel B, 2Gy, 4Gy and 8Gy. The double star
(**) in panel A denotes that the peak accumulation at 8Gy wassignificantly later
than that at 2 and 4Gy. Thestar (*) in panel B-8Gy, donotesthat the onset of
peak accumulation in the mutant-p53cell lines is significantly later than that in
the wt-p53 celllines.   
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5.3.6 p53 mutational status and the onset of peak accumulation at increasing
dosesofy-radiation
In general the wt-p53 cell lines appeared to reach maximum accumulation earlier
than the mutant-p53 cell lines (See Figure 27B for results at 2, 4 and 8Gy). The
timing at which the mean maximum numberofcell accumulated in G)+M at 2Gy
wasfoundto be 10.67+0.42h and 11.33+1.61h for the six wt-p53 and six mutant-p53
cell lines respectively. However, the rapidity with which the cancercell lines reached
this maximum delay in Gj+M following exposure to y-radiation, showed no
significant difference between the 6 wt-p53 or the 6 mutant-p53 cancercelllines as
determined by the Welch’s correction to the t-test (p=0.7046). After a dose of 4Gy
there was a similarly longer interval between irradiation and the time to peak
accumulation in the G2+M cell cycle phase, with the mutant-p53 cell lines taking
longer to accumulate maximally than the wt-p53cell lines. As at 2Gy,this difference
in time to peak accumulation failed to reach significance. The six wt-p53 cell lines
on average had a maximal accumulation at 11.3341.23h as comparedto that of the
mutant-p53 cell lines; that of 15.33+1.98h, with the differences in mean
accumulation giving a P value of 0.0583 r=0.477 (Unpaired t-test).
At 8Gy, the same relative increase in the time to peak accumulation following
irradiation was again seen. However, when consideringthe cell lines in terms oftheir
p53 mutational status, the difference in mean time to peak accumulation was
significant. The time taken for the onset of peak accumulation in G2+Mcell cycle
phase for the wt-p53cell lines was 13.33+1.33h following irradiation. This compares
to 19.33+1.91h for the mutant-p53 cell lines. This shorter period, that the wt-p53 cell
lines required to reach peak accumulation, was significantly different to that of the
mutant-p53 cell lines (P=0.0411, Unpaired t-test). Thus, the high level of 8Gy of
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ionising radiation wasnot only sufficient to induce a significant increase in the time
taken for humancancercell lines to reach maximal accumulation, as compared to 2
and 4Gy, but also that this high level of y-radiation was sufficient to manifest a
difference in the response of wt-p53 human cancercell lines when compared to
human cancercell lines possessing mutant-p53. This result was unexpected, asit
could be predicted that the wt-p53 cell lines could have been delayed in the G,-Scell
cycle phasetransit, thus resulting in a longer time to maximum G2+M accumulation.
These data may indicate that the humancancercell lines respond differently at 8Gy
than they do at 2 and 4Gy.
5.3.7 Increasing doses of ionising radiation cause a greater level of the
percentageoftotal cells to accumulate in G.+M
Following increasing doses of y-radiation, the percentage oftotal cells accumulating
in the G2+M phaseofthe cell cycle; the magnitude of the peak accumulation in the
the post-irradiation period, was seen to increase with dose (see Figure 28A). The
average peak percentage of total cells accumulating in G2+M was 14.8541.734%;
29.66£2.980%; and 42.92+3.780% following 2, 4 and 8Gy respectively. The
increases in the peak accumulation were both significant at 4Gy as compared to 2Gy
(P=0.0005, One tailed Wilcox-Paired t-test), and at 8Gy as compared to 2Gy
(P=0.0002, One tailed Wilcox-Paired t-test), and also at 8Gy as compared to 4Gy
(P=0.0002, One-tailed, Wilcox-Paired t-test). Thus, at each and every increase in the
level of y- radiation that the cells were exposed to, the response of the human cancer
cell lines was shownto be an increase in peak accumulation in the G2+M cell cycle
phase.
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Figure 28. The peak percentage of total cells accumulating in G,+M cell
cycle phase in 12 humancancercell lines the effect of p53-mutational status
at 2, 4 and 8Gy
The influence of increasing doses of radiation and p53-mutational status on the
level of maximum percentage cells accumulation in the G2+M phaseofthe cell
cycle as shown Figures 20-25 (pages 113-118), is given above. The peak
percentage population of cells accumulation for the twelve human cancersell
lines following 2, 4 and 8Gy ofionising y-radiation is shown in panel A, whilst
the effect of p53 mutational status at these increasing doses of radiationis in the
6 wt-p53, and 6 mutant-p53cell lines is shown in panel B, 2Gy, 4Gy and 8Gy. In
panel A, the star (*) at 4Gy indicates that the average magnitude of peak
accumulation in G2+M is significantly greater than that at 2Gy, whilst the double
star (**) at 8Gy indicates that the magnitude of delay in G)+Mis significantly
greater than that at 2gy and 4Gy. This was determined by two-tailed t-test as
indicated in section 5.3.7.    
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5.3.8 Peak percentage accumulation and p53 mutational status following
incrementally higher ionising radiation doses
The relationship between the peak percentage accumulation ofcells in the G2+M
phase of the cell cycle and p53 mutational status was not found to be significantly
different at 2Gy (p=0.085; twotailed t-test), nor was it seen to influence the peak
level of cell accumulation at 4Gy with mean accumulation of 29.84+3.33% and
29.48+5.29% for wt-p53 and mutant-p53 respectively. A t-test of these means gave a
P value of 0.937, showing nosignificant difference. Similarly, at 8Gy of y-radiation,
the mean values for the 6 wt-p53 cell lines, and six mutant-p53 cell lines for the peak
percentage accumulation was 43.61+5.63% and 42.2345.56% respectively. These
means were not found to be significantly different (P=0.818, by Mann-Whitney U-
test). Though increasing doses of ionising radiation resulted in increases in the peak
level of the percentage of cells accumulation in the G2+M phaseofthecell cycle, this
dose dependent cellular response did not appear to be p53 dependentas the increase
wasseen in both the wt-p53 and mutant-p53cell lines.
5.3.9 Gj+M Exit in human cancercell lines following increasing doses of y-
radiation
The determination of the rate of exit of cells accumulated in G.+M phaseofthe cell
cycle was performed as described in Chapter 2, of the methods. As can be seen from
the values in Table 14, generally, as the dose of radiation received increased, so did
the time taken for the cells to exit the accumulation in G2+M phaseofthe cell cycle.
Forall twelve cell lines an increased average T 50 times of 3.46+0.54h, 7.35+0.97h,
and 15.47+2.59h was observedat 2, 4 and 8Gyrespectively.
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G2+M Accumulation (Ts0)
Dose 2 Gy 4Gy 8 Gy
2780 2.59 7.00 13.65
» HEp2 4.07 9.75 32.85
& HRT18 3.15 6.05 8.85& [1407 5.30| 4.85] 9.55
= MGH-UI 3.70 6.00 6.10
2 OAW42 1.85 6.75 __17.75
8 Average 3.44 6.73 14.79cn Colo 320 7.10; 12.45] 32.10
A. H322 1.55] 12.55] 10.60
2 H417 5.30] 11.10] 19.20= H1T29.5 4.40| 2.90] 7.80
= RPMI 7951 1.00 5.90 9.95
RT112 1.55 2.90] 17.25
Average 3.48 7.97| 16.15
Pan-P53_ Average 3.46 7.35 15.47       
Table 14. G.+M exit (Tso) in twelve humancancercell lines
following increasing dosesof ionising radiation
The above table contains the Tso values for the twelve human cancer
cell lines used in this study at 2, 4 and 8Gy of y-radiation from a
GammaCell 1000 with a '°’Cs source. The cell lines are ranked
alphabetically and by p53 Mutational Status, with the average time of
exit from G2+M cell cycle accumulation calculated for both wt-p53
and mutant-p53, and for pan-p53, i.e. all cells regardless of mutational
status.     
Although an increase in the Ts) was the general trend, it was not always present in
the cell lines when considered individually as can be seen in the wt-p53 embryonic
intestinal epithelial cell line 1407, and the mutant-p53 colonic adenocarcinomaclonal
variant HT29.5, where the Tso times for 4Gy were greater than at 2Gy, and asis the
4Gy Tso time as compared to the 8Gy time in the mutant-p53 small cell carcinoma
cell line H322.
The obviousincreases in the duration of the rate of G2+M exit as measured by Tso
following increases in exposure of human cancer cells to ionising radiation as
represented by the increases in the mean exit times for the twelve cell lines was
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supported by the fact that these increases were significant by a Pairedt-test. The
increase in Tso following 2Gy and 4Gyirradiation gave a P-value of 0.002; r=0.776.
This difference was greater when comparing the Tso at 2Gy to that of 8Gy, which
generated a P-value of 0.0004, r=0.832. The increase in the mean Tso at 8Gy
compared to 4Gy gave a P-value of 0.004, r=0.744. Thus each and every increase in
the dose of y-radiation that the cells were exposedto resulted in a significant increase
in the time taken for the cells to exit the G.+M cell cycle phase accumulation.
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Figure 29. The peak percentageoftotal cells accumulating in G:+Mcell
cycle phase in 12 humancancercell lines the effect of p53-mutational status
at 2, 4 and 8Gy
Theinfluence ofincreasing doses of radiation and p53-mutationalstatus on the
level ofmaximum percentage cells accumulation in the G2+M phaseofthecell
cycle as shownfigures 20-25, is given above. The peak percentage population of
cells accumulation for the twelve humancancersell lines following 2, 4 and
8Gyof ionising y-radiation is shown in panel A, whilst the effect of p53
mutationalstatus at these increasing dosesofradiation is in the 6 wt-p53, and 6
mutant-p53 cell lines is shown in panel B, 2Gy, 4Gy and 8Gy.   
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5.3.10 Increasing doses of y-radiation, p53-mutational status, and the rate of exit
from G,+M accumulation (Ts) in humancancercell lines
Following ionising radiation, the six mutant-p53 cell lines, on average, delayed
longer than the six wt-p53 cell lines in Gy+M cell cycle phase. In the wt-p53 cell
lines the mean (4S.E.M) Tso exit times from a G)+M accumulation following
exposure to y-radiation were 3.44+0.49h, 6.73+0.68h and 14.79+3.98h, at 2, 4 and
8Gy respectively. The mutant-p53 cell lines had a Tso exit times of 3.48+1.01h,
7.97+1.88h and 16.15+3.67h at 2, 4 and 8Gyrespectively.
Though the mutant-p53 cell lines appeared to take longer to exit the G)+M phase of
the cell cycle following maximum accumulation at all doses, the increases did not
translate to a significant difference as determined by the unpairedt-test at either 2Gy
(P=0.972, r=0.011), 4Gy (P=0.5517, r=0.191), or 8Gy (P=0.8069, r=0.079). Thus,
though the mutant-p53 cells appear to take progressively longer to exit G)+M
following maximum accumulation,this increase in Tso appears to be independent of
p53 mutational status, though not necessarily independent of p53 protein.
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5.3.11 Survival fraction following increasing doses of y-radiation and the
intrinsic level of RAF-1 protein in 12 humancancercelllines
The intrinsic level of RAF-1 protein showed a negative relationship to post-
irradiation survival of cells following 2, 4 and 8Gy of ionising radiation, in the
twelve cancercell lines studied. Following 2Gy ofionising radiation, the percentage
of clonogenic cells as measured by SFin the twelve cancercell lines studied and the
level of RAF-1 protein showed a significant negative relationship (r=-0.766,
p=0.004) (see Figure 30A). This trend in decreased survival with higher levels of
RAF-1 protein was similarly found at 4Gy (SF,) (P=0.01, r=0.708) (see Figure 30B)
and although such a negative trend could be seen in RAF-1 protein level and
surviving fraction at 8Gy (SFs) (see Figure 30C), it was not found to be significant
(P=0.202, r=0.397). However it should be noted that at 8Gy very few cells
demonstrated the ability to proliferate, typically less than 1 in 18 of the cells plated
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for clonogenicassay.
5.3.12 Survival fraction, RAF-1 protein level and p53-mutational status in
humancancercell lines following increasing doses of y-radiation
When the p53 mutational status was taken into account when considering the
intrinsic level of RAF-1 protein and SF, the wt-p53 cancercell lines showed a very
strong negative relationship, (r=-0.918, p=0.004). This relationship demonstrates that
the cells with a shorter exit show a greater survival (SF2). A similar trend relating
SF, to RAF-1 protein expression was seen to be present within the mutant-p53 cell
lines, whilst this relationship was negative, this relationship did not reachstatistical
significance in the six mutant-p53 cancercell lines (r=-0.464, p=0.354).
Asat 2Gy, the increased dose of 4Gy resulted in a decrease in survival fraction with
an increase in the level of RAF-1 protein (See figure 31B and 31E). The resultant
correlation between RAF-1 protein level and radiosensitivity, as determined by the
survival fraction at 4Gy (SF4), was only foundto bestatistically significant in those
cells with a wt-p53. The correlation coefficients of the wt-p53 cell lines was
P=0.0243, r=0.870, whilst the values generated for the mutant-p53 cell lines was
P=0.2378, r=0.570.
A similar trend relating SFs to RAF-1 protein expression was seen to be present
within both the wt-p53 and mutant-p53 cell lines (Figure 31C and F respectively).
Whilst this relationship was negative, the correlation did not reach statistical
significance in either the six wt-p53 or the six mutant-p53 cancercell lines (P=0.311;
r=0.501 and P=0.4584; r=0.379 respectively).
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Figure 31. The relationship between RAF-1, survival (SF2), the exit from a
post-irradiated G2+M accumulation, and p53 mutational status
The effect of RAF-1 protein level on post-irradiated survival fraction, in the
context of p53 mutational status in twelve human cancercell lines is shown
above. The intrinsic RAF-1 protein level is plotted against survival fraction at for
the six wt-p53 cell lines in A, B, and C, with the six mutant-p53 cell lines in D, E,
and F at the increasing doses of 2Gy, 4Gy and 8Gyrespectively. Plots that
demonstrate a statistically significant relationship (i.e. p<0.05) are indicated by a
star (*).    
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5.3.13 Rate of G:+M exit following increasing doses of y-radiation and the
intrinsic level of RAF-1 protein in 12 humancancercell lines
At 2Gyofy-radiation, the intrinsic level of RAF-1 was not found to correlate with
the rate of G)+M exit (Tso) whenall twelve human cancercell lines were considered
together (P=0.897, r=-0.042).As at 2Gy, the intrinsic level of RAF-1 protein did not
correlate to the rate of exit from radiation induced accumulation at 4Gy (P=0.976,
t=0.098), see figure 32B, or at 8Gy (P=0.347, r=0.298), see figure 32C.
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5.3.14 G:+M exit, RAF-1 protein level and p53 mutational status in human
cancercell lines following increasing doses of y-radiation
The mutational status of p53 was shownto contribute to the correlation between
RAF-1 protein level and the rate at which cells exit the G.+M post-irradiation
accumulation, as determined by Tsat 2Gy. For the wt-p53cell lines a relationship of
high RAF-1 protein level and rapid exit from G2+M accumulation was observed
(P=0.002, r=0.965). This positive relationship observed in the wt-p53 cell lines
between the high levels of RAF-1 protein and the rapidity of exit from a G2tM
accumulation, as indicated by a low Tso, was reversed in the mutant-p53 cell lines
and wasnotstatistically significant (P=0.070, r=-0.775).
As can be seen from Figure 33B and E, at 4Gy there was no apparentrelationship in
the rate of G2+M exit and intrinsic RAF-1 protein level in either the wt-p53 or
mutant-p53 cell lines (P=0.998;r=0.001, or P=0.858; r=0.095, respectively). A
similar absence of a correlation between the Tso of G2+M exit following 8Gy to the
intrinsic level of RAF-1 protein expression wasseen to be present within the wt-p53,
P=0.900; 1=0.097 (Figure33C), However, in the mutant-p53 cell lines a strong
positive relationship between the rate of exit from y-radiation induced G2:+M
accumulation and the level of intrinsic RAF-1 protein expression was demonstrated
(P=0.032; r=0.850).
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Figure 33. Exit from post-irradiated G,+M accumulation, RAF-1 protein
level, and p53 mutationalstatus
The effect of RAF-1 protein level on post-irradiated exit from G.+M
accumulation (Tso), in the context of p53 mutational status in twelve human
cancer cell lines is shown above. The intrinsic RAF-1 protein level is plotted
against Tso for the six wt-p53 cell lines in A, B, and C, and for the six mutant-p53
cell lines in D, E, and F at the increasing doses of 2Gy, 4Gy and 8Gy
respectively. Plots that demonstrate a statistically significant relationship (i.e.
p<0.05) are indicated by star (*).   
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5.3.15 Increasing doses of radiation, rate of exit from G2:+M accumulation and
post-irradiation clonogenisity in human cancercell lines
Following a single fraction of y-radiation at 2Gy from a '°’Cs source, no apparent
relationship was found atthis clinically relevant dose in the twelve humancancercell
lines between the rate of exit from Gy+M accumulation, Tso, and proliferative
fraction as measured by clonogenic assay (correlation coefficient P=0.897, r=-0.04).
At 4 and 8Gy,a tentative negative relationship between the time taken for cells to
exit a pre-mitotic cell cycle accumulation and survival fraction appeared to develop.
With increasing doses of radiation, 4 and 8Gy, a trend of decreased radiosensitivity
with decreased Tso transit time (Figure 34B and 34C respectively). When this
putative relationship wastested, no significant link between survival fraction and Tso
was found (P=0.352; r=0.294 and P=0.152, r=0.440 respectively), although the
correlation at 8Gy wascloser to significance than at 4Gy.
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Figure 34. Intrinsic radiosensitivity and the rate of exit from G2+M cell cycle
accumulation following 2, 4 and 8Gy single fraction of y-radiation in 12
humancancercell lines
The relationship between survival fraction on the rate of exit from G)+M
following y-radiated doses of 2, 4 and 8Gy, in twelve human cancercell lines is
shown in graphs A, B, and C respectively. All points are shown with error bars
(S.E.M.). However, the error bars lie within the data point symbol.  
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5.3.16 Progressively higher doses of radiation and its effect on the rate of G.+M
exit (Tso) on radiosensitivity (survival fraction) in wt-p53 as compared to
mutant-p53 cancercell lines
As depicted in Figure 35A wt-p53 did appear to contribute to the rate of post-
irradiation G2+M exit, Tso, with relation to post-irradiation clonogenic survival
following 2Gy of y-radiation, SF2. In the cells lines expressing wt-p53 the rate at
whichcells exit the post-irradiation G)+M cell cycle accumulation appears to have a
strong positive influence on radiosensitivity, i.e. the longer cells take to exit the post-
irratiation induced G2+M accumulation the morecells survive. This relationship was
not present in the mutant-p53cell lines, see Figure 35D. In the wt-p53 cell lines the
relationship between the rate of G2+M exit and SF. was found to give a linear
regression of r=0.965 with a significance of P=0.002. In the mutant-p53 cell lines the
relationship between Tso and SF» failed to reach significance at 5%. Thusthe strong
positive relationship observed in the wt-p53 cell lines switched to a non-significant
negative relationship, that is cells exiting the G.+M accumulation more rapidly
demonstrated a greater clonogenic survival (P=0.070, r=-0.775).
At 4Gy (Figure 35B), the trend of radiosensitivity and rapid exit from G2+M cell
cycle phase delay still appeared in wt-p53 cell lines, however this relationship was
not found to be significant in either the 6 wt-p53 cell lines or the 6 mutant-p53 cell
lines (Figure 35E)(P=0.799; r=0.135 and P=0.263; r=0.545 respectively). As at 4Gy,
following 8Gy of y-radiation (Figure 35C and F), both the 6 wt-p53cell lines and the
mutant-p53cell lines resulted in a decreased survival fraction following a more rapid
exit from G2tM exit. Similarly, as at 4Gy this apparent trend was not found to be
significant with P-values of 0.349 and 0.424 andr-values of 0.468 and 0.407 for the
wt-p53 and mutant-p53cell lines respectively.
138
 
Wi
ld
Ty
pe
p53
Mu
ta
nt
p5
3
A) Tso at 2Gy vs. SF, B) Tso at 4Gy vs. SF, C) Tso at 8Gy vs. SF
 G
)+
ME
xit
(Ts
9)
ty
b
o
o *
°o
0.0 0.2 04 06 0.8
Radiosensitivity (SF2)  G
,+M
Ext(
Tso
)
0.0 0.1 0.2 03
Radiosensitivity (SF4)
 
04  
40
~ &2 30
5= 20
+S 10 a
a
0
0.00 0.05 0.10
Radiosensitivity (SFs)  
D) Tsat 2Gyvs. SF, E) Tso at 4Gy vs. SF, F) Tso 8Gy VS. SF:
 G,
+M
Exit
(Tso
)
 
0.0 0.2 0.4 06 0.8
Radiosensitivity (SF2)  G,
+M
Exit
(T
s)
0.0 0.1 0.2 0.3
Radiosensitivity (SF4)
04  
&
G,+
ME
xit
(Ts0
)
8
8
3 .
0
0.00 002 004 006 0.08
Radiosensitivity (SF)  
 
Figure 35. Exit from post-irradiated G;+M accumulation, radiosensitivity,
and p53 mutationalstatus.
The effect radiosensitivity following higher doses of radiation and post-irradiated
exit from G2+M accumulation (Tso), in the context of p53 mutational status in
twelve human cancercell lines is shown above. The intrinsic radiosensitivity is
plotted against Tso for the six wt-p53 cell lines in A, B, and C, and for the six
mutant-p53 cell lines in D, E, and F at the increasing doses of 2Gy, 4Gy and 8Gy
respectively. Plots that demonstrate a statistically significant relationship (i.e.
p<0.05) are indicated by star (*).   
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Chapter6
Post-irradiative relationship between RAF-1
protein expression, G,+M accumulation and
radiosensitivity in human cancercell lines
following inhibition of p53 by the small
molecule inhibitor Pifithrin-a
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6 Post-irradiative relationship between RAF-1 protein expression, G2+M
accumulation and radiosensitivity in human cancer cell lines following
inhibition of p53 by the small molecule inhibitor Pifithrin-a
6.1 Introduction
Previous studies to explore the putative relationship between RAF-1 protein level,
radiosensitivity and G2+M cell cycle phase accumulation following 2, 4 and 8Gy of
y-radiation have yielded some conflicting results [480, 506]. The key observation
throughoutthis thesis is the relationship between the proto-oncogene RAF-1 protein
level, exit from post-irradiated G2+M cell cycle accumulation and radiosensitivity at
2Gy whichis present in wt-p53 but not mutant-p53.
In 1999 Andrea Gudkov and co-workers published data on a small molecule,
Pifithrin a (derived from P-fifty-three inhibitor) (PFTa), which was capable of
protecting normal mouse tissue from the effects of high levels of radiation. It was
postulated that this increased radioresistance was by inhibition of p53-mediated
apoptosis [507]. Therefore PFTa was used to further explore the influence of p53
mutational status on RAF-1 radiosensitivity and the rate of exit of cells from G2+M.
6.2 Methods
6.2.1 Toxicity determination of the small molecule inhibitor of p53-PFTa in 10
human cancercell lines
In the following experiments, the effect of post-irradiation clonogenic cell survival of
modulating p53 function by PFTa is studied. It was initially necessary to identify a
dose of PFTo that wasnotitself toxic to the cells in a clonogenic cell survival assays.
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The effect of exposure to PFTa in ten adherent humancancercell lines with a range
ofPFTa doses wastherefore studied.
Cells were seeded into 6 well tissue culture plates at 100, 200 and 500cells per well
in triplicate, along with control plates to determine plating efficiency and were
incubated at 37°C in a humid incubator with 5% v/v CO)in air, for 6h such, that the
cells attached. This was visually confirmed microscopically. Cells were then treated
with 2, 5, 10, 15, 20 and 25uM PFTa in DMSO.Thefinal concentration of DMSO
was at 0.1%v/v for all samples. Following drug application the cells were then
returned to the incubator and examined frequently over a two-weekperiod.
The clonogenic assay was terminated once large colonies had formed, but before the
colonies started to merge. This was usually around 10 to 14 days after the initiation
of the assay. The media were aspirated; the plates were carefully washed twice with
PBSandthen fixed overnight in 70% v/v ethanol in RO water at room temperature.
The six-well plates were then stained in a 10% w/v giemsain ethanol for 30 min at
room temperature. Excess giemsa was washedoffthe plates by one wash in 70% v/v
ethanol followed by one wash in cold tap water. The plates were then allowed to dry
overnight at room temperature before counting. Only colonies containing over 50
cells were counted (as outlined in Materials and methods, section 2.2).
6.2.2 Determination of clonogenisity in 10 human cancercell lines following
ionising radiation in the presence of the p53-inhibitor PFTa
Radiosensitivity, the measurement of how sensitive cells are to radiation, is
determined clonogenically and expressed in terms of survival fraction SF,, at a given
dose, n. The SF, was determined for the ten adherent humancancercell lines used in
this study by exposure to a range of radiation doses following an overnight pre-
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treatment with 104M PFTa, a maximal non-toxic dose predetermined to cause less
than 5% death in the majority of the cell lines. PFTa was initially dissolved in
DMSOand then diluted to the required concentration by the addition of complete
HAMSF12 supplemented with 10% v/v FCS. The final DMSO concentration in
complete tissue culture media was 0.1% v/v.
Each of the ten human cancercell lines was exposed to progressively stepped doses
of y-radiation at 0, 1, 2, 3, 4, 6 and 8Gy. The clonogenic assays were otherwise
carried out as highlighted in section 2.2, with the same principles being used in the
calculation of the survival curves and determination ofthe alpha and beta values.
The survival curves were calculated using GraphPad Prism 3.0 (GraphPad Software,
Inc). The data wasfirst transformed using Y=log (Y) and then a second order
polynomial non-linear regression was undertaken, with constants A set to 0, i.e. no
death at 0Gy and the second andthird constants variable (second andthird constants
being the initial and late gradients of the curve and called a and B respectively)
giving the equation of SFp=exp (-«D — BD’), where D is dose and SF is survival
fraction. These survival curves are shown in Figures 36 and 37 and analysed to
determine whether the PFTa had affected radiation induced clonogenic cell survival
using two-way ANOVAofthe survival fraction data.
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6.2.3 Rate of G,+M exit (Tso) following 2, 4 and 8Gy of y-radiation in the
presence of PFTa.
All experiments were undertaken on asynchronous, exponentially growing cell
cultures as outlined in section 2.3 of the materials and methods.Prior to irradiation
the cells were pre-incubated with 101M PFToa for 24h under normal culture
conditions. Following pre-incubation with PFT« the cells were irradiated at 2, 4 or
8Gy such that the modulation of cell cycle delay and the rate of exit at these
incremental doses of ionising radiation could be investigated. The cells were seeded,
irradiated, harvested and analysed as indicated in section 2.3 in the Materials and
Methods.
6.3 Results
6.3.1 PFTa toxicity assays.
The toxicity of PFTa on the 10 human cancer cell lines was determined by
clonogenic assay following incubation with PFTa at 2, 5, 10, 15, 20 and 25uM.This
experiment was undertaken to determine the maximum dose that could be used on
the human cancercell lines before significant levels of cell death were induced.It
was determined that this should be no greater than 95% in the majority ofthe cell
lines, i.e. 6 of the 10. As can be seen in Figure 36,all the cancercell lines survived
10uM PFTa, however at 15uM only the wt-p53 cell lines 2780 and Hep2 survived.
Thusthe highest dose ofPFTa that 95% clonogenic survival cut-off criteria achieved
was 10uM.
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  Figure 36. Clonogenic determination of PFTatoxicity.Clonogenic assays were undertaken on the ten adherent human cancercell lines used in this study. All ten adherent cancercell lines areshownabove(see legend), along with the Do95 cut of point, i.e. thelevel of 95% cloning efficiency, which was used to determine theoptimal incremental doses ofPFTa to be utilised in the post-irradiationstudies.   
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6.3.2 Effect of the solvent DMSOoncellular radiosensitivity
The organic solvent DMSO canact as an anti-oxidant and as such is capable of
scavenging short lived free radicals of H* and OH” generated by ionising radiation
and thus protect against radiation induced damage and clonogenic cell death [508,
509].
Thus, as DMSO wasthe solvent for the p53 inhibitor PFTa, clonogenic assays were
undertaken for the ten adherent human cancer cell lines in 0.1% v/v DMSO in
complete culture media and compared these findings to historical clonogenic data,
whichhas been usedpreviously.
The 0.1% DMSOpre-treatmenthadlittle or no effect on the post-irradiation survival
of the wt-p53 cell lines 2780, HEp2, MGH-U1 and OAW 42, with ANOVAanalysis
resulting in P values of 0.0991, 0.6380, 0.9950 and 0.105 respectively when
compared to the untreated post-radiation clonogenic cell assays (see Figure 37A, 37B,
37E and 37F).
In two of the cell lines HRT18 and 1407 increases in radiosensitivity resulted from
pre-treatment with 0.1% v/v DMSO in the clonogenic media HAMS 12
supplemented with 10% foetal calf serum (See Figure 37C and 37D respectively).
For 1407 a highly significant P value of 0.0012 was generated from a two way
ANOVA, whilst the HRT18 cell lines gave a very highly significant P value of
<0.0001 for cells treated with DMSOasopposedto untreated cells.
In the four p53 mutant cell lines, H322, HT29.5, RPMI7951 and RT112 pre-
treatment did not result in any significant alterations on the post-irradiative
clonogenic survival (see Figure 38).
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Figure 38. The effect of the anti-oxidant DMSOand clonogenic survival
following y-irradiation in four mutant-pS53cell lines.
The clonogenic survival curves for four mutant-p53 cell lines following a
range of doses (0-8Gy) ofy-radiation are shown above. The open squares
represent the historical data whilst the filled squares represent the 0.1% v/v
DMSOpre-treated cells. All data points are plotted with error bars (S.E.M.).    
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6.3.3 Effect of 104M PFTa on cellular radiosensitivity
Comparison of the radiosensitivity of human cancer lines with and without 10uM
PFT« pre-treatment hadlittle or no effect on the post-irradiation survival at 0, 2, 4, 6
and 8Gyofy-radiation in three of the six wt-p53 cell lines (see Figure 39). ANOVA
analysis of the ovarian carcinoma 2780, squamous carcinoma of the Larynx HEp2
and the Transitional bladder carcinoma MGH-U1 resulted in P values of 0.8165,
0.9318 and 0.7729 respectively.
Onecell line demonstrated a decrease in radiosensitivity with PFTa treatment. The
ovarian cancer cell line OAW 42 gave significant increase in post-irradiative
clonogenic survival (P=0.0189 as determined by two-way ANOVA).
As in the 0.1% v/v DMSOtreated cells, the rectal adenocarcinoma HRT18 and the
intestinal epithelium 1407, demonstrated an increases in radiosensitivity following
pre-treatment with 10uM PFT«ain the clonogenic media HAMS 12 supplemented
with 10%v/v foetal calf serum. The responses of both these cell lines, HRT18 and
1407, mirrored that seen in the DMSOpre-treated cell lines (see Figures 37 and 39).
In 1407, the toxic effect of 101M PFTa in DMSOincreased as compared to that of
the cells without PFTa, (see Figures 37D and 39D). This increase was found to be
significant (P=0.001).
As in the DMSO pre-treatment post-irradiation clonogenic assay, the four mutant-
p53 cell lines, H322, HT29.5, RPMI7951 and RT112 pre-treatment with 10uM PFTa
did not result in any significant alterations on the post-irradiative clonogenic survival
(see Figure 40) (ANOVAP> 0.8253 for the four cell lines) .
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Figure 39. p53 inhibition with 104M PFTa and clonogenic survival
following irradiation in six wt-p53 cell lines
The clonogenic survival curves for six wt-p53 cell lines following a range of
doses (0-8Gy) of y-radiation are shown above. The open squaresrepresentthe
historical data whilst the filled diamonds represent the 101M PFT« pre-treated
cells. All data points were plotted with error bars (S.E.M.).   
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Figure 40. p53 inhibition with 10uM PFTa and clonogenic survival
following irradiation in four mutant-pS53cell lines
The clonogenic survival curves for four mutant-p53cell lines following a
range of doses (0-8Gy) of y-radiation are shown above. The open squares
represent the historical data whilst the filled diamonds represent the 104M
PFTapre-treated cells. All data points are plotted with error bars (S.E.M.).    
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6.3.4 Comparison of the p53 inhibitor PFTa and DMSOin post-irradiation
radiosensitivity in human cancercell lines
The next aim was to comparethe effect of the small molecule p53 inhibitor PFTa to
the organic solvent DMSO onradiosensitivity in six wt-p53 and four mutant-p53
human cancercell lines. Four of the six wt-p53 cell lines, 2780, HEp2, HRT18 and
MGH-U1 demonstrated no significant difference in their radiosensitivity for cells
treated with 0.1% v/v DMSO or 10HM PFTa (determined by two-way ANOVA
analysis with P values of 0.109, 0.395, 0.616 and 0.557 respectively) (Figures 40A,
40B, 40C and 40Erespectively).
In the 1407 cells, the 104M PFTa had an additional radiosensitising effect, in
addition to that seen in cells with 0.1% v/v DMSOalone (P<0.0001) (figure 41D),
whilst in OAW42, the PFTa showed the predicted radio-protective response,
although the difference in radiosensitivity is only slightly more than that of the
DMSOalonepre-treated cells, this decrease in post-irradiation sensitivity was found
to be significant by two-way ANOVA(P=0.033) (figure 40F). In the mutant-p53 cell
lines, no effect for the pre-incubation in 10uM PFTa as compared to 0.1% v/v
DMSO was observed (H322; P=0.062, HT29.5; P=0.067, RPMI 7951; P=0.986,
RT112; P=0.367) (see Figure 41).
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Figure 42. p53 inhibition with 101M PFTaand clonogenic survival
following irradiation in four mutant-p53cell lines
The clonogenic survival curves for four mutant-p53 cell lines following a
range of doses (0-8Gy) ofy-radiation are shown above. Thefilled squares
represent the 0.1% v/v DMSO data whilst the filled diamonds represent the
10uM PFTa pre-treated cells. All data points are plotted with error bars(S.E.M.).    
154
6.3.5 Accumulation of cells in G,+M cell cycle phase following progressively
highersteps in y-radiation dose following pre-treatment with PFTa
I have previously examined the percentage of cells accumulating in G)+M following
2, 4 and 8Gyofionising irradiation in a range of cancercell lines (shown in Figures
20-25, section 5.3.3). Investigated here was whether the small molecule inhibitor of
p53, PFTa, affected the time taken for irradiated cells to exit the G2t+Mcell cycle
accumulation. The time taken for the cells to reach 50% following peak
accumulation (Tso) in the pre-division stage and the method employed to determine
the duration of Tso in G2+M exit following 2, 4 and 8Gy were as outlined in section
2.3.7.
As can be seen in Figures 43 to 48, in the cells pre-treated with 10uM PFTa,
following a single fraction of y-radiation of 2, 4 or 8Gy, generally, resulted in an
increased time taken to exit the resulting G7+M accumulation at 4Gy when compared
to cells irradiaded at 2Gy and 8Gy as compared to 4Gy. The mutant-p53 cell line
HT29.5 demonstrated the smallest variation in Ts) at 2, 4 and 8Gy, increasing from
5.30h, 6.20h and 6.50h respectively, whilst the mutant-p53 colonic carcinomacell
line Colo320 gave the greatest increase in the duration of Tso, increasing from 4.70h
at 2Gy, to 7.45h at 4Gy and then 22.45h at 8Gy.
Though the duration of Tso generally increased along with increases in exposure to
ionising radiation, in 4 of the 10 cell lines a decrease in the duration of time taken to
exit from G2+M accumulation wasseen. Specifically, in OAW42 the Tso of exit from
G>t+M accumulation was 4.95 and 3.20h at 2 and 4Gy respectively. A decrease in the
duration of Ts) was also observed H322 (2.75h, 2.60h), RT112 (8.65h, 5.30h) and
RPMI 7951 (6.85h, 4.50h) following 2 and 4Gy respectively. Similarly, following
exposure to 4 and 8Gyofy-radiation generally resulted in an increase in Tso duration.
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However, in the wt-p53 cell line HRT18 and the mutant-p53cell lines, Tso exit from
G>+M accumulation decreased (8.05h, 10.10h and 6.20h, 6.95h at 8 and 4Gyfor the
two cell lines respectively). A statistical analysis of these data follows in section
6.3.8.
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Figure 44. Tso determination of G,+M exit following pre-incubation with
PFTaand 2,4 and 8Gyofy-radiation.
The amountof post-irradiated G2+M accumulation, as measured by PI DNA
staining and flow cytometry, in HRT18 and 1407 cells pre-incubated with
10uM PFTa is shown above. Enumeration of the percentage of total cells in
G2+M was interpolated using ModFit (Verity Software), the mathematical
modelling package. These graphs were then used to determine the Tso value,
the rate of exit from the G2+M accumulation, for each cell line.   
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Figure 45. Tso determination of G.+M exit following pre-incubation with
PFTa and 2, 4 and 8Gyofy-radiation
The amountof post-irradiated G2+M accumulation, as measured by PI DNA
staining and flow cytometry, in MGH-U1 and OAW42 cells pre-incubated
with 10uM PFT«ais shown above. Enumeration of the percentage of total cells
in Gyt+M wasinterpolated using ModFit (Verity Software), the mathematical
modelling package. These graphs were then used to determine the Tso value,
the rate of exit from the G2+M accumulation, for each cell line.    
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Figure 46. Tso determination of G,+M exit following pre-incubation with
PFTa and 2, 4 and 8Gyofy-radiation
The amountofpost-irradiated G2+M accumulation, as measured by PI DNA
staining and flow cytometry, in Colo 320 and H322 cells pre-incubated with
10uM PFToa is shown above. Enumeration of the percentage oftotal cells in
G2+M was interpolated using ModFit (Verity Software), the mathematical
modelling package. These graphs were then used to determine the Tso value,
the rate of exit from the G2+M accumulation, for each cell line.    
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Figure 47. Tso determination of G2+M exit following pre-incubation with
PFTaand 2, 4 and 8Gyofy-radiation
The amount of post-irradiated G2+M accumulation, as measured by PI DNA
staining and flow cytometry, in H417 and HT29.5 cells pre-incubated with
10uM PFT« is shown above. Enumeration of the percentage of total cells in
G»+M was interpolated using ModFit (Verity Software), the mathematical
modelling package. These graphs were then used to determine the Tso value,
the rate of exit from the G2+M accumulation, for each cell line.    
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Figure 48. Tso determination of G,+M exit following pre-incubation with
PFTaand2, 4 and 8Gyofy-radiation
The amount ofpost-irradiated G2+M accumulation, as measured by PI DNA
staining and flow cytometry, in RT112 and RPMI 7951 cells pre-incubated
with 101M PFT« is shown above. Enumeration of the percentage oftotal cells
in G2+M wasinterpolated using ModFit (Verity Software), the mathematical
modelling package. These graphs were then used to determine the Tso value,
the rate of exit from the G2+M accumulation, for each cell line.    
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6.3.6 Higher y-radiation dosesstill result in the later onset of G2+M cell cycle
maximum accumulationin cells pre-incubation with PFTa and DMSO
As described previously (section 5.3.5), the time at which the maximum
accumulation of cells in G2+M cell cycle phase increased with higher doses of
ionising radiation (Figure 27A, page 122). The average time at which the maximum
percentage of cells accumulated at 2Gy was 11.00h after irradiation. This increased
to 13.33h following irradiation at 4Gy in the twelve cancercell lines. This increase
was, however, not significant at 4Gy as compared to 2Gy. At 8Gy when comparedto
2 and 4Gy, with the mean time to maximum accumulation of 16.33h post-irradiation.
Following pre-treatment of the cells with 101M PFTa in the presence of 0.1% v/v
DMSO,the time of maximal accumulation across the ten cell lines (2780, H322,
HEp2, HRT18, HT29.5, 1407, MGH-U1, RT112, RPMI 7951) remained 11.00h
following 2Gy of ionising radiation (see Figure 49A below). At the doses of 4 and
8Gy, the cells pre-treated with the p53 inhibitor and DMSO reached the Peak
accumulation earlier than the ‘untreated’ irradiated cells. This would be expected if
the PFTa had negated p53 function, thus reducing the ability of cells to accumulate
in Gj, although why this observation was not seen at 2Gy is unclear. It may be that
2Gyofy-radiation is insufficient to trigger a G; arrest in the human cancercell lines
usedin this study.
Following 4Gy, the time of maximum accumulation across ten of the twelve cell
lines was 12.67+0.964h, was not significantly altered from the untreated cells
(13.50h) (P=0.5913, r= 0.913). Similarly, at 8Gy, though the cells reached the
maximum level of accumulation earlier than the untreated cells (15.00h as compared
to 16.33h respectively), this decrease in the time to peak accumulation following
irradiation, was howevernotsignificant (two-tailed pairedt-test, P=0.3944, r=0.258).
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Figure 49. The time of peak accumulation in G)+M cell cycle phase in 12
humancancercell lines and p53-mutationalstatus at 2, 4 and 8Gy
The influence of increasing doses of radiation and p53-mutational status on the
timing ofmaximum percentage cell accumulation in the G2+M phaseofthe cell
cycle as shown Figures 43-48, is given above. The timing of maximalcell
accumulation for the twelve human cancercell lines following 2, 4 and 8Gy of
ionising y-radiation is shown in panel A, whilst the effect of p53 mutational
status at these increasing dosesofradiation is in the six wt-p53, and six mutant-
p53 cell lines is shown in panel B, 2Gy, 4Gy and 8Gy.   
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6.3.7 p53 mutational status and the onset of peak accumulation following pre-
treatment with PFTa and DMSOatincreasing dosesof y-radiation
Pre-treatment of the wt-p53 and the mutant-p53 cell lines with PFTa in the presence
of DMSO did not yield obvious differences in the time taken for the cells to attain
maximum G2+M accumulation following irradiation. At 2, 4 or 8Gy the time to
maximum accumulation in G2+M for wt-p53 compared to the mutant-p53 cell lines
was not found to be change (studentt-test P = 0.534; r= 0.643, P=0.876; r=0.913 and
P=0.835; r=0.895 respectively) (see Figure 49B). Whereas, cells that were not pre-
treated with PFTa, the wt-p53 cell lines accumulated in the Gj+M cell cycle phase
earlier than their mutant-p53 counterparts (section 5.3.6). Pre-treatment of the twelve
cancercell lines studied with PFTa and 0.1% v/v DMSOnegatedthis relationship.
This may suggest the earlier accumulation of cells in G2+M could be p53 mediated,
howeverno significant changein the time taken for wt-p53cell lines pre-treated with
PFToa as compared to those without PFTa was observedat 2, 4 or 8Gy.
6.3.8 G.+M exit in human cancercell lines following increasing doses of y-
radiation
The determination of the rate of exit of cells accumulated in G2+M phase ofthe cell
cycle was performed as described in chapter 2. The results of these calculations are
given in Table 15 and their determination is demonstrated in Figures 43-48 (above),
by the graphs of G2+M accumulation following 2, 4 and 8Gyof y-radiation along
with the depiction of Tso calculation.
As can be seen from the values in Table 15, as the dose of radiation received
increased, so did the time taken for the cells to exit the accumulation in G7+M phase
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of the cell cycle. This is reflected in the increased average T so times of 5.17, 5.50
and 11.61h for 2, 4 and 8Gyrespectively.
Although, increased Tso exit time resulted following increased dose of y-radiation,
this general trend was is not always observed in the cell lines when considered
individually. In the wt-p53 rectal adenocarcinoma, HRT18 and the mutant-p53
colonic adenocarcinoma clonal variant HT29.5, the Tso times at 4Gy were greater
than at 8Gy and as was the 2Gy Tso time as comparedto the 4Gy time in the mutant-
p53 small cell carcinomacell line H322, the melanomacancercell lines RPMI 7951
andthe transitional bladder carcinoma RT112.
 
 GotM accumulation (Tso)
 
       
Dose 2 Gy 4Gy 8 Gy
2780 4.05] 10.15] 10.60
» |HEp2 2.70 5.30 8.65
& HRT18 4.85| 10.10 8.05= [1407 2.90| 6.05] 10.10
= MGH-UI 1.95 2.10 7.00
v OAW42 4.95 3.20] 11.60
8 Average 3.57 6.15 9.33
ms Colo 320 4.70| 745] 22.45
‘a. H322 2.75 2.60 4.85
= 417 2.75 6.95 21.65
= HT29.5 5.30 6.20 6.00
= RPMI 7951 6.85 4.50 7.70
RT112 8.65 5.30 7.00
Average 5.17 5.5 11.61
Pan-p53 Average 4.37 5.83 10.47  
 
Table 15. G,+M exit (Tso) in twelve human cancercell lines
following incubation with 101M PFTaandincreasing doses of
ionising radiation
The above table contains the Ts, values for the twelve human cancercell
lines used in this study at 2, 4 and 8Gyofy-radiation from a GammaCell
1000 with a '°’Cs source. Thecell lines are ranked alphabetically and by
p53 mutational status, with the average time of exit from G2+M cell
cycle accumulation calculated for both wt-p53 and mutant-p53, and for
pan-p53,i.e. all cells regardless of mutationalstatus.    
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Figure 50. The peak percentage oftotal cells accumulating in G2+M cell
cycle phase in 12 humancancercell lines the effect of p53-mutational status
at 2, 4 and 8Gy
The influence of increasing doses of radiation and p53-mutational status on the
rate of exit from G2+M accumulation shownFigures 43-48, is given above. The
Tso for cells accumulating in G2+M for the twelve humancancercell lines
following 2, 4 and 8Gyofionising y-radiation is shown in panel A, whilst the
effect of p53 mutational status at these increasing dosesofradiation is in the six
wt-p53 and the six mutant-p53cell lines is shownin panel B, 2, 4 and 8Gy. The
double stars (**) in panel A indicate that the Tso following 8Gyis significantly
higher than thatat either 2 or 4Gy.   
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6.3.9 8Gy results in a significant increase in time taken to exit a G2+M delay in
humancancercell lines following p53 inhibition.
The apparent increases in the duration of the rate of G2+M exit as measured by Tso
following increases in exposure of human cancer cells to ionising radiation as
represented by the increases in the mean exit times for the twelve cancercell linesis
indicated in Figure 50A. However, a significant change was only present, as tested
by a Paired t-test, at 8Gy. The increase in Tso following 2Gy and 4Gy gave a P-value
of 0.1250; r=0.448. Treatment ofthe cell with PFTa priorto irradiation resulted in an
increase in the duration of G)+M accumulation following 2Gy, 3.46 to 4.37h (see
Table 14, section 5.8.9), along with a decrease in the average time spent in Go+M
following 4Gy of y-radiation (7.35h without PFTa decreasing to 5.83h following
10uM PFTa). The difference between 2Gy to that of 8Gy Tso was highly significant,
which generated a P-value of 0.0067, r=0.709. Likewise, the increase in the mean Ts
at 8Gy as compared to 4Gy gavea significant P-value of 0.0132, r=0.665.
6.3.10 Increasing dosesof y-radiation, p53-mutational status and the rate of exit
from G2+M accumulation (Ts9) in human cancercell lines
Following ionising radiation the six mutant-p53cell lines, on average, delayed longer
than the six wt-p53 cell lines. The mean (S.E.M) Tso exit times were 3.57+0.50h,
6.15+£1.38h and 9.33+0.70h, for the wt-p53 cell lines and the mutant-p53 cell lines
having Tso values of 5.17+0.95h, 5.5040.73h and 11.61+3.33h at 2, 4 and 8Gy
respectively. Though the mutant-p53 cell lines did take longer to exit the G2+M
phaseofthe cell cycle following maximum accumulation at 2 and 8Gy, the changes
in Tso duration did not translate to a significant response as determined by the
unpairedt-test at either 2Gy (P=0.8983, r=0.060), 4Gy (P=0.5577, r=0.270), or 8Gy
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(P=0.5331, r=0.082). Thus, though the cells did take longer to exit G2+M following
maximum accumulation, inhibition of p53 by the small molecule PFTa did notalter
Tso in the wt-p53, or mutant-p53 cell lines. Similarly, when checked against the
mean Tso values for cell lines not treated with PFTa, no significant change in the
mean Ts) was observed.
6.3.11 Survival fraction following increasing doses of y-radiation and the
intrinsic level of RAF-1 protein in human cancercell lines pre-treated with
PFTa and DMSO
In contrast to p53 mutationalstatus, the intrinsic level of RAF-1 protein was related
to both the duration of G)+M exit as measured by Tso and cellular radiosensitivity
(Chapter 3), although the former was shown to be wt-p53 dependent, whilst the
radiosensitivity as measured by SF2 was foundto be presentin all twelve cell lines as
a whole, although being strongest in the wt-p53 cell lines. The intrinsic level of
RAF-1 protein showed a negative relationship to post-irradiation survival of cells
following 2, 4 and 8Gy. This trend in decreased post-irradiative survival with higher
levels of RAF-1 protein is seen across the doses, although failing to be significant at
8Gy. In the cells which underwent pre-treatment with the p53 inhibitor PFTin the
presence of the organic solvent DMSO,this trend in decreased post-irradiative
survivalin cells with high intrinsic RAF-1 levels is maintained (see Figure 51).
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  Figure 51. Survival fraction following 2, 4 and 8Gy and intrinsic RAF-1protein level in 12 human cancercell linesThe relationship between intrinsic RAF-1 protein level on post-irradiated survivalfraction (SF) at 2, 4 and 8Gy, in twelve humancancercell lines is shown in graphsA, B, and C respectively. Statistical significant correlation (i.e. ps<0.05) isindicated bya star (*).  
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6.3.12 Disruption of p53 by PFTa, survival fraction, RAF-1 protein level and
p53-mutational status in humancancercell lines following increasing dosesofy-
radiation
The mutational status of p53 was shown to contribute to the correlation between
RAF-1 protein level and radiosensitivity at 2Gy (chapter 3) and at 4Gy (chapter 4)
following ionising radiation, with the wt-p53, but not the mutant-p53, cell lines
presenting this correlation. As can be seen from Figure 52 (below), the relationship
that held at both 2Gy and 4Gyin the absence of PFTa is abolished by the incubation
of the cells in 104M PFTa and 1% v/v DMSO.Thisisstill the case when the two wt-
p53 cell lines, HRT18 and 1407, are removed from the analysis. This does suggest
that 10uM PFTa is capable of affecting p53 function in human cancercell lines and
tentatively supports the observation that RAF-1 level is inversely related to post-
irradiation survival in cells processing wt-p53.
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Figure 52. The relationship between RAF-1 protein level and survival at 2, 4
and 8Gyand p53 mutational status
The effect of RAF-1 protein level on post-irradiated survival fraction, in the
context of p53 mutational status in twelve human cancercell lines is shown
above. The intrinsic RAF-1 protein level is plotted against survival fraction for
the six wt-p53 cell lines in A, B, and C, with the six mutant-p53 cell lines in D, E,
and F at the increasing doses of 2Gy, 4Gy and 8Gyrespectively.   
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6.3.13 Survival fraction following increasing doses of y-radiation and the rate of
exit from radiation induced G,;+M accumulation in humancancercell lines pre-
treated with PFTa and DMSO
In contrast to p53 mutationalstatus, the intrinsic level of RAF-1 protein was related
to both the duration of G)+M exit as measured by Tso and cellular radiosensitivity
(chapter 3), although the former was shown to be wt-p53 dependent, whilst the
radiosensitivity as measured by SF2 was foundto be present in all twelvecell lines as
a whole, although being strongest in the wt-p53 cell lines. The rate of exit from the
post-irradiative induced Gy+M accumulation decreases with increases in post-
irradiation survival of cells following 2, 4 and 8Gy. This trend in decreased post-
irradiative survival with longer Tso times is seen across the doses, although it was
only significant at 2Gy. Depicted in Figure 53 are the data from ten adherent cell
lines which underwent pre-treatment with the p53 inhibitor PFTa in the presence of
the organic solvent DMSO.Earlier exit from the G)+M accumulation resulted in
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SFoprta SFaprta SFeprta    Figure 53. Survival fraction following 2, 4 and 8Gy, and Tsoprra in 10 humancancercell linesTherelationship between Tsoprra and post-irradiated survival fraction (SF) at 2, 4and 8Gy, in twelve human cancer cell lines is shown in graphs A, B and Crespectively.   
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decreased survival at 2, 4 and 8Gy. However, these relationships at 2, 4 and 8Gy
failed to reach significance irrespective of dose.
6.3.14 Disruption of p53 by PFTa, survival fraction, the rate of G.+M exit and
p53-mutational status in human cancercell lines following increasing dosesofy-
radiation
The mutational status of p53 was shownto contribute to the correlation between exit
from a post-irradiative Go+M accumulation and radiosensitivity at 2Gy (Chapter 3),
with the wt-p53, but not the mutant-p53, cell lines presenting this correlation. The
chief reason behind using the small molecule p53 inhibitor, PFTa, was to try to
destabilise this putative relationship between radiosensitivity and Tso and wt-p53
protein function. As can be seen from Figure 54 (below), the relationship that held at
2Gyis still maintained by the incubation of the cells in 104M PFTa and 0.1% v/v
DMSO.
174
 Wt-
p53
mu
ta
nt
p5
3
A) SF2 vs. Tsoprta B) SF4 vs. Tsoprta C) SF8 vs. Tsoprta
0.00 025 050 075 1.00
SFopeta  
 
SFaprte  0.00 0.02 004 006 0.08SFeprra
D) SF2 vs. Tsoprta F) SF8 vs. Tsoprra
 
 
 SFaprta  0.00 002 004 006 0.08SFeprta
  Figure 54. The relationship between Tsoprro, the exit from a post-irradiatedG.+M accumulation, survival at 2, 4 and 8Gy and p53-mutational statusTsoprra and post-irradiated survival fraction, in the context of p53-mutationalstatus in twelve humancancercell lines is shown above. The Tsoprra is plottedagainst survival fraction for the six wt-p53cell lines in A, B and C, with the sixmutant-p53 cell lines in D, E and F at the increasing doses of 2, 4 and 8Gyrespectively.  
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There were 154,161 deaths from cancer in 2006 in the UK alone. This is in excess of
27 percent ofall recorded deaths for 2006 (figures from Cancer Research UK). For
the treatment of cancer, radiotherapyis still the primary non-surgical method used
for most malignancies and although the use of radiation has long been known to an
effective form of treatment, for certain local early stage tumours suchasbreast [510],
colon [511] and lung [512], many tumoursstill prove resistant to radiotherapy [513].
Furthermore, there are still no clear markers to aid in the identification of patients
that harbour tumoursthat are not radioresponsive. For this reason I chose to study 12
cell lines with a varied histological background to reflect many of the common
cancers.
The ability of radiation to cause a multitude of both reversible and irreversible delays
in cell cycle progression in G;, S and G)+M have been demonstrated for over 50
years [514], thus it is reasonable to suggest that the proteins controling cell cycle
progression could influence radiosensitivity [515]. At the time the work for this
thesis commenced great steps had been taken in identify the molecular mechanisms
controlling cell cycle progression. The tumour suppressor gene p53 and positive
signal transduction factors such as RAS [516], RAF-1 [4] and MYC [517] have been
shown to play important roles in cell cycle progression and may also be used as
predictive indicators for malignancy and radiotherapeutic outcome. It is against this
background that I undertook a study into the possible relationship of proteins
involved in the cell cycle in an attempt to see if levels of these cell cycle related
proteins correlated with radiosensitivity at the therapeutically significant dose of 2Gy.
In the current study, at 2Gy, no relationship was found for the intrinsic protein
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expression for CDK4, CDK1ortheir regulatory partners Cyclin B and Cyclin D1
respectively with regard to radiosensitivity, however, a positive relationship between
the level of RAF-1 and radiosensitivity was foundin all cell lines tested. Furthermore,
the relationship wasstrongest in cells with a wt-p53 protein. Additionally, the level
of RAF-1 and the surviving fraction of cells at 2Gy correlated to the rate at which
cells exited a radiation induced G2+M cell cycle accumulation.
To test whetherthe relationship between RAF-1 level, radiosensitivity and the rate at
which cells exit from a post-irradiative cell cycle accumulation at 2Gy would hold
true at higher doses ofradiation. I elected to undertake further studies on cell cycle
disruption at the widely used doses of 4 and 8Gy.
The relationship between intrinsic RAF-1 protein level and radiosensitivity, as
measured by the clonogenically determined post-irradiation survival fraction, still
held at 4Gy in the wt-p53 but not the mutant-p53 cell lines. However, this
relationship was not found in cancercells at 8Gy regardless of p53 mutational status.
Similarly, the relationship between radiosensitivity and the rate at which the cell
exited the radiation induced G2+M accumulation was not manifest at 4 or 8Gy
independent of p53 mutational status. As the majority of cells die following the
comparatively high doses of 4 and 8Gy, (approximately 75% and 95% respectively),
whilst only approximately 50% the cells die following 2Gy, it may be conceivably
that the relationship between the intrinsic level of RAF-1 and post-irradiative cell
cycle G2+M accumulation is associated with ionising radiation damage repair
mechanismsrather than cell death.
In 1999, Andrea Gudkov and Co-workers presented data on the use of a p53 inhibitor,
PFTa. They postulated that by the transient inhibition of p53 systemically could
allow for more aggressive use of radiotherapy by negating some of the adverse side-
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effects such as the formation of secondary tumours [507]. Gudkov reported that
“pifithrin-alpha, protected mice from the lethal genotoxic stress associated with
anticancer treatment without promoting the formation of tumours”. With the
exception of the wt-p53 ovarian carcinomacell line OAW42, PFToa did not increase
radioresistance in the human cancercells studied in this thesis. Therefore my data
show that the initial concept of using PFTa as a protective agent for non-malignant
wt-p53 cells in subjects undergoing radiotherapy is supported. However, I did not
include any normalcells in my investigation, i.e. foreskin derived humanfibroblasts,
thus I cannot commentdirectly on the protective nature of PFTa in normal human
cells to ionising radiation. I therefore hypothesise that PFTa does not increase
radiosensitivity in human tumoursin vivoor invitro.
In the human colon carcinoma cell line HCT116, PFTa failed to stop p53
accumulation following genotoxic stress, as observed in Gudkov’s original work
[507]. However expression of p21 following etoposide treatment was observed along
with a reduction in the level of apoptosis, leading to speculation that PFTa modulates
p53 transcriptional activities [518]. PFTa modulation of p53 transcriptional activity
was supported by the observation that p53 mediated up-regulation of CD95
following Doxorubicin exposure was ablated by PFTa [519]. It is in the context as a
transcriptional regulator of p53 that I utilised PFTa since the mutant-p53 cells
demonstrate a G; and G)+M cell cycle arrest following y-irradiation [4, 484], I
initially hypothesised that notall the p53-mutations present within the cell line panel
may be functionally active. The six mutant-p53 cell lines used in this study
demonstrate a variety of mutations. Both Colo320 and H322 share a common
mutation of arginine to tryptophan substitution in domain IV at codon 245 and
RT112 hasa arginine to glycine substitution at codon 248, whilst HT29.5 also within
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domain IV of p53 protein, has a point mutation at codon 273, a substitution of
arginine to histidine. Both H417 and RPMI7951 are truncated at codons 298 and 166
respectively. The p53 truncation in RPMI 7951 lies within the SV40 large T antigen
binding region and the truncation of H417 lies between DNA-binding domain and
the tetramerization domain(see the structure of p53 section 1.5.3).
Since impairment of p53 tetramerization reduced p53 DNA binding [520, 521] I
expected that PFTa would notalter cell cycle arrest or radiosensitivity in H417 or
RPMI7951, although I thought that Colo320, H322, RT112 and HT29.5 may
undergo modification to cell cycle delay and radiosensitivity. RT112 and H322 have
a mutation in the region of p53 associated to Li Fraumeni syndrome, a disorder
associated with the early onset of cancer and radioresistance [522]. RT112
demonstrated an increase in_ radiosensitivity, although not significant.
Radiosensitivity was increased in HT29.5 following treatment with PFTa, although
again this small change wasnot foundto be significant. Thus I could not ascribe any
mutational functionality to transcriptional inactivation of p53 by PFTa in the p53
mutants usedin this thesis. To determine the role played by PFTa in modulating p53
transcription, a more informative approach, other than relying on the ‘random’
mutations found in various cancercell lines, may be to systematically mutate p53 by
site-directed mutagenesis. A specific RNA array aimed at known p53 transcriptional
targets following irradiation could then be undertaken. This approach would reduce
any artefacts that may result from the complex variations that exist between un-
related cancercelllines.
I also employed PFTa to investigate the relationship between RAF-1 level,
radiosensitivity and exit from G2+M accumulation following ionising radiation in the
context of p53-mutational status. My data supports the hypothesis that RAF-1
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requires wt-p53 in determining the duration of G)+M accumulation and
radiosensitivity following 2Gy of y-radiation, a relationship that is not found at the
higher doses of 4 and 8Gy. ThusI elected to disrupt wt-p53 function using the small
molecule inhibitor PFTa and studied the cell cycle delay and clonogenic survival at
doses of 2, 4 and 8Gy.
Surprisingly, post-irradiation survival of the cancer cells was not significantly altered
by incubation with PFTo prior to irradiation in the wt-p53 or the mutant-p53 cell
lines (as determined clonogenically), when considered irrespective of p53 mutational
status or when grouped by p53-muational status. Since PFTa had been postulated to
inhibit p53 function and promote post-irradiation survival in wt-p53 cells, I would
have anticipated significant increases in radioresistance in the wt-p53 cancercell
lines utilised in my study.
Despite the lack of any apparent mediation of radiosensitivity by PFTa in the cancer
cell lines used in this study, pre-incubation with PFTa disrupted the relationship
betweenthe intrinsic level of RAF-1 in the wt-p53 cells and the post-irradiation rate
of exit from G2+M accumulation. This outcome supports the notion of a co-operative
relationship, be it direct or otherwise, between the intrinsic level of RAF-1 and p53
in determining radiosensitivity.
Following irradiation, the mutant-p53 cell lines reached a peak accumulation in
G>tM cell cycle phase earlier than the wt-p53 cell lines. I therefore hypothesise that
this is because the mutant-p53 cells do not undergo an early delay in G; following
irradiation. However, following incubation of cells with PFTa, the earlier onset of
maximal G2+M accumulation following exposure to ionising radiation was not
observed in any of the cell lines tested independent of their p53 status. Thusit is
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likely that addition of PFTa disrupts a p53 dependent early G; delay following
ionising radiation.
Dueto the use of PI to visualise cell cycle accumulation only a snap-shot ofcell
distribution at any given time is obtained. Therefore, it is not practicle to determine
the precise cell cycle kinetics for any given cell using PI. A conventional method
used to examine cell progression through the cell cycle is to pulse-label cells with
bromodeoxyuridine [523]. However, the inclusion of halogenated pyrimidines into a
cell to undergo radiation studies is complicated by induction of the Auger cascade
which increases the effective dose recieved by cells following ionising radiation
[524]. Thus it may be preferential to use cyclin D3 and cyclin B fluorescent fusion
proteins [525] and time lapse imagining to measure precisely the rate at whichcells
progress through each part of the cell cycle following radiation. This method could
also be used to determine if PFTa negates a putative early post-irradiation G; delay.
The precise mechanism by which PFTo acts in humansis unclear and the majority of
data published to date is from rodent models. PFTa may promote binding of p53 to
the transcription factor p300, thus competitively inhibiting NF-Kappa B [526]. In
2003 Gudkov showedthat PFTa inhibitory capacity could act through a mechanism
other than p53. Indeed, PFTa reduced signalling through Heat Shock Transcription
Factor 1 and reduce glucocorticoid receptor activity in mouse thymocytes [527]. In a
recent paper Sohn et al. demonstrated that although PFTa did reduce apoptosis
following genotoxic assault, this was independent of p53 [528], whilst Kaji et al.
found that PFTa enhanced apoptosis in JB6 mouse epithelial cells following
exposure to UVB and doxorubicin [529].
In 2005 Walton and co-workers [530] published data that support my observations;
PFTo did not alter post-irradiation clonogenisity in two human cancercell lines,
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HCT116 and 2780. This manuscript reported that PFTa was unstable in in vitro cell
culture media. In agreement with my observations Walter et al. found that above
20uM PFTa wastoxic to 2780 cells (ICso of 21.3+8.14M). There was no effect on
the expression of p53, p21 or MDM-2 protein following ionising radiation. No
evidence of abrogation of p53-dependent ionising radiation induced cell cycle arrest
by PFToa wasobserved.In this study Walton employed UV radiation and only looked
at cell cycle distribution at 16h post-irradiation. In the 2780 cells utilised in my study
I observed differences in the distribution of cells in the cell cycle following
irradiation in both PFTa treated and non-PFTa-treated cells. However at 16h post-
irradiation the number of cells in G.+M converged for irradiated cells with or
without 20uM PFTo. Thus differences observed between my current study and that
carried out by Walton et al. may be explained by the more comprehensive
examination of cell cycle distribution at a greater range of time points investigated in
this thesis.
In the mouse fibroblast cell line LMCAT, Murphyef al. reported that PFTa was
capable of inhibiting p53 signalling, but only following hsp90 mediated nuclear
translocation [531]. Taking this observation along with the instability of PFTo in cell
culture media [530], it may be necessary to add PFT« at the time of cell irradiation.
If more time was available to investigate whether p53 mediates the rate of exit of
cells from accumulation in G)+M following y-radiation I would add PFT«to thecell
culture media immediately prior to irradiation in an attempt to verify that PFTa is
functional in the assays utilised in this thesis. Additionally, the advent of a new PFTa
salt, PFTB, which demonstrates lower levels of toxicity than PFTa would allow re-
evaluation of the effects of PFTa on the HRT18 and 1407 cell lines that showed a
toxic response by clonogenic assay.
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In addition to the cell lines already used in the current study I would also include a
normal cell line, i.e. foreskin fibroblasts, to investigate whether PFTa also promotes
radioresistance in p53 normalcelllines. It might also be informative to explore the
role of PFTa on humanfibroblasts immortalised with the viral proteins SV40 large T
antigen [532], as well as or instead by E2F [533]. I would predict that if PFTa
interact directly through p53 to make normalcells radioresistant then these viral
proteins would negate PFTa induced radioresistance. Further, it may be possible to
utilise FRET [534] to investigate whether PFTo interacts directly with p53 protein.
The tetrahydrobenzothiazol ring of PFTa contains a primary amine making PFTa
easily amenable to conjugation with many fluorochromes. FRET could be employed
on fluorescently conjugated PFTin a cell line expressing a p53 fluorecent fusion
protein [535]. This approach could demonstrate PFTo. direct interaction with p53 and
also could highlight the temperal and cell compartmental nature of any possible
interactions.
In conclusion I have shownherethat the level of the protoncogene RAF-1 correlates
strongly with radiosensitivity at the clinically relavant dose of 2Gy. Further, in cells
expressing wt-p53theintrinsic level of RAF-1 is predictive of the rate at which cells
exit from a y-radiation induced accumulation in G2+M cell cycle phase and that this
rate is correlative to post-irradiation cell survival. These findings point to a role for
both p53 and RAF-1 in Gy+M cell cyle progression following genotoxicassault.
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